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The conversion of peptides and proteins from their native states to highly struc-
tured fibrillar aggregates, that accumulate in the extracellular or in the intracellular 
space, is a defining characteristic of many human disorders, including Alzheimer’s 
disease, Creutzfeldt-Jacob disease, type II diabetes and a number of systemic amy-
loidoses. It is generally thought that amyloid oligomers formed early in the process 
of protein aggregation, or released from mature amyloid fibrils, are the pathogenic 
species in protein deposition diseases. This pathological feature appears likely to re-
sult, at least in part, from the ability of oligomers to interact with cell membranes, 
modifying the properties of the phospholipid bilayer, the stabilities and functions of 
its associated proteins and to enter the cell, thus causing cell dysfunction. The N-
terminal domain of the prokaryotic hydrogenase maturation factor (HypF-N) is a 
valuable model system for investigating the structural basis of the cellular impair-
ment caused by misfolded protein oligomers. In fact, it can rapidly be converted into 
stable oligomers under conditions that promote its unfolding into partially folded 
species and can generate a cascade of events, resulting in cytoxicity and death, when 
added to cells.  
Alzheimer’s disease (AD) is a common form of dementia that results in memory 
loss and impairment of cognitive function in the elderly. A major pathological hall-
mark of AD is the formation of extracellular senile plaques composed of aggregated 
amyloid β-peptide (Aβ), which is generated by sequential enzymatic cleavage of the 
amyloid precursor protein (APP) by β-secretase and the γ-secretase complex. Several 
lines of evidence suggest that soluble oligomers may be the principal neurotoxic 
agent in AD. Indeed, amyloid-derived diffusible ligands (ADDLs) are found in the 
cerebrospinal fluid of AD patients and the ADDL content of human brains better 
correlates with disease severity than do classical amyloid plaques containing insolu-
ble Aβ deposits. Moreover, there is a rising consensus on major role of membranes 
as initial triggers of the biochemical modifications culminating with neuronal death. 
In spite of the intense research carried out in recent times, the role of cholesterol as a 
risk factor for AD remains controversial. The content of membrane cholesterol can 
modulate Aβ peptide production, aggregation and clearance in various ways, partic-
ularly by affecting the stability of lipid rafts and other membrane domains where 
APP and some APP processing secretases are located, as well as the activity of raft 
associated proteins. Increasing evidence now shows that Aβ can tightly associate 
with GM1 ganglioside (a component of lipid rafts), and it was originally postulated 
that this may act as a seed for its accumulation and aggregation. These findings, to-
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gether with the presence, in the raft domains, of ligand-gated calcium channels (the 
AMPA and NMDA glutamate receptors) involved in Ca2+ influx into neuronal syn-
aptic ends and in Ca2+ permeabilization of amyloid-exposed cells has implicated li-
pid rafts as likely primary interaction sites for ADDLs.  
Taking into account these observations, the aim of the present study is to get 
clues into the molecular basis of amyloid cytotoxicity with particular interest in the 
interaction of different types of oligomers, related or not with diseases, with cell 
membrane (or its subfractions, as lipid rafts) and the resulting cascade of events, 
culminating in cellular dysfunction and death. We also focused our attention to the 
role of membrane cholesterol and GM1 as possible modulators of the interaction be-
tween amyloid aggregates and the plasma membrane of exposed cells. Finally, con-
sidering that cell therapy is a promising approach for the treatment of neurodegen-
erative conditions such as AD, we investigated the relative vulnerability of human 
mesenchymal stromal cells and their neuronally differentiated counterparts to Aβ42 
oligomers in view of the presence of toxic aggregates in tissue, which raises the ques-
tion of whether grafted stem cells are susceptible to amyloid toxicity before they dif-
ferentiate into mature neurons. 
 
The present studies provide evidence that:  
I) Cell resistance to amyloid toxicity is strictly related to lipid raft cholesterol 
content in SH-SY5Y cells. In particular, in our model cells, membrane cholesterol 
modulation was achieved by supplementing the cell culture media with water soluble 
cholesterol (PEG-chol) to increase the levels of membrane cholesterol; on the other 
hand, cholesterol levels were diminished by using methyl-β-cyclodextrin (β-CD) or 
mevastatin (Mev). A moderate enrichment of membrane cholesterol in PEG-chol 
treated cells appeared to reduce the ADDLs interaction with the monosialogangli-
oside GM1 while an increased colocalization was found in cholesterol depleted cells 
following treatment with β-CD or Mev. Aβ oligomers interact with the plasma 
membrane preferentially at the raft domains and any structural modification of the 
latter following increase or decrease of cell cholesterol results in alterations of 
ADDL-raft interaction. In addition, cholesterol enrichment protects lipid rafts from 
perturbation induced by Aβ42, indeed cholesterol-enriched lipid rafts did not dis-
play any significant change of the structural order upon exposure to Aβ42 oligomers. 
On the contrary, cholesterol loss resulted in increased rigidity of rafts exposed to oli-
gomers, which penetrated and stiffen the raft bilayer. Accordingly, as imaged by 
AFM, the presence of the peptide clearly altered DRM morphology, giving rise to the 
formation of cavities in all samples, whose depth and size were significantly reduced 
in cholesterol-enriched samples with respect to those displayed by cholesterol-
depleted samples. These results showed that the content of cholesterol affects the 
ability of ADDLs to interact with the cell membrane by modulating membrane phys-
ical features at the raft level. 
II) Two lipidic raft components, that are cholesterol and GM1, affect the suscep-
tibility of Familial Alzheimer’s Disease (FAD) fibroblasts to Aβ42 oligomers in op-
posite ways, by modulating amyloid binding to lipid rafts and its subsequent toxic 




effects. In the present study, primary fibroblasts from FAD patients carrying APP or 
PS1 gene mutations, secreted elevated amounts of Aβ42 peptide and showed greater 
membrane permeability and lipid peroxidation with respect to fibroblasts obtained 
from healthy subjects, suggesting partial disruption of membrane integrity and 
chronic oxidative stress associated with enhanced Aβ production. Lipoperoxidation 
was higher in DRMs compared to the entire cell membrane, pointing to lipid rafts as 
preferential sites for Aβ42 interaction at the cell surface. Indeed, as observed by con-
tact mode AFM, the increased release of Aβ42 in FAD fibroblasts was associated 
with evident alteration of lipid raft morphology, resulting in the formation of 
steps/cavities in DRMs purified from FAD fibroblasts. Moreover, Aβ treatment in-
duced greater aggregate-ganglioside colocalization and DRM structure perturbation 
in FAD fibroblasts, with respect to WT controls. Moreover, in our model cells, 
membrane cholesterol modulation was achieved by supplementing the cell culture 
media with water soluble cholesterol (Chol) to increase the levels of membrane cho-
lesterol; on the other hand, cholesterol levels were diminished by using mevastatin 
(Mev). In addition, an increase in GM1 content was achieved treating cells with 
GM1 from bovine brain (GM1), whereas GM1 depletion was obtained exposing cells 
to D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), a gluco-
sylceramide synthase inhibitor that blocks the natural synthesis of GM1. The in-
crease in cytosolic Ca2+ content and alteration of membrane permeability was much 
smoother and milder in cholesterol-enriched or GM1-depleted fibroblasts exposed 
to amyloid oligomers with respect to similarly treated control cells with basal choles-
terol or GM1 content. In contrast, membrane cholesterol depletion or GM1 enrich-
ment triggered a greater increase in cytosolic Ca2+ levels and membrane permeabil-
ity. Even in primary rat cortical neurons membrane GM1 content influences Aβ42 
toxicity and intracellular Ca2+ homeostasis, corroborating our hypothesis at the neu-
ronal level. Moreover, pre-treateatment with anti-GM1 antibodies, cholera toxin 
subunit B –a specific GM1 ligand– or with NAA, an enzyme that leaves the content 
and structure of GM1 unchanged except for the removal of the negatively charged 
sialic acid moiety, completely suppressed Aβ-induced Ca2+ spikes and membrane 
damage, suggesting that the negative charge on GM1 is a key factor determining cal-
cium dyshomeostasis and membrane permeabilization, which results in cell vulner-
ability to Aβ oligomers. Overall, our data suggest that raft cholesterol and GM1, by 
modulating membrane fluidity and charge, respectively, may specifically influence 
the binding of Aβ42 oligomers, their insertion into the phospholipid bilayer and 
their ability to disrupt membrane structure, which ultimately triggers cell death. 
III) The degree of toxicity of the oligomeric species results from a complex in-
terplay between the structural and physicochemical features of both the oligomers 
and the cellular membrane. In particular, we modulated the structural rigidity 
and/or charge density of the plasma membrane by altering in a variety of ways the 
levels of either cholesterol or GM1, or of both at one time. We analyzed the cytotoxi-
city to cultured neuroblastoma cells with a normal or a rationally altered content of 
membrane lipids, of two types of pre-formed HypF-N oligomers that we previously 






both type A and B oligomers were internalized and sorted into endocytotic vesicles 
in the exposed cells. However, interaction of oligomer with the cell membrane and 
internalisation were significantly decreased in cells enriched in membrane cholester-
ol or with a reduced content of GM1; in particular, type B oligomers, that were una-
ble to cross the plasma membrane of SH-SY5Y cells with a basal lipid content, be-
came increasingly internalised in cells with a reduced content of cholesterol. Moreo-
ver, the cytotoxicities of Aβ42 oligomers and of the two types of misfolded HypF-N 
oligomers used in this study were dramatically affected by the physicochemical fea-
tures of the cell membrane. In particular, the oligomers found to be toxic to the cells 
with basal lipid content became increasingly significantly less toxic as the membrane 
cholesterol level was increased or that of GM1 was decreased, whereas the opposite 
effect was found with cells treated so as to reduce their content of membrane choles-
terol. Conversely, the oligomers that were not toxic to untreated cells remained 
harmless to cells with an increased content of cholesterol or a reduced content of 
GM1, but became increasingly harmful as the content of cholesterol in the mem-
brane was decreased or that of GM1 was increased, reaching levels of toxicity com-
parable to those shown by the toxic oligomers with untreated cells. A number of 
characteristic features known to underlie oligomer cytotoxicity were also found to be 
modified in the cells with an altered membrane lipid composition, including cell 
membrane permeability, the levels of intracellular Ca2+ and ROS, and the apoptotic 
response. The data obtained using cells with an altered content of both membrane 
cholesterol and GM1 show that the alteration in the GM1 levels plays a dominant 
role in determining the resulting effects. The importance of GM1 relative to choles-
terol in determining oligomer-mediated cytotoxicity is also supported by our find-
ings of an inverse relationship between the content of cholesterol and of GM1 in the 
plasma membrane of our cell model. The data reported here, therefore, lead us to 
conclude that the level of cytotoxicity of a specific type of protein oligomer, or in-
deed of other amyloid-related structures, is the result of a complex interplay between 
two critical factors: the specific properties of the aberrant protein assemblies (e.g., 
relative stability, disorder, flexibility and exposure of hydrophobic surface) and the 
physicochemical features of the interacting cell membranes that are associated with 
their lipid composition (e.g. fluidity, electrostatic potential, curvature, lateral pres-
sure). 
IV) Neuronal differentiation of human mesenchymal stromal cells increases 
their resistance to Aβ42 aggregate toxicity. In this study, we investigated whether, 
and to what extent, undifferentiated human mesenchymal stromal cells (hMSCs) 
and their neuronally differentiated counterparts (hMSC-n) were affected by the of 
Aβ42 oligomer toxicity. Our data show that the two cell types displayed differential 
susceptibility to Aβ aggregate-induced toxicity. We found that undifferentiated cells 
were much more vulnerable to Aβ42 oligomers than their differentiated counter-
parts. The more vulnerable, undifferentiated cells displayed significantly higher 
membrane GM1 content, thus explaining their ability to bind and to be permea-
bilized by Aβ42 oligomers, together with the resulting increase in Ca2+ and ROS and 
loss of cell viability. We report that a neuronally differentiated cell model is intrinsi-




cally more resistant to Aβ42 oligomer-induced cytotoxicity than the undifferentiat-
ed, cognate cell line, and that the molecular basis of this differential susceptibility 










1.1 Protein aggregation and amyloidoses 
A broad range of human diseases arises from the failure of a specific peptide or 
protein to adopt, or remain in, its native functional conformational state. These 
pathological conditions are generally referred to as protein misfolding (or protein 
conformational) diseases. The largest group of misfolding diseases, however, is rep-
resented by amyloidoses (Chiti and Dobson, 2006). These diseases are characterized 
by the presence of deposits of fibrillar aggregates found as intracellular inclusions or 
extracellular plaques whose main constituent is a specific peptide or protein, differ-
ent in the varying disorders (Table I) (Stefani, 2004). These diseases include a range 
of sporadic, familial or transmissible degenerative diseases, some of which affect the 
brain and the central nervous system (e.g. Alzheimer’s and Creutzfeldt-Jakob diseas-
es), while others involve peripheral tissues and organs such as the liver, heart and 
spleen (e.g. systemic amyloidoses and type II diabetes) (Stefani and Dobson, 2003). 
In addition, there are others diseases (Parkinson’s and Hungtington’s diseases) char-
acterized by the presence of intracellular, rather then extracellular, deposits localized 
in the cytoplasm, in the form of specialized aggregates known as Lewy bodies, or in 
the nucleus (Table I). 
Despite the large differences in the structures of the proteins and peptides aggre-
gated in the assemblies found in the differing amyloidoses or produced in vitro, 
amyloid fibrils share basic structural features and an ordered core structure. A typi-
cal amyloid fibril is straight, unbranched, 6-12 nm in width and reaches around 1 
μm in length; it is formed by a variable number of elementary filaments (protofila-
ments) twisted around each other, typically 1.5-2.0 nm in diameter (Serpell et al., 
2000). The main structural hallmark of amyloid fibrils is the ordered core of their 
protofilaments. The latter results from a double beta sheet which extends along the 
main filament axis and whose beta strands provided by each monomer stacks in reg-
ister and run perpendicular to the fibril axis (what is known as cross-beta structure, 
whose signatures are the reflections at 4,8 and 9,6-11 Å in X-ray diffraction patterns) 
(Nelson et al., 2005). Moreover, this cross-β structure confers to the amyloid fibrils 
specific biophysical characteristics and a variety of tinctorial properties, notably 
staining with thioflavin T (ThT) and Congo red (CR). 
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Table I. A summary of the main amyloidoses and the proteins or peptides involved. Condi-
tions affecting the central nervous system are written in italic. From (Stefani, 2004). 
The cross-β structure can be therefore considered as the main structural hall-
mark of the amyloid aggregates. (Fig. 1) (Chiti and Dobson, 2006). 
 





Figure 1. Close-up view of the structural organization of an amyloid fibril. The four protofil-
aments are wound around each other and their core structure is a row of β-sheets where each 
strand runs perpendicular to the fibril axis. From (Stefani, 2004). 
1.1.1 Mechanisms of amyloid fibril formation 
Protein folding and protein aggregation must be distinct but competing path-
ways the same polypeptide chain can undergo depending on the environmental 
conditions (Stefani, 2008). The view that protein folding and aggregation are com-
peting paths considers both as distinct yet not mutually excluding processes relying 
on a more general energy landscape including conformational states not involved in 
protein folding, yet potentially accessible to a polypeptide chain (Jahn and Redford, 
2008). The two sides of the protein energy landscape highlight the competition be-
tween intramolecular (folding) and intermolecular (aggregation) interactions, which 
increases considerably the roughness of the whole landscape (Fig. 2) (Stefani, 2008). 
Moreover, protein folding and protein aggregation rely on similar physicochem-
ical parameters of the polypeptide chain including a significant propensity to gain 
secondary structure, a low net charge, and a relatively high content of hydrophobic 
residues (Stefani, 2008). Any alteration of a protein’s expression level or structure 
(increased synthesis or reduced degradation, presence of specific mutations or 
chemical modifications) or any minor, even subtle, change in the environmental 
conditions can trigger the build-up of the precursor, aggregation-prone, species that 
nucleate rapid growth of aggregates. The latter include heath shock, oxidative stress 
or chemical modifications, alterations of the intracellular macromolecular crowding, 
presence of suitable surfaces, absence of stabilizing ligands, any impairment of the 
quality control of protein folding in the cell, and others (reviewed in Chiti and Dob-
son, 2006; Stefani and Dobson, 2003; Stefani, 2010a). It is widely established that 
amyloid fibril formation has many characteristics of a “nucleated growth” mecha-
nism. The time course of the conversion of a peptide or protein into its fibrillar form 
(measured by ThT fluorescence, light scattering, or other techniques) typically in-
cludes a lag phase that is followed by a rapid exponential growth phase (Pedersen et 






“nuclei” to form. The lag phase can be shortened or eliminated by the addition of 
preformed aggregates to fresh solutions, a process known as seeding. Once a nucleus 
is formed, fibril growth is thought to proceed rapidly by further association of either 
monomers or oligomers with the nucleus. (Chiti and Dobson, 2006). The first phase 
in amyloid formation seems to involve the formation of soluble oligomers as a result 
of relatively non specific interactions, although, in some cases, specific structural 
transitions, such as domain swapping, might be important (Sirangelo et al., 2004). 
The earliest species visible by electron or atomic-force microscopy (AFM) generally 
resemble small bead-like structures having a diameter of 2–5 nm, sometimes linked 
together, and often described as amorphous aggregates or as micelles. These early 
‘prefibrillar aggregates’ then transform into species with more distinctive morpholo-
gies, often called ‘protofilaments’ or ‘protofibrils’ (Fig. 3).  
 
 
Figure 2. A combined energy landscape model for protein folding (left) and aggregation 
(right) starting from the unfolded ensemble. Both sides display considerable roughness, but 
amyloid fibrils display a remarkably higher stability and lower energy content than the na-
tively folded structure. The picture highlights the multitude of the different conformational 
states available to a protein when they are stabilized by either intramolecular (monomeric 
protein) or intermolecular (aggregation intermediates and mature fibrils) contacts. The pres-
ence of intermolecular contacts increases dramatically the ruggedness of the landscape for 
protein aggregation with respect to what is shown in the folding side. From (Stefani, 2008). 







Figure 3. A schematic representation of the general mechanism of aggregation to form amy-
loid fibrils. Unfolded or partially unfolded proteins associate with each other to form small, 
soluble aggregates that undergo further assembly into protofibrils or protofilaments and then 
mature fibrils. Modified from (Williams and Serpell, 2011). 
 
These structures are commonly short, thin, sometimes curly, fibrillar species 
that are thought to assemble into mature fibrils, perhaps by lateral association ac-
companied by some degree of structural reorganization. The nucleation-dependent 
polymerization mechanism of fibril growth, whose physical bases approach those of 
the ordered assembly occurring in crystal growth, also supports fibril stability and 
represents a key difference between protein folding and protein aggregation (Stefani, 
2010a). The aggregates that form first are likely to be relatively disorganized struc-
tures that expose a variety of segments of the protein that are normally buried in the 
globular state (Bucciantini et al., 2002). In some cases, however, these early aggre-
gates appear to adopt quite distinctive structures, including well-defined annular 
species (Dobson, 2003; Lashuel et al., 2002). Analogous spherical and chain-like pro-
tofibrillar structures have been observed for many systems, including amyloid-β 
peptide (Aβ) peptide (Harper et al., 1997; Walsh et al., 1999) α-synuclein (Conway et 
al., 2000), amylin (Kayed et al., 2004), the immunoglobulin light chain (Ionescu-
Zanetti et al., 1999), transthyretin (Quintas et al., 2001), polyQ-containing proteins 
(Kayed et al., 2004), β2-microglobulin (Gosal et al., 2005). These species are general-
ly characterized by extensive β-structure and sufficient structural regularity to bind 
ThT and CR (Chiti and Dobson, 2006).  
1.1.2 Oligomer structural polymorphism: fibrillar and prefibrillar oligomers  
The heterogeneity, remarkable instability and intrinsically disordered nature of 
oligomeric species makes it very difficult to get solid data on their conformational 
features. An important contribution on this issue has came from the use of antibod-






cific structural features present in different forms of these assemblies and hence to 
discriminate among them. A previous study reported the generation of two confor-
mational antibodies, A11 and OC, recognising oligomers and fibrils, respectively 
(Glabe, 2008; Kayed et al., 2003; O’Nuallain et al., 2002). It has been proposed two 
distinct types of oligomers: prefibrillar oligomers that are A11-positive and OC-
negative, and fibrillar oligomers that are A11-negative and OC-positive (Fig. 4) 
(Glabe, 2008; Kayed et al., 2003). As prefibrillar oligomers are not recognized by the 
fibril-specific antibodies, and are considered to be transient intermediates in the fi-
bril formation process, a conformational change is necessary for them to become fi-
brils. It should be noted that the oligomer specific A11 antibody also recognizes sol-
uble oligomers from various proteins, such as those from α-synuclein, islet amyloid 
polypeptide, polyglutamine (PolyQ), lysozyme, human insulin and fragment of pri-




Figure 4. Schematic representation of the distinct types of amyloid oligomers and fibrils. The 
aggregation pathway can diverge into two paths depending on which conformation it adopts. 
Monomers can aggregate to form prefibrillar oligomers that are A11-positive and OC-
negative (left pathway). These prefibrillar oligomers may then undergo a concerted confor-
mation change “en bloc” to form fibrils. In the other pathway, monomers aggregate to form a 
fibrillar conformation that is OC-positive and A11-negative (right pathway). These fibrillar 
oligomers may represent fibril nuclei or seeds that are aggregates capable of elongating by re-
cruiting additional monomers at their ends. Fibrils may be distinct from fibrillar oligomers 
on the basis of their content of multiple protofilaments. Modified from (Glabe, 2008). 
These findings suggest that various proteins may form prefibrillar oligomers that 
share a common structure regardless of their amino acid sequence (Chiti and Dob-
son, 2006; Glabe, 2008; Kayed et al., 2003; Sakono and Zako, 2010). However, be-




cause the fibrillar oligomers are recognized by the fibril-specific antibody, but not by 
A11, they at least possess the structural characteristics of fibrils. Thus, it is plausible 
that the fibrillar oligomer might represent fibril nuclei to which the monomers can 
attach before elongation (Glabe, 2008). Aβ oligomers formed at a low pH, but not 
those formed at a neutral pH, are recognized by the 6E10 antibody (Necula et al., 
2007). These results strongly suggest the existence of a structural polymorphism of 
Aβ oligomers. These data suggest the existence of at least two alternative aggregation 
nuclei for amyloid fibrils: one type evolving into mature fibrils directly but only after 
extensive structural reorganization and another type, possibly the true fibril precur-
sor, growing into increasingly sized aggregates where added monomers acquire a 
new structure when incorporated into the oligomer. In general, the use of conforma-
tional antibodies raised specifically to amyloid oligomers, prefibrillar assemblies and 
mature fibrils has provided an invaluable tool to distinguish these distinct entities, 
clearly showing the existence of differences in their structural features (Glabe et al., 
2004; Kayed and Glabe, 2006; Kayed et al., 2007; Mamikonyan et al., 2007). It has 
also provided knowledge to show that the same protein/peptide at the onset of ag-
gregation can generate oligomeric and prefibrillar assemblies with clearly different 
structural features (Kumar and Udgaonkar, 2009), thus providing a tool to investi-
gate the conformational modifications underlying the hierarchical growth of amy-
loid fibrils as well as oligomer structural heterogeneity. Overall, these findings indi-
cate that prefibrillar aggregates of different proteins and peptides share some basic 
structural features that are different from those displayed by the folded monomers 
or their fibrillar counterparts. These features can include the different exposure to 
the aqueous environment of hydrophobic patches normally buried into the compact 
structure of the monomeric protein following protein unfolding. On this aspect, 
chemical modifications and, more generally, environmental conditions can play a 
pivotal role not only in promoting/hindering protein misfolding and aggregation, 
but also in affecting the structural features of the aggregation nuclei, thus targeting 
them to organize into fibril precursors and mature fibrils with different structures, 
stabilities and cytotoxicities (Bravo et al., 2008; Chen and Kokholyan, 2005; Danzer 
et al., 2007). The structural features of amyloid oligomers, besides explaining the in-
trinsic instability of the latter, also provide clues to explain the tendency of amyloid 
oligomers and other unstable prefibrillar aggregates to interact inappropriately with 
cellular components and, accordingly, their toxic potential. 
1.1.3 Oligomer toxicity: common mechanism of pathogenesis  
The presence of highly organized and stable fibrillar deposits in the organs of pa-
tients suffering from protein deposition diseases led initially to suggest a causative 
link between protein misfolding, aggregation and pathological symptoms, often 
known as the “amyloid hypothesis”. Until recently, mature amyloid fibrils were con-
sidered the key agents responsible for cell damage and tissue impairment since they 
were the form of the aggregates commonly found in the pathological deposits (extra-






genic features of amyloid diseases resulted from the interaction with cell compo-
nents of the deposits of the aggregated material. By providing a theoretical frame to 
understand the molecular basis of amyloid diseases, such a view stimulated the ex-
ploration of therapeutic approaches to amyloidoses mainly aimed at hindering fibril-
lar aggregate growth and deposition. However, the idea that mature fibrils are the 
main agents responsible of cell demise in the affected tissues is presently challenged 
by an impressive body of experimental data (reviewed in Stefani, 2010a). The differ-
ent assemblies grown in the fibrillization path differ greatly not only in their cytotox-
ic potential but also in the cellular mechanisms and functions they interfere with, 
that appear to be specific for the aggregation state. For example, small Aβ42 oligo-
mers found in the brains of Alzheimer’s disease (AD) people impair long-term po-
tentiation (Klyubin et al., 2005; Walsh et al., 2002) and raise endoplasmic reticulum 
stress (Chafekar et al., 2007) whereas the neuroinflammatory response in AD brain 
appears more specifically associated to the presence of fibrillar Aβ (Eikelemboom et 
al., 2002). Moreover, at least in the case of the Aβ peptides, cytotoxicity appears to be 
mediated by aggregation state-specific uptake; in fact, oligomer internalization by 
endocytosis into lysosomes appears associated with oligomer toxicity, whereas 
harmless amyloid fibrils are not internalized (Chafekar et al., 2008). Actually, alt-
hough in some cases mature amyloid fibrils can impair directly cell viability (Gha-
ribyan et al., 2007; Novitskaya et al., 2006), most often the oligomeric assemblies 
transiently arising in the path of fibrillization of several peptides and proteins are the 
main or even the sole cytotoxic species (Lambert et al., 1998; Reixach et al., 2004; 
Walsh et al., 1999; Walsh et al., 2002). The idea that prefibrillar aggregates are the 
most highly toxic species among amyloids has led to consider mature fibrils as sub-
stantially inert, harmless deposits of the toxic precursors and their growth as a cell 
defense mechanism; it can also explain the lack of direct correlation between amy-
loid load in the brains of AD patients and severity of their clinical symptoms (Dick-
son, 1995). Recent studies on this issue indicate that amyloid oligomers are highly 
flexible and dynamic assemblies growing as in-path or off-path intermediates of am-
yloid fibrils. In general, they expose patches of hydrophobic residues on their surface 
and in differing environmental conditions they can exhibit remarkable structural 
differences even when they are grown from the same peptide/protein underlying 
their growth into mature fibrils with different structural, physical and morphological 
features (reviewed in Stefani, 2010a). Although most of these fibrillar amyloids as-
semblies are considered intermediates in the path of fibrillization, some of them, 
such as the frequently imaged small annular oligomers (“doughnuts”), could be 
“dead end” products of the process or, at any rate, structurally and functionally dis-
tinct types of amyloid oligomers (Kayed et al., 2009). Finally, soluble oligomers 
grown in the fibrillization path of several peptides and proteins have also been re-
peatedly detected in, and purified from, cultured cells and tissues where the mono-
meric precursors are expressed (Billings et al., 2005; Cleary et al., 2005; Koffie et al., 
2009; Lesné et al., 2006). These data reinforce the idea that amyloid oligomers are 
really formed in vivo and are directly associated with cell/tissue impairment (Koffie 
et al., 2009).  




The presence of toxic aggregates inside or outside cells can impair a number of 
cell functions that ultimately lead to cell death by an apoptotic mechanism. Recent 
research suggests, however, that in most cases initial perturbations to fundamental 
cellular processes underlie the impairment of cell function induced by aggregates 
(Stefani and Dobson, 2003). 
1.1.3.1 Biological surfaces as primary sites of amyloid aggregation, interaction 
and toxicity 
Peptides and proteins can interact with, and be actively recruited by, inorganic, 
synthetic, or biological surfaces, in particular membranes (Bokvist et al., 2004), but 
also macromolecules (Bravo et al., 2008; Cherny et al., 2004; Relini et al., 2006; Suk 
et al., 2006), thus modifying their conformational states, resulting in non-native, ag-
gregation-prone conformations. Such a view has led to the proposal that surfaces can 
catalyse amyloid aggregate nucleation and growth by a mechanism substantially dif-
ferent from that observed in the bulk solution (reviewed in Sethuraman and Belfort, 
2005; Stefani, 2007; Stefani, 2010b). Surfaces, apart from populating aggregation-
prone conformers possibly different from those arising in solution, can also strongly 
increase the local concentration of the latter, thus speeding up aggregate nucleation, 
possibly accompanied by structural alterations of membrane integrity (Porat et al., 
2003). These considerations account for the increasing interest in the investigation 
of the physicochemical features of protein interaction with, and aggregation on, arti-
ficial or natural surfaces, even in relation to the structure and lipid composition of 
the latter. Apart from favouring protein misfolding and aggregation, synthetic and 
natural phospholipid bilayers can also be key interaction sites with prefibrillar ag-
gregates (reviewed in Stefani, 2007; Stefani, 2010b). In general, protein aggregation 
onto, or aggregate interaction with, cell membranes results in lipid extraction, loss of 
membrane integrity, derangement of selective permeability and impairment of spe-
cific membrane-bound protein function and signalling pathways (reviewed in 
Stefani, 2007; Stefani, 2010b). In the past, several cell surface proteins have been con-
sidered as possible candidate receptors of Aβ aggregates. These receptors could be 
specific for the shared cross-β fold rather than for any peculiar structural feature of 
the Aβ peptides although, in some cases, they could also be monomer-specific, as in 
the β-amyloid precursor protein (APP) or Abeta-TNFR1 (tumour-necrosis factor 
receptor-1) interactions proposed to be at the origin of Aβ cytotoxicity (He et al., 
2004; Shadek et al., 2006). Since 1996, the receptor for advanced glycation end prod-
ucts (RAGE) has been proposed as a major candidate as amyloid receptor (Yan et al., 
1996). RAGE is increased in systemic amyloidoses, is able to interact with amyloid 
assemblies made from serum amyloid A, amylin and prion-derived peptides (Yan et 
al., 2000) and appears involved in Alzheimer’s and Creutzfeldt-Jacob diseases (Sasa-
ki et al., 2002; Yan et al., 1998). In addition to RAGE, several cell surface proteins, 
including the cellular, non-infectious form of prion protein (PrPc) (Chen et al., 
2010; Lauren et al., 2009) voltage-gated (Hou et al., 2007) or ligand-gated calcium 






amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptors 
have also been considered as possible receptors or specific interaction sites for amy-
loids (De Felice et al., 2007; Pellistri et al., 2008). In addition, tissue-type plasmino-
gen activator (tPA) has also been proposed as a multi-ligand specific for the cross-β 
structure (Kranenburg et al., 2002). The presence of specific effects mediated 
through the preferential, or even specific, interaction with membrane proteins could, 
at least in part, explain the variable vulnerability to amyloids of different cell types 
(Cecchi et al., 2005). However, in spite of these and other data on specific interaction 
sites for amyloids, the tendency of early amyloid aggregates to interact with synthetic 
lipid membranes supports the idea that the interaction can be non-specific but, pos-
sibly, modulated by the membrane lipid content (Stefani, 2008). This is confirmed 
by the key well-known role of anionic surfaces (anionic phospholipid-rich lipo-
somes, glycosaminoglycans, nucleic acids, natural membranes) both as triggers of 
protein/peptide fibrillization and as potent inductors of β-sheet structures (reviewed 
in Stefani, 2007; Stefani, 2010b). It has been suggested that a shared fold in amyloid 
aggregates grown from different peptides and proteins could recognize, although 
with different efficiency, clusters of negative charges in cell membranes (Zhao et al., 
2004). In addition cholesterol and gangliosides could also play a role in modulating 
protein aggregation at, and aggregate interaction with, cell membranes. Actually, the 
biochemical and biophysical features of the cell membrane can affect the confor-
mation, distribution and proteolytic processing of membrane proteins involved in 
neurodegenerative conditions such as AD or prion disease; in addition, the pro-
tein/peptide interaction, with the cell surface is considered an important require-
ment for cytotoxicity (reviewed in Stefani, 2007; Stefani and Liguri, 2009; Waka-
bayashi and Matsuzaki, 2007). Overall, the data presently available support the idea 
that membrane cholesterol and gangliosides can modulate conformational changes 
and aggregation of specific protein/peptides (Wakabayashi and Matsuzaki, 2009), 
even though it may affect protein/peptide oligomerization into amyloids in several 
ways (reviewed in Stefani and Liguri, 2009). Conflicting results have indicated that 
cholesterol can either inhibit (Curtain et al., 2003) or promote (Qiu et al., 2009) 
Aβ40 penetration into model liposomes, depending on the molar ratio of cholesterol 
in the membrane. The enhanced binding of Aβ and acceleration of fibril formation 
with ganglioside-containing membranes has been reported by several studies (But-
terfield and Lashuel, 2010; Matsuzaki, 2007; Okada et al., 2007; Okada et al., 2008). 
In fact, ganglioside clusters have been proposed by Matsuzaki to form sites on the 
cell membrane that are designated for the sequestering of Aβ after cleavage from the 
APP and the seeding of its fibril formation (Fig. 5). The binding of Aβ to gangli-
oside-containing membranes induces a random-coil-to β-sheet transition, which 
then triggers fibril formation (Fig. 5) (Okada et al., 2007). 
 





Figure 5. Templating of Aβ-fibril formation on ganglioside clusters in lipid rafts. From (But-
terfield and Lashuel, 2010) 
1.1.3.2 Calcium homeostasis 
To explain the genesis of Ca2+ dysregulation in diseases associated to misfolding 
and aggregation of amyloid proteins, three main mechanisms have been postulated: 
the activation of pre-existing ion channels, the formation of calcium-permeable am-
yloid pores and the disruption of membrane lipid integrity (Fig. 6). 
Interaction with several Ca2+-permeable channels has been described for amy-
loid proteins, potentially leading to an intracellular Ca2+ rise. The glutamatergic sys-
tem has been thoroughly studied, on the basis of the role played by glutamate recep-
tors in the excitotoxic neuronal cell damage, whose over stimulation leads to exces-
sive intracellular Ca2+ rise (Choi, 1992). Several in vitro studies showed that incuba-
tion of neuronal cultures with Aβ oligomers increased Ca2+ influx through NMDA 
receptors. The moderate-affinity, uncompetitive NMDA receptor antagonist me-
mantine protects against Aβ oligomer toxicity by attenuating intracellular Ca2+ in-
crease (De Felice et al., 2007). Currently, memantine is the only approved treatment 
for AD, besides acetylcholinesterase inhibitors, although the therapeutic efficacy is 
limited (Mayeux, 2010). Interactions of Aβ with other Ca2+ permeable channels have 
been documented, such as voltage-gated Ca2+ channels (MacManus et al., 2000; 
Rovira et al., 2002) nicotinic acetylcholine (Dougherty et al., 2003; Liu and Zhao, 
2004; Mehta et al., 2009) catecholamine (Fu et al., 1998), serotonin and intracellular 
inositol trisphosphate (IP3Rs) receptors (Ju Yeon and Yeon Hee, 2005). A role for 
calcium-permeable channel has been described for other amyloid proteins. Ca2+ in-
flux via N-type voltage dependent Ca2+ channels has been described following α-
synuclein treatment in rat synaptosomes (Adamczyk and Strosznajder, 2006). Over 
activation of NMDA receptors, followed by an abnormal neuronal Ca2+ signaling, is 
believed to play a role in Huntington disease(HD) pathogenesis (Bezprozvanny and 








Figure 6. Schematic representation of the mechanisms proposed to explain Ca2+ dysregula-
tion in diseases associated to misfolding and aggregation of amyloid proteins. From (Demuro 
et al., 2010). 
 
Increasing evidence indicates that the toxicity of amyloid forming proteins is di-
rectly correlated with their shared ability to disrupt the membrane barrier function. 
Since 1993 it was proposed by Arispe and co-workers the “channel hypothesis” of 
amyloid toxicity: Aβ exhibits ion-channel activity in planar lipid bilayers led to early 
proposals that the toxicity of Aβ is based on an ion-channel mechanism that causes 
membrane depolarization, Ca2+ leakage, and a disruption of ionic homeostasis 
(Arispe et al., 1993; Lin et al., 2001; Pollard et al., 1995; Kagan et al., 2004). Channel 
activity was later reported for a number of other amyloidogenic proteins, including 
islet amyloid polypeptide (IAPP) (Mirzabekov et al., 1996), α-synuclein (Kim et al., 
2009, Volles and Lansbury, 2002), polyglutamine (Monoi et al., 2000), and prion-
derived peptides (Kourie et al., 2001). Thus, the toxicity of these proteins may be re-
lated to their shared capabilities to form channels or pores in membranes and to en-
able unregulated ion leakage in analogy to the mode of action of the pore-forming 
toxins, which permeabilize membranes forming oligomeric pores characterized by 
β-sheet structure (Kagan et al., 2004; Lashuel and Lansbury, 2006). Morphological 
studies at transmission electron microscopy (TEM) and AFM levels have shown that 
oligomers of many amyloid proteins, such as Aβ and α-synuclein (Volles et al., 
2001), serum amyloid A, amylin (Quist et al., 2005), and calcitonin (Diociaiuti et al., 
2006), have a characteristic annular morphology, reminiscent of cation permeable 
membrane pores (Kagan and Thundimadathil, 2010). Furthermore, TEM analysis 
has also revealed the presence of Aβ pore-like structures in the cell membrane of 
brains from AD patients but not from age-matched healthy patients (Inoue, 2008). 
Cells exposure to a wide range of oligomeric, but not fibrillary, amyloid proteins, in-




cluding Aβ, prion peptide, IAPP, polyglutamine, and lysozyme, induced increase in 
intracellular calcium. The increase could not be attributed to activation of endoge-
nous Ca2+ channels, because the responses were unaffected by the potent endoge-
nous Ca2+ channel blocker cobalt (Demuro et al., 2005).  
Recently, Sokolov et al. showed that purified preparations of Aβ oligomers, 
which stained positive with anti-oligomer antibodies, also caused a general increase 
in model bilayer conductivity in a concentration-dependent manner when added 
externally to the bilayer, without single-channel current jumps supportive of ion-
channel formation (Sokolov et al., 2006). These studies support a model in which 
amyloid oligomers bind to the membrane surface and disrupt lipid packing to cause 
membrane thinning and an increase in membrane leakiness without the formation 
of defined pores (Sokolov et al., 2006). The different hypotheses are not mutually ex-
clusive and can cooperate towards Ca2+ dysregulation. Recently, it has been pro-
posed that amyloid oligomers may act at two steps, separated in time, a first, very 
rapid step, where Ca2+ increases due to glutamate receptor stimulation by the oligo-
mers, followed by a second, delayed step, where oligomers permeabilize non specifi-
cally the cell membrane, possibly via the formation of amyloid pores (Malchiodi-
Albedi et al., 2011; Pellistri et al., 2008) 
1.1.3.3 Reactive oxygen species (ROS) and oxidative stress 
There is accumulating evidence that suggests a key role of oxidative stress in the 
pathophysiology of AD and in other age-related neurodegenerative disorders. Oxi-
dative stress is caused by an imbalance in the free radicals and antioxidant systems. 
Oxidative stress may cause lipid peroxidation, protein, DNA and RNA oxidation. A 
modification of the intracellular redox status in cells exposed to aggregates is associ-
ated with a sharp increase in the quantity of reactive oxygen species (ROS). In addi-
tion, changes have been observed in reactive nitrogen species, lipid peroxidation, de-
regulation of nitric oxide (NO) metabolism (Kourie, 2001), protein nitrosylation 
(Guentchev et al., 2000) and upregulation of heme oxygenase-1, a specific marker of 
oxidative stress (Choi et al., 2000). It is not clear why protein aggregation is fol-
lowed, even in vitro, by production of ROS. In the case of Aβ42, Met35, Gly29 and 
Gly33 have been suggested to be involved (Brunelle and Rauk, 2002); a role has also 
been proposed for metal ions such as Fe, Cu and Zn, for example, through the gen-
eration of hydroxide radicals from hydrogen peroxide (Tabner et al., 2002). An up-
regulation of the activity of hydrogen peroxide-producing membrane enzymes, such 
as plasma membrane nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH oxidase) and endoplasmic reticulum cytochrome P450 reductase, has also 
been reported in Aβ-induced neurotoxicity in microglia and in cortical neurons 
(Pappolla et al., 2001; Qin et al., 2002). More generally, intracellular oxidative stress 
could be related to some form of destabilisation of cell membranes by toxic species 
leading to a failure to regulate appropriately plasma membrane proteins such as re-
ceptors and ion pumps and/or to impairment of mitochondrial function (Mattson, 






this regard, a key factor in Aβ peptide neurotoxicity could be the opening of mito-
chondrial permeability transition pores by Ca2+ entry in neuronal mitochondria fol-
lowed by release of cytochrome c, a strong inducer of apoptosis (Moreira et al., 
2002). It has been suggested that intracellular ROS elevation following exposure to 
amyloid aggregates is a consequence of Ca2+ entry into cells followed by stimulation 
of oxidative metabolism aimed at providing the ATP needed to support the activity 
of membrane ion pumps involved in clearing excess Ca2+ (Squier, 2001). ROS eleva-
tion would in turn oxidise not only the proteins involved in ion transfer but also 
proteins such as calmodulin that when oxidised is unable to activate the Ca2+-
ATPase (Squier, 2001). The down-regulation of the Ca2+-ATPase activity would then 
reduce the need for ATP, and hence ATP synthesis and ROS production by oxida-
tive metabolism, leading to an increase in intracellular Ca2+ concentration (Squier, 
2001). The same could happen in old age, where the ATP levels tend to be lower re-
sulting in an energy deficiency. This hypothesis can explain the relationship between 
ROS, apoptosis, mitochondrial damage and intracellular free Ca2+ increase shown by 
cells exposed to toxic amyloid aggregates (Kawahara et al., 2000; Kourie and Henry, 
2002; Selkoe, 2001; Wyttenbach et al., 2001). Indeed, many studies have suggested a 
close relationship between Alzheimer’s, Parkinson’s and prion diseases and the 
dysregulation of calcium homeostasis. The increase in intracellular free Ca2+ levels is 
thought to be a consequence of the impairment of membrane permeability; the latter 
may be a consequence of the presence into the membrane of aspecific amyloid pores 
or may follow oxidative stress, membrane lipid peroxidation producing reactive 
alkenals such as 4-hydroxynonenal, and the chemical modification of membrane 
proteins acting as ion pumps (Butterfield et al., 2001; Varadarajan et al., 2000). 
1.1.4 Amyloid formation is an inherent property of polypeptide chains: function-
al amyloid and disease unreleated amyloid 
An increasing number of proteins with no link to protein deposition diseases has 
been found to form, under some conditions in vitro, fibrillar aggregates that have the 
morphological, structural, and tinctorial properties that allow them to be classified 
as amyloid fibrils (Chiti and Dobson, 2006; Stefani and Dobson, 2003). This finding 
has led to the idea that the ability to form the amyloid structure is an inherent or ge-
neric property of polypeptide chains, although the propensity to form such a struc-
ture can vary dramatically with sequence. This generic ability can increasingly be 
seen to have been exploited by living systems for specific purposes, as some organ-
isms have been found to convert, during their normal physiological life cycle, one or 
more of their endogenous proteins into amyloid fibrils that have functional rather 
than disease-associated properties. One particularly well-studied example of func-
tional amyloid is that of the proteinaceous fibrils formed from the protein curlin that 
are used by Escherichia Coli to colonize inert surfaces and mediate binding to host 
proteins. Consistent with the characteristics of other amyloid structures, these fibrils 
are 6–12 nm in diameter, possess extensive β-sheet structure, as revealed by circular 
dichroism (CD) spectroscopy, and bind to CR and ThT (Chapman et al., 2002). A 




second example involves the filamentous bacterium Streptomyces coelicolor that pro-
duces aerial hyphae, which allow its spores to be dispersed efficiently; a class of se-
creted proteins called chaplins has been identified in the hyphae of this organism 
with the ability to form amyloid fibrils that act cooperatively to bring about aerial 
development (Claessen et al., 2003). As well as these examples from bacteria, the 
formation of functional amyloid like structures has recently been observed in a 
mammalian system. The melanosomes, lysosome-related organelles that differen-
ziate in melanocytes to allow the epidermal production of the melanin pigment, are 
characterized by intralumenal fibrous striations upon which melanin granules form. 
This fibrous material, sharing significant analogies with amyloid fibrils, is assembled 
from the intra-lumenal domain of the membrane protein Pmel17 that is proteolyzed 
by a proprotein convertase (Berson et al., 2003). This result is a direct indication that 
even in higher organisms amyloid formation can be physiologically useful for specif-
ic and specialized biological functions, provided it is regulated and allowed to take 
place under highly controlled conditions. 
Until 1998 it was commonly believed that the ability to polymerize into ordered 
fibrillar aggregates of amyloid type was a shared property of the few proteins and 
peptides found aggregated in tissue in the various amyloid diseases possibly arising 
from some structural peculiarity. However, in 1998 it was found that two proteins, 
unrelated to any amyloid pathology, the SH3 domain from bovine phosphatidyl-
inositol-3’ –kinase (PI3-SH3) and fibronectin type III, were able to aggregate in vitro 
into fibrillar assemblies undistinguishable from the classical amyloid fibrils (Gujiar-
ro et al., 1998; Litvinovich et al., 1998). Amyloid aggregation could be achieved de-
liberately by a rational choice of solution conditions (Chiti et al., 1999; Chiti et al., 
2001). Since then a substantial number of similar studies have been reported (Chiti 
et al., 2001 and references therein). In each case aggregation of a full-length protein 
to form amyloid fibrils was found to require solution conditions (such as low pH, 
lack of specific ligands, high temperature, moderate concentrations of salts or co-
solvents such as trifluoroethanol) such that the native structure was partially or 
completely disrupted but under which interactions such as hydrogen-bonding were 
not completely inhibited. It was also found that many peptides, both fragments of 
natural proteins or artificially designed sequences, that were unable to fold to stable 
globular structures readily formed fibrils (Tjernberg et al., 2002). These results pro-
vided strong support for the suggestion that the ability to form amyloid fibrils is a 
generic property of peptides and proteins, and that the structures were the result of 
the inherent physico-chemical properties of the polypeptide main-chain rather than 
the specific interactions of side-chains. The tendency to aggregate arises from the 
primordial tendency of polypeptide chains to self-organize into polymeric assem-
blies stabilized by hydrogen bonds between parallel or anti-parallel polypeptide 
stretches in the β-strand conformation provided by the monomers. The resulting 
polymers display the ordered cross-β structure that characterizes the amyloid fold 
(reviewed in Stefani and Dobson, 2003). This does not imply that the side chains of 
the polypeptide chain are not important; rather, they determine the environmental 






considers natural proteins as a group of evolved amino acid polymers whose the 
amino acid sequences disfavour aggregation whilst favouring folding into compact 
states resulting mainly from the tertiary interactions among the side chains that 
shield the peptide backbone. Conversely, protein aggregation into amyloid, which is 
mainly stabilized by secondary interactions, is considered the expression of the in-
trinsic primordial tendency of the peptide backbone to give secondary intermolecu-
lar interactions between backbone groups (reviewed in Stefani and Dobson, 2003). 
1.2 HypF-N: model protein of amyloid aggregation unrelated to disease 
1.2.1 Function, structure and aggregation of HypF-N 
The N-terminal domain of the procariotic protein HypF is a peptide with no link 
to protein deposition diseases able to form, under various conditions in vitro, fibril-
lar aggregates characterized by the morphological, structural, and tinctorial proper-
ties tipical of the amyloid fibrils (Stefani and Dobson, 2003). HypF, a large protein of 
about 82 KDa that assists the folding of [NiFe]-hydrogenases, key enzymes in the 
hydrogen metabolism of prokaryotes (Colbeau et al., 1998). In their fully functional 
forms, the iron atoms of the active sites of these [NiFe]-hydrogenases are stabilized 
in the low oxidation state (Fe2+) by binding to the carbon monoxide (CO) and cya-
nide (CN-) ligands (Nicolet et al., 1999). Both molecules have been shown to origi-
nate from the processing of carbamoylphosphate (Paschos et al., 2001). Thus, the 
assembly of the complex hydrogenase system requires the coordinated action of dif-
ferent maturation and regulatory factors. Indeed, hydrogenase operons contain a 
number of accessory genes (HypA-F) encoding maturation and regulatory proteins, 
including the essential maturation factor HypF (Casalot and Rousset, 2001). E. coli, 
as any other prokaryote, expresses a HypF protein, that contains an N-terminal 
acylphosphatase-like domain (residues 1-91) (HypF-N) (Fig. 7).  
 
 
Figure 7. Three-dimensional structure of native HypF-N from X-ray crystallography. The red 
and blue colours indicate α-helices and β-strands, respectively. From (Marcon et al., 2005). 




The HypF-N displays sequence and structural homology with other members of 
the acylphosphatase-like structural family. Acylphosphatases (AcPs) are small en-
zymes specifically catalysing the hydrolysis of carboxyl-phosphate bonds in 
acylphosphates such as carbamoylphosphate, succinylsphosphate and 1,3-
bisphosphoglycerate (Stefani et al., 1997). Recent experiments shed light on the role 
of E. coli HypF in the conversion of carbamoylphosphate into CO and CN-, and on 
the coordination of these ligands to the assembled hydrogenase metal cluster 
(Reissmann et al., 2003). According to these results, HypF-N acts as a car-
bamoyltransferase that transfers the carbamoyl moiety of carbamoyladenylate to the 
C-terminal cysteine of the partner protein HypE, forming an enzyme-thiocarbamate. 
HypE dehydrates the S-carbamoyl moiety in an ATP-dependent process to yield the 
enzyme thiocyanate. Finally, the cyano group can be nucleophically transferred to an 
iron complex (Reissmann et al., 2003). The structure of HypF-N has been resolved 
by X-ray crystallography and is well defined for residues 5-91 (Fig. 7) (Rosano et al., 
2002).The domain has a ferredoxin-like fold, which consists in a α/β sandwich, with 
βαββαβ topology. Following the sequence identity with AcPs, it has been assigned 
to the acylphosphatase-like structural family. The five β-strands of the domain form 
a slightly twisted β-sheet (β4-β1-β3-β2-β5 strand arrangement), which faces on one 
side two α-helices; the other side is instead fully solvent-exposed. Overall, the do-
main has a size of about 43x28x27 Å. This compact globular state displays the main 
structural strategies exploited by all-β and α/β proteins to escape amyloid aggrega-
tion (Richardson and Richardson, 2002). HypF-N forms amyloid-like fibrils under 
conditions that promote its partial unfolding, such as in the presence of trifluoroeth-
anol (TFE) or following a decrease of pH. Formation of amyloid-like fibrils has been 
obtained initially at pH 5.5 with 30% (v/v) TFE or at pH 3.0 in citric acid (Chiti et 
al., 2001). The formation of a partially folded state is a key event in the aggregation 
pathway of this protein in vitro, even under mild destabilising conditions in which 
the folded state is by far the predominant species. Indeed, under mild denaturing 
conditions generated by moderate concentrations of TFE [6–12% (v/v)], the native 
state of HypF-N is in rapid equilibrium with a partially unfolded state, whose popu-
lation is about 1–2%; a kinetic analysis has shown that amyloid aggregation under 
these conditions arises from molecules accessing this amyloidogenic state (Campioni 
et al., 2010). Recently, new aggregation conditions for HypF-N, enabling the charac-
terization of the partially folded state populated prior undergoing aggregation, have 
been described, such as at pH 5.5 in the presence of 12% (v/v) TFE, or at pH 1.7 in 
the presence of salts (NaCl). A detailed structural investigation of this partially fold-
ed state has also been performed and achieved by means of different biophysical and 
biochemical techniques. (Canale et al., 2006). The resulting species have been im-
aged with tapping mode AFM, have been shown to increase the fluorescence of ThT, 
indicating the presence of intermolecular β-sheet structure typical of amyloid aggre-
gates. In general, the data obtained suggest that the aggregation process of this pro-
tein starts from a partially folded state that can be either fully populated or in rapid 
equilibrium with the native state when the latter is destabilized by mutations and/or 






pathway in which the native protein first converts into a partially folded state sepa-
rated from the native state by an energy barrier comparable to that of (un)folding. 
This monomeric state converts into globular small aggregates and small beaded fi-
brils that further associate into ring-like structures. Finally, the ring-like structures 
convert into ribbon-like fibrils that associate into fibrillar tangles (Relini et al., 2004). 
As many disease-involved systems aggregate following similar pathways, HypF-N 
represents a useful model system to determine the common principles underlying 
amyloid formation. 
1.2.2 HypF-N protofibrils interact with cell membranes originating a cytotoxic 
cascade 
It is increasingly suggested that the oligomers formed by proteins that are not re-
lated to any human disease can be toxic when added to the extracellular medium of 
cultured cells, whereas the same proteins in monomeric or fibrillar forms are not 
(Bucciantini et al., 2002). The observation that the oligomers formed from such a 
heterogeneous group of proteins impair cell viability suggests that these species 
share the ability to “misinteract” with the macromolecular components of living or-
ganisms, such as membranes and proteins, and interfere with their normal function. 
The early prefibrillar aggregates of HypF-N formed in 30% TFE were shown to be 
able to interact with, insert into, and eventually disassemble synthetic membranes 
and supported phospholipid bilayers (Canale et al., 2006; Relini et al., 2004). Moreo-
ver, these species can interact with the plasma membrane of cultured cells and be in-
ternalized inside the cytoplasm, resulting in cell impairment and death (Bucciantini 
et al., 2005; Cecchi et al., 2005). Recently, it was found that their interaction with cell 
membranes is disfavoured by a high membrane cholesterol content (Cecchi et al., 
2006; Cecchi et al., 2008a,b). Similarly to the protofibrillar aggregates of disease-
related proteins and peptides, treatment of the cells with HypF-N protofibrils leads 
to an increase of ROS and free Ca2+ levels inside the cells, which ultimately die by 
apoptosis or necrosis (Bucciantini et al., 2005; Cecchi et al., 2005). Moreover, the in-
crease of intracellular Ca2+ levels is associated with both the activation of plasma 
membrane receptors with Ca2+ channel activity, such as AMPA and NMDA, and un-
specific membrane permeabilization, with the former effect being more important at 
early times (Pellistri et al., 2008). The susceptibility of different cells to HypF-N ag-
gregates was shown to depend on their ability to counteract these early impairments, 
which increases during cell differentiation (Cecchi et al., 2005; Cecchi et al., 2008a). 
Remarkably, HypF-N protofibrils can also induce a loss of cholinergic neurons when 
injected into rat brains, demonstrating that these species can act as toxins even in 
higher organisms (Baglioni et al., 2006). These data strongly support the hypothesis 
that a common mechanism of cytotoxicity exists, which is related to the misfolded 
nature and oligomeric state of a protein rather than to its sequence. In spite of this 
advancement, a structural characterization of the conformational properties of the 
oligomers finalized to an understanding of the relationship with their toxic effect is 
still lacking, mainly due to the fact that the transient formation of these species and 




their structural heterogeneity have hampered considerably their investigation. The 
structural determinants of the protein oligomers that are responsible for cell dys-
function are starting, only these days, to be elucidated. Recently, the functional and 
structural properties of the spherical aggregates formed by HypF-N in two distinct 
environmental conditions can be compared. It is therefore nowadays essential to de-
termine in detail the structure of the toxic oligomeric species in order to identify 
new therapeutical targets, and to understand whether it represents a single common 
fold or rather exhibits some polymorphism. 
1.2.3 A causative link between the structure of HypF-N oligomers and their abil-
ity to cause cellular dysfunction 
It is well known that incubation of the same protein/peptide under different ex-
perimental conditions causes the formation of oligomers or fibrils with different 
morphologies and that such differences result in different degrees of toxicity (Kayed 
et al., 2009; Lee et al., 2007; Petkova et al., 2005). Similarly, mutations or covalent 
modifications result in different levels of oligomers or different fibrillar structures 
with completely different toxicities (Hung et al., 2008). However, little experimental 
information is available on the structural features of oligomers grown under differ-
ent conditions and on the relationship between their structure and their ability to 
cause cell dysfunction. Recently, it has been found that oligomers formed from the 
same protein (HypF-N) under different conditions (pH 5.5 in the presence of 
12%(v/v) TFE or pH 1.7 in the presence of 330 mM NaCl) exhibited similar mor-
phological and tinctorial properties, yet differed in their molecular structure. Com-
parisons of the two types of aggregates indicated that their structural differences re-
sulted from different degrees of packing of the hydrophobic residues within their 
cores with a consequent different level of structural flexibility and solvent-exposure 
of such residues (Campioni et al., 2010). Thus, whilst the ability to form amyloid-
like structures is generic to polypeptide chains, whether or not such species are 
pathogenic will depend on their structural features, notably the extent to which hy-
drophobic residues are flexible and exposed on their surfaces within the environ-
ment of a living organism. These findings, however, do not seem to be limited to the 
HypF-N aggregates, and could indeed explain the toxic properties of the oligomers 
formed by disease-related systems. In fact, several studies indicated a correlation be-
tween the size and surface hydrophobicity of Aβ40 aggregates and their ability to de-
crease the bilayer fluidity of model membranes (Kremer et al., 2000), suggesting that 
the exposure to the solvent of hydrophobic surfaces determines the ability of these 
species to interact with cell membranes. A correlation between hydrophobicity, ten-
dency to form aggregates and aggregate cytotoxicity has also been observed in com-
parative studies where the behavior of different homopolymeric amino acid (HPAA) 
stretches was investigated (Oma et al., 2005). It has been recently reported that ex-
panded huntingtin-exon1 forms fibrillar aggregates at two different temperatures 
that have different structural and physical properties as well as different cytotoxici-






gates are comparable with those extracted from regions of mouse brains affected to 
different extents by huntingtin deposition. In both pairs of structures a direct rela-
tionship between structural flexibility and cytotoxicity of amyloid assemblies was 
found, supporting the generality of previous conclusions (Petkova et al., 2005). Fi-
nally, all these data lend support to the idea that a key feature in the generation of 
toxicity is the conversion of a species of aggregates where stability is associated with 
extreme burial of hydrophobic residues to one where such residues are substantially 
exposed and disorganized (Cheon et al., 2007). Recently, it has been suggested that 
for therapeutic purposes the toxicity can be dramatically reduced if the hydrophobic 
residues are incorporated to a greater extent within the interior of the oligomeric as-
semblies, even in the absence of an effective change in morphology (Campioni et al., 
2010). Approaches of this type will facilitate the elucidation of the causative link be-
tween the molecular structure of aberrant protein oligomers and their ability to 
cause cell dysfunction, with the aim of understanding the pathogenesis of protein 
deposition diseases and identifying therapeutic strategies to combat them. Moreover, 
a detailed understanding of the forces that determine the structure of amyloid-like 
oligomers will also enable to identify the factors that can modulate it, and eventually 
alter the biological activities of these species.  
1.3 Alzheimer’s disease 
1.3.1 The Alzheimer phenotype 
AD is a complex disorder, representing the most common form of dementia 
among the elderly population and the fourth leading cause of death in Western 
countries. AD is characterized by a well defined neuropathological profile which in-
cludes intracellular neurofibrillary tangles (NFT), extracellular β-amyloid-
containing plaques, reduced synaptic density and neuronal loss in selected brain are-
as. NFT has been detected in distal dendrites as neuropil threads, and in the abnor-
mal neurites that are associated with some β-amyloid plaques (neuritic plaques). 
Their major proteinaceous component are abnormal filaments which are termed ei-
ther straight (SF) or paired helical filaments (PHF) (Crowther and Wischik, 1985; 
Wischik et al., 1985). The core protein of these filaments is tau, a microtubule-
associated protein (Goedert et al., 1988). In the course of the disease tau becomes 
abnormally phosphorylated, it adopts an altered conformation and is re-localized 
from axonal to somato-dendritic compartments. The most relevant protein kinases 
involved in tau modifications in neurofibrillary degeneration are GSK3β (Imahori 
and Uchida, 1997; Ishiguro et al., 1992; Takashima et al., 1993) and Cdk5 (Alvarez et 
al., 1999; Michel et al., 1998; Patrick et al., 1999; Tsai et al., 1994). Phosphorylation 
tends to dissociate tau from microtubules. Since this increases the soluble pool of tau 
it might be an important first step in the assembly of tau filaments (Buee et al., 2000; 
Chen et al., 2004; Goedert et al., 1995; Götz, 2001; Götz et al., 2004; Lee et al., 2001; 
Lichtenberg et al., 1988; Schweers et al., 1994). Physiological functions of tau include 
the assembly and stabilization of microtubules. Additional roles have been assigned 




to tau in signal transduction, organization of the actin cytoskeleton, intracellular 
vesicle transport, and anchoring of phosphatases and kinases (Anderton et al., 2000; 
De Ferrari and Inestrosa, 2000; Ebneth et al., 1998; Flanagan et al., 1997; Jenkins and 
Johnson, 1998; Lee and Rook, 1992; Maas et al., 2000; Morishima-Kawashima and 
Kosik, 1996; Reszka et al., 1995; Sontag et al., 1999). In adult human brain, six tau 
isoforms are produced by alternative mRNA splicing of exons 2, 3 and 10. All six 
brain tau isoforms are found in neurofibrillary lesions of AD brains (Goedert et al., 
1992). 
The other major lesion is the amyloid plaque. These are extracellular deposits of 
insoluble, 8–10-nm amyloid fibrils that are polymers of Aβ (Glenner and Wong, 
1984; Masters et al., 1985). There are two major varieties of Aβ plaques: neurit-
ic/cored and diffuse plaques. The natural evolution of plaque morphology appears to 
be from diffuse to mature cored plaques. Aβ is a naturally occurring peptide present 
in the brain and cerebrospinal fluid (CSF) of healthy individuals (Sjogren et al., 
2001). Whilst the etiology of AD still remains controversial, the most widely accept-
ed theory is the amyloid cascade hypothesis which has provided the intellectual 
foundation for many AD clinical trials (Masters et al., 2006). Although the hypothe-
sis continues to evolve, its core principle has remained essentially unaltered in that 
Aβ plays a central role in the etiology of AD. The theory entails that AD is a result of 
an imbalance between Aβ production and clearance. This affects Aβ stability or ag-
gregation and leads to its accumulation in the brain, which initiates a multistep cas-
cade, involving gliosis, inflammatory changes, excitotoxicity, formation of neurofi-
brillary tau tangles, oxidative stress, synaptic and neuronal dysfunction. This ulti-
mately results in the memory loss and impaired cognitive functions of dementia 
(Masters et al., 2006).  
1.3.2 The elaborate processing of APP 
Aβ is a 38–43-residue proteolytic fragment of APP (Kang et al., 1987) that is 
generated normally throughout life by virtually all mammalian cells (Haass et al., 
1992; Seubert et al., 1992; Shoji et al., 1992) (Fig. 8). APP is a ubiquitous Type I 
membrane glycoprotein that occurs as a heterogeneous group of polypeptides aris-
ing from alternative splicing, N- and O-linked glycosylation, phosphorylation, sul-
phation, glycosaminoglycan addition and complex proteolysis. The processing of 
APP takes place along the secretory pathway and in endosomes after endocytosis. 
APP can be cleaved, within the Aβ domain, by α-secretase, a member of the disinteg-
rin and metalloprotease (ADAM) family, leading to the release of the α-sAPP 
(Buxbaum et al., 1998; Koike et al., 1999; Postina et al., 2004). The resultant trans-
membranar C83 fragment is cleaved by γ-secretase, a transmembrane protein com-
plex that includes presenilin-1 (PS1) or presenilin-2 (PS2), nicastrin, anterior phar-
ynx-defective-1, and PS enhancer 2, originating the extracellular p3 and the APP in-
tracellular C-terminal domain (AICD) fragment (Fig. 8) (De Strooper, 2003). AICD 
can migrate to the nucleus leading to gene transcription and thus activating signal 






amyloidogenic pathway because it precludes the formation of Aβ. APP can also be 
processed through an amyloidogenic pathway, which involves the cleavage by β-
secretase, such as the β-site APP-cleaving enzyme (BACE, also known as memapsin 
2, a type I transmembrane aspartic protease) 1 (Repetto et al., 2004) or BACE2 (Far-
zan et al., 2000), originating the N-terminal soluble extracellular β-secretase-cleaved 
APP (β-sAPP) and the transmembranar C99 fragment. Cleavage of C99 by γ-
secretase results in generation of Aβ peptide and AICD. The APP cleavage by α- or 
β-secretases is a prerequisite for γ-secretase cleavage. Some studies show that α- and 
β-secretases may compete for APP substrate and, thus, increased activity of one 




Figure 8. Schematic representation of the amyloid precursor protein (APP) and its metabolic 
derivatives. (A) Diagram of APP showing a large extracellular domain and short intracellular 
segment. Cleavage of APP by either α- or β-secretases produces large soluble N-terminal 
fragments, α-APPs or β-APPs and 10 and 12 kDa membrane-bound C-terminal fragments, 
C83 and C99, respectively. Both C83 and C99 can be further cleaved by γ-secretase leading to 
the release and secretion of non-pathogenic p3 peptide or Aβ. (B) Amino acid sequence of Aβ 
showing the most common APP secretase cleavage sites, including sites for Aβ40 and Aβ42 
generation, as indicated by arrows. From (Fodero-Tavoletti et al., 2011). 
 
In normal cells, the non-amyloidogenic pathway predominates. γ-secretase can 
cleave APP successively beginning in amino acid 43 until amino acid 36 of Aβ pep-
tide; however, it stops the cleavage mainly at amino acid 42 or 40. In the amyloido-
genic pathway, Aβ with 40 amino acids is formed in higher quantity (about 90%) 
than Aβ isoform with 42 amino acids (about 10%). Furthermore, Aβ42 has a greater 
tendency to aggregate and is more toxic to neurons than Aβ40. However, for some 
authors, the sequence of amino acids 25 to 35 of Aβ (GSNKGAIIGLM) is the re-
sponsible for the toxicity of the native full length peptide (Kaneko et al., 2001), lead-
ing to increased rate of Aβ aggregation (Liu et al., 2004), induction of neuronal cell 




death (Resende et al., 2007), neuritic atrophy and synaptic loss (Grace et al., 2002), 
and inhibition of neurogenesis (Li and Zuo, 2005). 
1.3.3 The genetics of Alzheimer’s disease  
The familial form of Alzheimer’s disease (FAD) accounts for nearly 5–10% of all 
cases of AD and is characterized by early manifestations of dementia, in some cases 
in patients approximately 40 years of age (Rosenberg, 2000). Four genes that confer 
increased susceptibility to this disease have been unequivocally confirmed, and mu-
tations or polymorphisms in them either enhance Aβ production, or interfere with 
its clearance (Table II). 
 
 
Table II. The four confirmed genetic determinants of increased susceptibility for Alzheimer’s 
disease. From (Selkoe, 2007). 
 
The apolipoprotein E (ApoE) polymorphism is associated with late-onset AD in 
a significant proportion of cases (Corder et al., 1993; Poirier et al., 1993), and ap-
pears to promote the formation of insoluble Aβ oligomers and plaques (Holtzman et 
al., 2000). Missense mutations in the APP gene have been found in a small number 
of families with early-onset AD, and are associated with increased production of Aβ 
(Cai et al., 1993; Citron et al., 1994; Goate et al., 1991; Scheuner et al., 1996; Suzuki 
et al., 1996). Trisomy of chromosome 21, on which the APP gene is located, is also 
associated with an AD-like pathology (Wisniewski et al., 1985). The most aggressive 
forms of the disease, however, are associated with mutations in the PS1 and PS2 
genes, located on chromosomes 14 and 1, respectively (Levy-Lahad et al., 1995; Sher-
rington et al., 1995). Mutations of PS1 and PS2 are associated with increased pro-
duction of the most damaging form of the Aβ-protein, Aβ42. Increased production 
of Aβ42 is thought to be the critical change that initiates AD as it has been shown to 
be the initial constituent of plaques in AD and is thought to trigger conformational 
changes in other Aβ species rendering them prone to aggregation into plaques (Jar-
rett et al., 1993; Younkin, 1998). Plasma concentrations of Aβ42 were significantly 
elevated in subjects with familial AD-linked PS1 and PS2 mutations compared with 
controls, as well as in subjects with APP mutations, as were Aβ42 concentrations in 
fibroblast media from subjects with PS1 and PS2 mutations (Scheuner et al., 1996). 
Cellular production of Aβ42 was also significantly increased in hamster ovary cells 
transfected with mutant PS1 or PS2 (Xia et al., 1997). Finally, brain Aβ42 was in-
creased in mice that overexpress mutant PS1, but not those that overexpress wild-






came apparent when it was identified as the active site of the γ-secretase enzyme 
(Wolfe et al., 1999). Deletion of the PS1 gene in mice greatly reduces γ-secretase ac-
tivity (De Strooper et al., 1998), and mutation of either of two fully conserved in-
tramembrane aspartate residues in PS1 substantially reduces Aβ production (Wolfe 
et al., 1999).  
1.3.4 Peripheral cells as a tool to identify and test hypotheses on AD pathophysi-
ology 
The use of peripheral cells is based on the hypothesis that AD might be a system-
ic disease that affects several tissues in the body. The specific brain damage could be 
the expression of a greater sensitivity to injury in postmitotic cells of the brain. Fur-
thermore, a potential genetic defect underlying the disease may be manifest in sever-
al body tissues that express the gene involved. Peripheral tissues suitable for explor-
ing pathophysiological hypotheses and possibly for providing a useful biological 
marker for diagnosis of AD include skin fibroblasts, platelets, lymphocytes, as well as 
body fluids such as plasma or CSF (Gasparini et al., 1998). Among these tissues, cul-
tured skin fibroblasts have been successfully used to elucidate the molecular and bio-
chemical bases of many inborn errors of metabolism that cause neurological disease. 
Moreover, fibroblasts are an appropriate model for studies of those genetic diseases 
of the nervous system, including FAD, because they can be easily cultured, stored 
and contain the complete genomic information of the organism. Growth properties 
and in vitro aging of AD and control fibroblast cultures do not differ under standard 
conditions (Tesco et al., 1993), although this topic is still controversial. Since growth 
properties and biological age in culture can have profound effects on the properties 
of cells cultured from skin, including the expression of genes (which could be related 
to AD) (Adler et al., 1991), reproducible and interpretable results with the AD fibro-
blasts model require attention to the reproducibility of culture conditions including, 
but not limited to, matching AD and control cells for age, sex of the donors, and bio-
logical age in culture.  
Alzheimer’s disease diagnosis appears to be the major challenge posed by AD in 
its sporadic late-onset form, which still represents the vast majority of all cases. On 
the other hand, data obtained using fibroblasts from individuals with known gene 
defects, although representing only a small proportion of all AD cases, could be very 
informative about the cellular pathophysiology of AD. Fibroblast lines from FAD 
patients can therefore be classified according to the specific gene defect to see 
whether a particular genetic abnormality alters cellular function in a unique manner. 
Peripheral cells are therefore useful in identifying and testing hypotheses on the 
primary pathophysiological mechanisms leading to AD and for avoiding variables 
derived from a postmortem state. On the other hand, peripheral cells cannot be used 
to answer other clinically relevant questions that require an intact organism. Low or 
absent expression of neuronal proteins by peripheral cells cultured under standard 
conditions is an important limiting factor. In the study of AD and other neurological 
diseases, affecting either the central nervous system (CSN) and other tissues, periph-




eral cells are however a useful adjunct, providing the tools to study in vitro the dy-
namic alteration of metabolic processes that neuropathological examination indi-
cates might be targets of the disease (Gasparini et al., 1998). 
1.3.5 Adult neurogenesis and stem cell technology for AD 
Several evidence have demonstrated that, in adulthood, neurogenesis operates 
mainly in two areas of the mammalian CNS, in the anterior part of the subventricu-
lar zone (SVZ) along the lateral ventricles, and in the subgranular zone (SGZ) of the 
dentate gyrus (DG) of the hippocampus (Abrous et al. 2005; Colucci-D’Amato et al., 
2006; Taupin and Gage, 2002). In both areas, neurogenesis progresses as a complex 
multi-stage process, which starts with the proliferation of neural precursors residing 
in the SVZ and the SGZ (Abrous et al. 2005; Taupin and Gage, 2002). These areas 
(also known as neurogenic niches) contain multipotent neural stem cells (NSCs) 
(Seaberg and van der Kooy, 2002; Taupin and Gage, 2002). The NSCs that exhibit 
slow self-renewal produce neural progenitor cells (NPCs) with a faster dividing cell 
cycle, which ultimately differentiate into neurons or neuroglia; the differentiation 
process is regulated by numerous trophic factors (Abrous et al., 2005; Lois and Alva-
rez-Buylla, 1993; Seaberg and van der Kooy, 2002). Another important pool of neu-
ral precursor cells is represented by astrocytes residing in the germinal centres of the 
adult brain; these astrocytes retain the stem cell properties throughout the life span, 
and are involved in both neuro- and glio-genesis (Alvarez-Buylla et al., 2001; 
Doetsch et al., 1999; Gotz and Huttner, 2005; Mori et al., 2005). In addition, astro-
cytes appear to regulate the rate of proliferation of hippocampal stem cells, and fa-
vour the generation of new neurons (Song et al., 2002). Immature neurons generated 
in the SVZ migrate via the rostral migratory stream to the olfactory bulb, where they 
differentiate into local interneurons (Lledo and Gheusi, 2003) Although many thou-
sands of new neurons are generated in the SVZ and in the SGZ daily, only a minority 
of them survive and acquire adult neuronal properties (Abrous et al., 2005; Lois and 
Alvarez-Buylla, 1993; Seaberg and van der Kooy, 2002). These newly generated neu-
rons receive synaptic inputs, extend axons along the mossy fibres tract that pass 
through the hilus and exhibit electrophysiological properties similar to those of ma-
ture dentate granule cells (Levison and Goldman, 1993; Paterson et al., 1973). In ad-
dition, these newly generated neurons express the full complement of ionotropic and 
metabotropic membrane receptors (Kempermann and Gage, 1999). Incidentally, 
those cells may act as neuronal replacements after injury or disease (Brandt and 
Storch, 2008). From a functional point of view, CNS neurogenesis and, more specifi-
cally, hippocampal neurogenesis, play an important role in structural plasticity and 
network maintenance. Therefore, it is likely to contribute to information storage, as 
well as learning and memory processes (Abrous et al., 2005; Kempermann and Gage, 
1999; Levison and Goldman, 1993; Paterson et al., 1973). 
The hippocampus is affected early in AD. Therefore, the pathological process as-
sociated with AD is likely to impinge upon neurogenesis. Impaired neurogenesis, in 






nitive impairments linked with neurodegeneration (Chevallier et al., 2005; Haughey 
et al., 2002; Jin et al., 2004; Lopez-Toledano and Shelanski, 2007; Rodrıguez et al., 
2009; Verret et al., 2007; Zhao et al., 2008). Current treatment options for AD are 
centered on regulating neurotransmitter activity. Enhancing cholinergic function 
improves AD behavioral and cognitive defects (Lunn et al., 2011). Targeting the cho-
linergic system using stem cell therapies may provide environmental enrichment. 
Since that neurogenesis in the hippocampus decreases as we age and is exacerbated 
in AD (Drapeau and Nora Abrous, 2008; Shruster et al., 2010); therefore, cellular 
therapies that enhance neurogenesis or replace lost neurons may also delay the pro-
gression of AD. Enhancing brain-derived neurotrophic factor (BDNF) levels, which 
are decreased with age and in AD, promotes neurogenesis and protects neuronal 
function (Li et al., 1999). Rodent AD models receiving NPC grafts demonstrate in-
creased hippocampal synaptic density and increased cognitive function associated 
with local production of BDNF (Blurton-Jones et al., 2009). Similarly, BDNF up-
regulation along with NPC transplants also improves cell incorporation and func-
tional outcomes in an AD rat model (Xuan et al., 2008). Many studies have shown 
that bone marrow-derived mesenchymal stromal cells (MSCs) can be used for neural 
cell regeneration. MSCs are an alternative source of multipotent self-renewing cells 
and are derived from adult bone marrow. Naturally, they differentiate to produce 
osteoblasts, chondrocytes, and adipocytes; however, there is evidence that they can 
transdifferentiate to a neural lineage (Satija et al., 2009). MSCs provide an accessible 
alternative to embryonic stem (ES) cells and potentially circumvent the need for 
immunosuppression in cellular therapies because they are derived from an autolo-
gous source. Combining engineered growth factor overexpression with the benefits 
of stem cells integration into neural networks may provide an enhanced approach to 
treating AD. Furthermore, given the widespread neuronal loss involved in AD path-
ogenesis, targeting multiple systems simultaneously may be advantageous. 
1.4 Cholesterol and gangliosides in the central nervous system (CNS) 
1.4.1 Brain cholesterol metabolism 
Cholesterol is an essential component of the plasma membrane of all cells, where 
it increases membrane rigidity reducing lipid disorder; together with sphingolipids 
and gangliosides, is concentrated in detergent-resistant membrane fractions (lipid 
rafts) and plays key roles in neuronal development as well as in the maintenance of 
neuronal plasticity and function (reviewed in Ledesma and Dotti, 2006). The brain 
synthesizes essentially all of its cholesterol and does not appear to depend on the cir-
culating pool of the steroid; actually, the plasma lipoproteins do not cross the blood-
brain barrier (BBB) and do not deliver significant amounts of cholesterol to the CNS 
(Turley et al., 1996). Neuronal cells appear to synthesize cholesterol during devel-
opment, whereas mature neurons progressively lose such ability, getting cholesterol 
from glial cells, particularly astrocytes (Pfrieger, 2003; Poirier et al., 1993). The rate-
limiting step of cholesterol synthesis is the reaction catalyzed by 3-hydroxy-3-




methylglutarylCoA reductase (HMGCoAR), whose activity is controlled by the lev-
els of cholesterol itself. Thus HMGCoAR has been a good candidate for pharmaco-
logical treatment of hypercholesterolemia using statins, chemical analogues of cho-
lesterol. In the adult brain, the astrocytes not only synthesize, but also internalize 
and recycle the cholesterol released from degenerating nerve terminals to deliver it 
back to neurons (Jurevics and Morell, 1995); this activity requires cholesterol bind-
ing to one of the variants of ApoE, a major lipoprotein in the CNS (Mahley, 1988). 
ApoE is a ligand for cell surface lipoprotein receptors such as the LDLR (LDL-
receptor) and the LDLR-related proteins (LRP); ApoE also regulates lipid transport 
to neurons and clears cholesterol from the extracellular space (Poirier, 2003). The 
fusion with lysosomes of the internalized endosomes containing ApoE-cholesterol-
phospholipid complexes results in the intracellular release of cholesterol, with reduc-
tion of endogenous synthesis by HMGCoAR inhibition and storage upon fatty acid 
esterification by acylCoA:cholesterol acyltransferase (ACAT) (Poirier, 2003). The 
main product of brain cholesterol metabolism is the 24-hydroxy derivative (24SOH-
Chol) that is translocated to the circulating blood through the BBB which hinders 
the direct passage to the CNS of the blood cholesterol and limits the reverse passage 
of cholesterol from the CNS to the venous circulation. Since most of the circulating 
24SOH-Chol arises from brain cholesterol, its levels can be considered a measure of 
cholesterol turnover in the CNS (Kölsch et al., 2004). Finally, a fraction of brain cho-
lesterol could be translocated to the blood by transport systems involving ATP-
binding cassette membrane transport proteins such as ABCA1. 
1.4.2 Ganglioside metabolism 
Gangliosides are sialic acid-containing glycosphingolipids that are expressed in 
the outer leaflet of the plasma membrane of all vertebrate cells. Gangliosides are in-
volved in a variety of functions, including serving as antigens, receptors for bacterial 
toxins, mediators of cell adhesion, and mediators and modulators of signal transduc-
tion (Hakomori, 2003). About 200 gangliosides are known today, differing in their 
carbohydrate components (Yu et al., 2007). Gangliosides are most abundant in the 
nervous system. Their expression in the nervous system is cell specific and develop-
mentally regulated, and their quantities and species undergo dramatic changes dur-
ing differentiation of the cell (Ngamukote et al., 2007; Yanagisawa and Yu, 2007; Yu, 
1994). Gangliosides also play an important role in the pathogenic mechanisms of 
many immune-mediated neurological disorders, such as Guillain-Barre´ syndrome 
(Yu et al., 2006). GM1 ganglioside is present in endocytic organelles, in the trans-
Golgi network, and in the plasma membranes. More recently, it has been demon-
strated that GM1 ganglioside is also present in nuclear membranes, adding another 
interesting facet to the myriad biological functions of gangliosides (Ledeen and Wu, 
2007). In the plasma membrane, where the bulk of GM1 is deposited, GM1 is not 
distributed uniformly but is more concentrated in non-coated invaginations (Par-
ton, 1994). Gangliosides are also known to exist in clusters and to form microdo-






2000). This specific localization of gangliosides enables them to interact with a varie-
ty of bio-effectors, such as glycoproteins, antibodies, peptide hormones, and growth 
factors (Ariga et al., 2001; Yang et al., 1996). Furthermore, gangliosides can promote 
cell differentiation and induce neuritogenesis (Hakomori and Igarashi, 1995; Ledeen 
et al., 1998). Gangliosides are also known to provide a neuroprotective role in in vivo 
and in vitro models of neuronal injury (Hadjiconstantinou and Neff, 1998). The 
mechanisms of the neuroprotective effect of GM1 and related gangliosides, however, 
are still obscure (Sokolova et al., 2007). 
1.4.3 Lipid rafts 
Lipid rafts are dynamic highly ordered membrane microdomains enriched in 
cholesterol, gangliosides, particularly GM1, sphingolipids and saturated phospholip-
ids distinct from the surrounding bilayer of mostly unsaturated phospholipids. Bio-
chemically, lipid rafts are defined by their relative insolubility in non-ionic deter-
gents at low temperature, conferring upon them the alternative name, detergent-
resistant membranes (DRMs). Lipid rafts are particularly enriched in glycosyl-
phosphatidylinositol (GPI)-anchored and acylated proteins due to the preferential 
intercalation of the saturated acyl chains into the liquid-ordered environment (Si-
mons and Ikonen, 1997). Other proteins can also associate with lipid rafts either di-
rectly or through binding to other cofactors or ligands (Allen et al., 2007). The dy-
namic clustering and pinching off of lipid rafts regulates the spatial and temporal as-
sembly of signalling and trafficking molecules, forming short-lived but vital signal-
ling platforms (Allen et al., 2007). Lipid rafts are implicated in various essential cel-
lular functions, including signal transduction, cell adhesion and protein/lipid sorting 
(Lewis and Hooper, 2011). Of particular relevance are cell signalling, sorting and ax-
on guidance, as these processes are essential for neural development and synaptic 
plasticity (Guirland and Zheng, 2007; Kamiguchi, 2006). Indeed, lipid rafts serve to 
compartmentalise cellular processes by concentrating certain proteins and lipids 
within the same microenvironment serving as platforms regulating the induction of 
signaling pathways, owing to their ability to recruit or exclude specific lipids and 
proteins (Simons and Ikonen, 1997; Simons and Toomre, 2000). They are often 
thought to exert a positive effect by maintaining various signaling components (re-
ceptors, coupling factors, enzymes and substrates) in a restricted domain, thus in-
ducing a more rapid and efficient coupling. Lipid rafts play a more subtle regulatory 
role due to the fact that different signaling components can be localized in both the 
raft and non-raft parts of the membrane (Harder and Engelhardt, 2004; Pike, 2003). 
The fact that lipid microdomains are dynamic structures in which both lipids and 
proteins can move with different kinetics is essential for their role in signal transduc-
tion, but this dynamism has also made it exceedingly difficult to study their func-
tional presence in living cell membranes. Thus, controversy has arisen concerning 
their size and even their existence under steady-state conditions (resting cells) versus 
the activated state (Kenworthy et al., 2004). Crucially, neuronal lipid rafts are also 
required for the maintenance of dendritic spines and healthy synapses, which are vi-




tal for neural communication including learning and memory; processes which fail 
in AD (Hering et al., 2003). The observation that lipid rafts are much more abun-
dant in mature hippocampal neurons than in other cell types emphasises their phys-
iological importance within the memory centre of the healthy brain, and may ex-
plain why hippocampal neurons are a primary target for Aβ oligomer toxicity and 
destruction in AD (Malchiodi-Albedi et al., 2011). 
1.4.4 Role of cholesterol in AD 
In spite of the intense research carried out in recent times, the role of cholesterol 
as a risk factor for AD remains controversial (reviewed in Koudinov and Koudinova, 
2005; Puglielli et al., 2003; Shobab et al., 2004; Sjögren et al., 2006; Stefani and Liguri, 
2009). In the past 15 years, several epidemiological studies have stressed an associa-
tion between high plasma cholesterol, mainly in mid age, and increased susceptibil-
ity to sporadic late-onset AD (reviewed in Shobab et al., 2004). The lack of a direct 
effect of circulating cholesterol on AD risk is further supported by the notion that 
there is very little exchange between circulating and brain cholesterol thus question-
ing the importance of statins (inhibitor of the geranylgeranyl isoprenoids synthesis) 
able to cross the BBB (including atorvastatin, simvastatin and lovastatin) as possible 
drugs for AD therapy (reviewed in Ledesma and Dotti, 2005). The use of statins as 
possible pharmacological agents in the treatment of AD stems from retrospective 
clinical studies indicating that individuals chronically treated with these drugs dis-
play lower risk of developing late-onset AD (Zandi et al., 2005). However, recent 
studies do not support these conclusions (reviewed in Ledesma and Dotti, 2005; 
Shobab et al., 2004) and other prospective studies failed to show a beneficial effect of 
statins in AD treatment (MRC/BHF Heart Protection Study, 2002).  
The content of membrane cholesterol can modulate Aβ peptide production, ag-
gregation and clearance in various ways, particularly by affecting the stability of lipid 
rafts and other membrane domains where APP and some APP processing secretases 
are located, as well as the activity of raft associated proteins. In particular, the follow-
ing effects/actions have been highlighted: (i.) membrane cholesterol can affect the 
cellular localization and the activity of the APP and the secretases modulating APP 
processing through the amyloidogenic or the non-amyloidogenic pathway; (ii.) 
membrane cholesterol can affect the way Aβ peptides interact with the plasma 
membrane favouring or disfavouring aggregate nucleation; (iii.) membrane choles-
terol can hinder the interaction of Aβ oligomers with the cell membrane thus avoid-
ing their cytotoxic effects. 
1.4.4.1 Membrane cholesterol modulates Aβ production affecting the amyloido-
genic and the non-amyloidogenic pathways  
Lipid rafts harbour many membrane proteins including APP and some secre-
tases (Ehehalt et al., 2003; Kakio et al., 2003; Lee et al., 2003). The content of mem-






affect the way APP is processed by the α-, β-, and γ-secretases thus favouring the 
non-amyloidogenic or the amyloidogenic pathway, with increased or reduced 
Aβ40/42 production (Abad-Rodriguez et al., 2006; Crameri et al., 2006; Kojro et al., 
2001). The raft dependence of the generation of amyloidogenic derivatives of pro-
teins and peptides does not appear to be limited to APP and Aβ peptides. Actually, 
several lines of evidence support the idea that the pathological conversion of the cel-
lular prion protein (PrPc) to the infectious scrapie (PrPsc) form of the prion protein 
occurs at the lipid rafts (Harris, 1999; Prusiner et al., 1998). However, conflicting da-
ta have been reported on the effect of membrane cholesterol on APP processing; two 
models have been proposed. The “high neuronal membrane cholesterol models of 
AD pathogenesis” postulates that two pools of APP do exist in the cells, one associ-
ated with membrane rafts and another out of rafts, where α-cleavage occurs, sug-
gesting that only the raft-localized APP processing results in Aβ generation (Ehehalt 
et al., 2003). Such a scenario would be favoured by high levels of brain cholesterol 
possibly associated with the ApoE4 phenotype or during lipid rafts co-clustering in 
the endocitotic process (Fig. 9A). Several data indicate that in peripheral and neu-
ronal cell lines low membrane cholesterol and increased membrane fluidity stimu-
late the non-amyloidogenic pathway (α/γ-secretase cleavage); this could result from 
reduced activity of BACE, the enzyme starting the amyloidogenic pathway, and from 
increased α-secretase activity and APP content in the cell membrane, where it can 
undergo α-secretase cleavage (Kojro et al., 2001). Moreover, in the hippocampus of 
both humans and transgenic mice only a very moderate amount of APP and BACE 
is found in the same membrane environment; these co-localized APP and BACE 
fractions increase markedly in AD patients and in rodents with a moderate reduc-
tion of brain cholesterol (Abad-Rodriguez et al., 2004).  
 
 
Figure 9. The high (A) and low (B) neuronal membrane cholesterol models of AD pathogene-
sis. The high cholesterol model assumes that low neuronal membrane cholesterol is protec-
tive against AD. In fact, high membrane cholesterol would result in increased lipid raft co-
clustering and APP-BACE co-localization thus favouring the amyloidogenic pathway of APP 




processing with increased Aβ production. On the contrary, the low membrane cholesterol 
model envisages a protective role of relatively high amounts of membrane cholesterol assum-
ing that APP is located in non-raft membrane domains. High membrane cholesterol would 
maintain APP and BACE separated into different membrane domains thus reducing Aβ gen-
eration. Under low cholesterol conditions, following lipid raft disassembly BACE would 
translocate to non raft domains thus favouring its association with APP and starting the amy-
loidogenic pathway of APP processing. Under these conditions, the production of Aβ pep-
tides would be further increased by the reduced activation of plasminogen to plasmin, a raft-
associated event From (Stefani and Liguri, 2009).  
The opposite “low neuronal membrane cholesterol models of AD pathogenesis” 
claims that BACE, but not APP, is localized in lipid rafts (Abad-Rodriguez et al., 
2004). As a consequence, a moderate loss of membrane cholesterol would result in 
raft disassembly and increased BACE-APP co-localization in non-raft membrane 
domains, with increased β-cleavage (Fig. 9B). The protective effect of cell cholesterol 
against Aβ production and cytotoxicity is convincingly confirmed by more recent 
investigations on the relation between Seladin-1 (DHCR24, 3-β-hydroxysterol delta-
24-reductase, which catalyzes the reduction of the Δ24 double bond in desmosterol 
to produce cholesterol), cholesterol levels and Aβ generation in neuronal cells. In-
deed, the beneficial effect of increased cholesterol following Seladin-1 over expres-
sion has recently been reported in a study showing that cultured cells enriched in 
membrane cholesterol by Seladin-1 over expression display reduced ability to bind 
externally supplied Aβ oligomers with increased resistance to their cytotoxic effects, 
whereas the opposite was seen in the same cells made poor in cholesterol following 
treatment with the Seladin-1 inhibitor desmosterol (Cecchi et al., 2008b). These da-
ta, together with those indicating a specific down-regulation of Seladin-1 (Greeve et 
al., 2000) and a reduced level of cholesterol in the brains of AD patients (Mason et 
al., 1992), establish a role of this enzyme in lipid raft formation, modulation of APP 
processing, Aβ generation and clearance, and cell resistance to Aβ oligomer cytotox-
icity.  
1.4.4.2 Membrane cholesterol modulates Aβ aggregation 
In solution, Aβ peptides display a substantially unfolded conformation with re-
duced content of secondary structure; however, the latter increases considerably in 
phospholipid vesicles particularly when enriched in cholesterol thus underscoring 
the role of membranes in modulating peptide structure and aggregation (Choo-
Smith et al., 1997; Ji et al., 2002). Actually, structural perturbations may be expected 
to occur in proteins/peptides following their interaction with membranes thus en-
hancing their rate of fibrillization (reviewed in McLaurin et al., 2000). Therefore, it is 
not surprising that membrane lipid composition affects remarkably the effect of a 
membrane on a protein/peptide structure and aggregation propensity. The ability of 
Aβ peptides to insert into the membrane seems to depend on the membrane choles-
terol:phospholipids ratio. In synthetic, low cholesterol dimyristoylphosphatidylcho-






an aggregation-prone β-structure; on the contrary, in the same vesicles containing 
33% cholesterol the C-terminal tail of the peptide inserts into the membrane with an 
altered, α-helix rich structure that hinders peptide aggregation (Ji et al., 2002). These 
data support the idea that the content in cholesterol affects the way Aβ peptides in-
teract with the phospholipid bilayer and their ability to insert in the latter, modulat-
ing its aggregation into fibrillar assemblies. 
1.4.4.3 Membrane cholesterol modulates Aβ cytotoxicity 
Aβ oligomer toxicity has been associated basically with the ability of these as-
semblies to interact with the cell membranes. Such an interaction results in loss of 
membrane integrity, derangement of selective ion permeability and impairment of 
specific membrane-bound protein function (De Felice et al., 2007; Kourie and Hen-
ry, 2002; Mattson, 1999; Resende et al., 2007), and appears modulated by the content 
of cholesterol in the membrane, increasing in cholesterol-poor membranes and vice 
versa (Cecchi et al., 2005; Cecchi et al., 2008c, Pensalfini et al., 2011). Actually, many 
data support the idea that Aβ oligomer cytotoxicity following association with the 
cell membrane depends on membrane physical features including fluidity, compact-
ness, curvature and others, resulting from lipid composition. Since differing cell 
types display different average membrane lipid composition, for example in terms of 
cholesterol or ganglioside content, this could contribute to explain the variable sus-
ceptibility to the same toxic oligomeric species of varying cell types in culture and in 
tissue, or of the same cells in different differentiation stages or cell cycle phases (Cec-
chi et al., 2005; Cecchi et al., 2008c). Membrane cholesterol can modulate aggregate-
cell interaction by affecting the physical state of the rafts harbouring for example 
glutamatergic calcium channels such as the AMPA and NMDA receptors, which 
have been suggested to act a binding site for Aβ oligomers (De Felice et al., 2007; 
Resende et al., 2007).  
1.4.5 Role of gangliosides in AD 
In brain cells, ganglioside and lipid abnormalities, in addition to pathogenic Aβ 
production, may contribute to the pathological conditions found in AD (Mutoh et 
al., 2006). Several earlier studies showed alterations in ganglioside metabolism in AD 
brain (Kalanj et al., 1991; Kracun et al., 1992; Svennerholm and Gottfries, 1994). 
This is manifested as reductions in gangliosides in the majority of brain regions, in-
cluding the cerebral cortex, hippocampus, basal telencephalon, and frontal white 
matter, and especially in the frontal cortex and white matter (Kalanj et al., 1991). 
The pattern of ganglioside alterations in AD differs according to age of onset (Ariga 
et al., 2008). A fundamental question concerning the pathogenic mechanism of AD 
is how non toxic Aβ is converted to its toxic aggregates in the brain (Yanagisawa, 
2007). Yanagisawa et al. (Yanagisawa et al., 1995) found that GM1 ganglioside 
bound to Aβ42, to form a complex termed “GAβ” in AD brains. GAβ has unique 
characteristics, including an extremely high aggregation potential and an altered pat-




tern of immunoreactivity, which results in seeding for amyloid fibril formation in 
brains. The formation of GAβ serves as one of the critical factors in the development 
of AD and may provide new insights into its pathophysiology (Yanagisawa, 2007) 
(Fig. 10).  
 
 
Figure 10. Interactions of gangliosides and amyloid β-proteins in lipid rafts. Form (Ariga et 
al., 2008). 
 
In addition, several evidence confirmed that Aβ binds to membranes containing 
ganglioside GM1, and upon binding, undergoes a conformational transition from 
random coil to an ordered structure rich in β-sheet. This interaction appears to be 
ganglioside specific because no changes in Aβ40 conformation were found in the 
presence of various phospholipids or sphingomyelin. The peptide binds selectively 
to membranes containing gangliosides with a binding affinity ranging from 10-6 to 
10-7 M, depending on the type of the ganglioside sugar moiety (Choo-Smith et al., 
1997; McLaurin and Chakrabartty, 1996; Terzi et al., 1995).	  Thus, favourable interac-
tions between Aβ and GM1 in the cell membrane provide a mechanism for Aβ fibril-
logenesis in vivo, and Aβ-induced disruption of the cell membrane may provide a 
pathway by which Aβ exerts toxicity (Chi et al., 2007). Indeed, surface-associated, β-
sheet-rich, peptide micro-aggregates could then act as a specific template (“seed”) to 
recruit additional peptide molecules from solution and promote fibril formation by a 
β-sheet augmentation mechanism (Choo-Smith et al., 1997) (Fig. 10). Aβ aggrega-
tion in brain is accelerated through an increase in the level of GM1 in neuronal 
membranes (Yamamoto et al., 2004). Further studies have demonstrated that GM1 
and trisialoganglioside GT1b promote the aggregation and cytotoxicity of Aβ40, and 
these gangliosides, especially GM1, catalyze the formation of neurotoxic fibrils 
(Okada et al., 2007). This effect is dose dependent. Using surface plasmon resonance 






the following order of binding strength: GQ1bα > GT1aα > GQ1b > GT1b > GD3 > 
GD1a = GD1b >LM1 >GM1 >GM2 =GM3 >GM4 (Ariga et al., 2001). The gangli-
oside sugar moiety, specifically the sialic acid, plays an important role in the Aβ-
gangliosides interaction. The sialic acid residue of the ganglioside head-group is im-
portant for determining the nature of the conformational change in Aβ peptides fol-
lowing its binding to ganglioside (Mandal and Pettegrew, 2004; Williamson et al., 
2006). 
Gangliosides are enriched in the lipid rafts of brains of AD patients (Molander-
Melin et al., 2005). It has been reported the presence of gangliosides in DRMs isolat-
ed from 10 AD and 10 age-matched control brains. DRMs from the frontal and tem-
poral cortices of AD brains contained a significantly higher concentration of gangli-
osides GM1 and GM2 (Molander-Melin et al., 2005). The DRMs derived from tem-
poral cortex of AD patients were depleted of cholesterol compared with control sub-
jects. However, it has been reported that seeding formation is facilitated by choles-
terol; Aβ binding to GM1 is markedly accelerated in a cholesterol-rich environment 
at lipid rafts level (Kakio et al., 2001; Mizuno et al., 1999). According some research-
ers, increases in intramembrane cholesterol content, which are likely to occur during 
aging, appear to be a risk factor for amyloid fibril formation (Kakio et al., 2001). Li-
pid rafts containing ganglioside clusters may serve as a conformational catalyst to 
generate a membrane-active form of Aβ with seeding ability rather than providing a 
specific binding site for the protein (Kakio et al., 2003). 
Administration of GM1 have been used to inhibit progression of AD, but this 
treatment is still at an experimental stage, as are efforts to prevent the formation of 
amyloid plaques (Gottfries, 1994). In vivo GM1 administration may reduce or pre-
vent brain amyloidosis (Matsuoka et al., 2003). This anti-amyloidogenic effect could 
be attributed to a “peripheral sink” effect, i.e., that GM1-bound Aβ alters cen-
tral/peripheral dynamics, drawing Aβ out of the brain. In addition, GM1-bound Aβ 
in the blood is no longer available to BBB and incorporate into plaques centrally. 
Thus, peripheral administration of GM1 may be effective in reducing amyloid ag-
gregation in AD. A potential difficulty, however, in tapping the neuroprotective ef-
fects of GM1 is the low level of gangliosides that can enter into the brain. In this re-
gard, it has been reported that only 1% of peripherally administered GM1 crosses the 
BBB to enter the brain (Saulino and Schengrund, 1994). Exogenous GM1 treatment 
has also been used to treat symptoms of Parkinson’s disease, in both human and an-
imal models (Fazzini et al., 1990; Pope-Coleman et al., 2000; Rothblat and Scneider, 
1999; Schneider et al., 1992). In addition, it has been developed a novel monoclonal 
antibody raised against purified GAβ from AD brain, which substantially inhibits in 
vitro Aβ assembly (Hayashi et al., 2004). These findings add a new dimension to the 
development of novel therapeutic strategies by targeting seeded Aβ in the brain, 
which selectively inhibits the initial step of the pathological process of AD (Kimura 
and Yanagisawa,2007; Yanagisawa, 2007). Recent studies suggest that Aβ aggrega-
tion occurs in lipid rafts mediated by a cluster of GM1 (Yuyama et al., 2006). Inter-
estingly, rifampicin and nordihydroguaiaretic acid have been shown to inhibit bind-
ing of Aβ to GM1 liposomes by competitively binding to the membranes and/or di-




rect interaction with Aβ in solution, thus at least partly preventing fibrils from form-
ing. These small compounds can therefore be utilized for therapeutics. With the 
finding that GAβ has a conformation distinct from that of soluble Aβ, it may be pos-
sible to develop a novel therapeutic strategy to specifically inhibit the initiation of 
oligomerization polymerization of Aβ in the brain (Hayashi et al., 2004; Yamamoto 
et al., 2005). 
1.5 Aim of the study 
Increasing evidence supports the idea that the initial events of Aβ oligomeriza-
tion and cytotoxicity in Alzheimer’s disease involve the interaction of amyloid Aβ-
derived diffusible ligands (ADDLs) with the cell membrane. This also indicates lipid 
rafts, ordered membrane microdomains enriched in cholesterol, sphingolipids and 
gangliosides, as likely primary interaction sites of ADDLs. To shed further light on 
the relation between ADDL-cell membrane interaction and oligomer cytotoxicity, 
we investigated the dependence of ADDLs binding to lipid rafts on membrane cho-
lesterol content in human SH-SY5Y neuroblastoma cells (Results I). Confocal laser 
and contact mode atomic force microscope analyses, anisotropy fluorescence meas-
urements suggest that cholesterol reduces amyloid-induced membrane modifica-
tions at the lipid raft level by altering raft physicochemical features. 
These results were also confirmed in primary fibroblasts from FAD bearing APP 
Val717Ile, PS1 Leu392Val or PS1 Met146Leu gene mutations (Results II). In addi-
tion, Aβ has been found to be tightly associated with GM1 and it was originally pos-
tulated that this interaction might act as a seed for Aβ accumulation and aggrega-
tion. However, no clear mechanistic evidence regarding the relationship between li-
pid raft content and amyloid toxicity is currently available. In this regards the modu-
lation of specific raft physicochemical properties, such as mild depletion of GM1 
content and interference with GM1 exposure or negative charge, was tested analyz-
ing the interaction of amyloid aggregates with the plasma membrane and the result-
ing cell damage in FAD fibroblasts and in primary cortical neurons from rat brains 
(Results II). These findings suggest a specific role for raft domains, as primary medi-
ators of amyloid toxicity in AD neurons. 
In view of the undoubted importance of the structural features of amyloid oli-
gomers in determining their pivotal role as major cytotoxic species, several recently 
reported studies have tried to assess the oligomer structure-toxicity relationship by 
focusing on features of the oligomers, including stability and exposure of hydropho-
bic surfaces. In particular, it has been recently published that two types of stable oli-
gomers generated from the small prokaryotic protein HypF-N under different desta-
bilising conditions differ significantly in their sub-microscopic structural properties 
and cytotoxicities, though displaying similar morphological and tinctorial proper-
ties. To study the relationship between the physicochemical properties of the protein 
aggregates and physicochemical features of the cell membranes with which the oli-
gomers interact, membrane cholesterol and GM1 content has been modulated in 






HypF-N. The results, confirmed using oligomers formed by Aβ peptide associated 
with Alzheimer’s disease, reveal that toxicity is not inherent to protein oligomers on-
ly, but results from a complex interplay between the structural and physicochemical 
features of both the oligomers and the cell membrane (Results III). 
Cell therapy is a promising approach for the treatment of neurodegenerative 
conditions such as Alzheimer’s and Parkinson’s diseases. However, the presence of 
toxic aggregates in tissue raises the question of whether grafted stem cells are suscep-
tible to amyloid toxicity before they differentiate into mature neurons. To address 
this question, we investigated the relative vulnerability of human mesenchymal 
stromal cells and their neuronally differentiated counterparts to Aβ42 oligomers and 
whether susceptibility correlates with membrane GM1 content, a key player in oli-
gomer toxicity. We found that our cell model was highly susceptible to aggregate 
toxicity, whereas neuronal differentiation induced resistance to amyloid species (Re-
sults IV). This data correlated well with the content of membrane GM1, levels of 
which decreased considerably in differentiated cells. These findings extend our 
knowledge of stem cell vulnerability to amyloid species, which remains a controver-
sial issue, and confirm that amyloid-GM1 interactions play an important role in cell 
impairment. 
  








All reagents were of analytical grade or the highest purity available. Media and 
sera for cell cultures, except from those for mesenchymal stromal cells (hMSC) 
cultures (Euroclone; Wetherby, West York, UK) and primary cultured cortical 
neurons (Life Technologies; Milan, Italy) were purchased from Sigma (Milan, Ita-
ly). Tissue plastic-ware was obtained from Steroglass (Perugia, Italy). 1,2-bis(2-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid acetoxymethylester (BAPTA-
AM), 1,6-diphenyl-1,3,5-hexatriene (DPH), dimethylsulfoxide (DMSO), disialo-
ganglioside (GD1a), fetal bovine serum (FBS), filipin III, hexafluoro-2-isopropanol 
(HFIP), methyl-β-cyclodextrin (β-CD), mevastatin (Mev), monosialotetrahexosyl-
ganglioside (GM1), neuroaminidases (NAA), phosphate buffered saline (PBS), 
pluronic acid F-127, polyoxyetanyl-cholesteryl sebacate (PEG-cholesterol), 
trisialoganglioside (GT1b), vitamin E (Vit E), water-soluble cholesterol balanced 
with methyl-β-cyclodextrin (40 mg of cholesterol per gram of β-CD-Chol) (Chol) 
and other chemicals were from Sigma (Milan, Italy). D-Threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) was obtained from Matreya 
LLC (PA, USA). 
2.1.2 Fluorescent probes 
2’,7’-dichlorodihydrofluorescein diacetate (CM-H2DCFDA), 4,4-difluoro-3a,4a-
diaza-s-indacene (BODIPY) 581/591 C11, Alexa Fluor 647-and 555-conjugated chol-
era toxin subunit B (CTX-B), Alexa Fluor 633- and fluorescein- conjugated wheat 
germ agglutinin (WGA), calcein acetoxymethyl ester (calcein-AM), fluo3 ace-
toxymethyl ester (fluo3-AM), N-(3-triethylammoniumpropyl)-4-(6-(4-
(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM4-64) were from Mo-
lecular Probes (Eugene, OR). CM-H2DCFDA, BODIPY, calcein-AM, Fluo3-AM and 
FM4-64 were prepared as stock solutions in DMSO, dried under N2 and stored in 
light-protected vessels at −20 °C until use. 
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2.1.3 Peptides and aggregation protocols 
Aβ42 and Aβ42-1 reverse peptides (as trifluoroacetate salts) were purchased 
from Sigma (Milan, Italy) and from Bachem (Bübendorf, Switzerland), respectively; 
Aβ42 amine-reactive succinimidyl esters of carboxyfluorescein (Aβ42-FAM) was 
from AnaSpec (San Jose, CA, USA). Lyophilized Aβ42, Aβ42-FAM and Aβ42-1 were 
initially incubated 1.0 mM in HFIP at least for 1 h at room temperature to allow 
complete peptide monomerization. Then, aliquots of peptide solutions were dried 
under N2 and stored at −80 °C. Prefibrillar aggregates of the Aβ42 peptide were ob-
tained according to Lambert’s protocol (Lambert et al., 2001). Briefly, aliquots of 
Aβ42 were dissolved in DMSO to a final concentration of 5.0 mM, incubated in ice-
cold F12 medium to a concentration of 100 µM at 4 °C for 24 h and then centrifuged 
at 14,000 x g for 10 min to remove insoluble structures. The supernatant, defined as 
the amyloid β-derived diffusible ligand (ADDL) preparation, consisted of a fibril-
free solution of globular assemblies, as assessed by AFM (Cecchi et al., 2009). Fluo-
rescein-labeled Aβ42-FAM aggregates were prepared as described above, except that 
the aggregation mixture contained a combination of Aβ42-FAM peptide with 2 mo-
lar equivalents of unlabeled Aβ42 peptide (at a 1:2 ratio) to minimize possible inter-
ference of the fluorophore with the aggregation, while retaining sufficient fluores-
cence signal (Simakova and Arispe, 2007). For fibrillar conditions, 10 mM HCl was 
added to bring the peptide to a final concentration of 100 µM, and the peptide was 
incubated for 24 h at 37 °C (Dahlgren et al., 2002).  
HypF-N protein, expressed and purified as previously reported (Marcon et al., 
2005), was converted into stable oligomers by incubation to 48 μM for 4 h at 25 °C in 
two different experimental conditions: 50 mM acetate buffer, 12% (v/v) trifluoroeth-
anol (TFE), 2 mM dithiothreitol (DTT), pH 5.5 (condition A) and 20 mM trifluoro-
acetic acid (TFA), 330 mM NaCl, pH 1.7 (condition B) (Campioni et al., 2010). Both 
types of HypF-N oligomers were centrifuged at 16,100 x g, dried under N2 to remove 
the TFE and TFA when necessary, dissolved in the appropriate culture media at 48 
µM concentration and immediately added to cultured cells at 12 µM final concentra-
tions. Native HypF-N was tested by diluting the protein stock solution in the same 
cell media. Tapping-mode AFM revealed the presence of spherical bead-like aggre-
gates with heights in the range of 2-6 nm and 2-7 nm under conditions A and B, re-
spectively (Campioni et al., 2010). For the internalization experiment, monomeric 
HypF-N was labelled with fluorescein-5-isothiocyanate (5-FITC) using AnaTagTM 
5-FITC Microscale Protein Labeling Kit (AnaSpec, San Jose, CA, USA) and then 
converted into oligomers. These oligomeric species did not re-solubilize when 
placed under physiological conditions, as indicated by the preservation of their abil-
ity to bind ThT (Campioni et al., 2010). Moreover, neither type of oligomer under-
went any detectable structural reorganization following re-suspension in cell culture 
medium (Campioni et al., 2010). 
Prion protein fragment 106-126 (PrP 106-126), as a trifluoroacetate salt, was 
purchased from Bachem. Lyophilized PrP 106-126 was dissolved 1.0 mM in HFIP 
and incubated for 10 min at room temperature. Aliquots of protein were ten-fold 




diluted, incubated for 15 min at room temperature and then centrifuged for 15 min 
at 14,000 × g. The supernatant were dried under N2 to eliminate HFIP. Samples were 
then heated for 30 min at 65 °C and stirred for 6 h at 22 °C to obtain soluble oligo-
mers (Demuro et al., 2005). 
2.2 Cell cultures 
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 Ham with 25 mM N-
2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) and NaHCO3 (1:1) 
supplemented with 10% FBS, 1.0% glutamine and 1.0% antibiotics. The cell culture 
was maintained in a 5.0% CO2 humidified atmosphere at 37 °C and grown until 80% 
confluence for a maximum of 20 passages. 
Fibroblasts were obtained from three patients belonging to Italian families bear-
ing the APP Val717Ile mutation (mean ± SD age = 53.3 ± 7.1 years) and from three 
patients belonging to other Italian families bearing the PS1 Leu392Val and 
Met146Leu mutations (mean ± SD age = 56.7 ± 8.6 years), respectively. They un-
derwent clinical assessment according to published guidelines and the AD diagnosis 
fulfilled the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-
IV) (American psychiatric association, 1994; The dementia study group of the italian 
neurological society, 2000). Primary fibroblasts were also obtained from three age-
matched healthy subjects (mean ± SD age = 49.7 ± 8.3 years), carrying neither APP 
or PS1 mutations nor diagnosis of neurological disorders. The local ethical commit-
tee approved the protocol and written consent was obtained from all subjects or, 
where appropriate, their caregivers. Skin biopsies of 3 mm punch were obtained 
from the volar side of the upper arm of FAD patients and healthy controls. The cells 
were grown in DMEM supplemented with 10% FBS, 1.0% glutamine and 1.0% anti-
biotics and harvested in T-25 flasks until confluence, 7 days after previous subcul-
ture (Pensalfini et al., 2011).\ All nine fibroblast lines were subjected to an equal 
number of passages (ranging from 10 to 18) and analyzed in three different experi-
ments before confluence. The release of endogenous Aβ42 into the cell culture me-
dia was quantified using an Aβ42 ELISA kit (Molecular Probes). 
Primary cortical neurons were obtained from embryonic day (ED)-17 Sprague-
Dawley rats (Harlan, Italy). The experimental procedure was in accordance with the 
standards set forth in the Guide for the care and use of laboratory animals (pub-
lished by the National Academy of Science, National Academy Press, Washington, 
DC, USA). The uteri were removed from the gravid rat under anesthesia. Cerebral 
cortices were dissociated in sterile Dulbecco’s PBS (D-PBS; Sigma), and neurons iso-
lated in the same medium containing trypsin (0.5% in sterile Dulbecco’s phosphate-
buffered saline) for 10 min at 37 °C. After centrifugation, dissociated neurons were 
re-suspended in neurobasal medium (NBM) supplemented with 2.0% B-27 and 0.5 
mmol/L glutamine, and then plated in poly-L-lysine-coated 24-well plates at a densi-
ty of approximately 4.5 x 104/well. Cultures were maintained in NBM at 37 °C in a 






Human mesenchymal stromal cells (hMSCs) were obtained from the iliac crest 
of healthy donor marrow aspirates, as previously reported (Benvenuti et al., 2006). 
Permission was obtained from all subjects and the protocol approved by the local 
ethical committee. Cells were cultured at 104 cells/cm2 in 100-mm dishes in DMEM 
supplemented with 50 μg/ml gentamycin and 10% FBS at 37 °C in a humidified at-
mosphere containing 95% air and 5.0% CO2. 
2.3 Methods 
2.3.1 Separation processes 
2.3.1.1 Cell lysis 
Total cell lysates were obtained from cells by three freeze–thaw cycles followed 
by 5 s ultrasonication in ice in 20 mM Tris–HCl buffer, pH 8.0, containing 1.0% Tri-
ton X-100, 137 mM NaCl, 10% glycerol, 6.0 M urea, 0.1 mM PMSF, 10 μg/ml 
leupeptin, 10 μg/ml aprotinin and by centrifugation at 14,000 × g for 10 min at 4 °C. 
Protein content was measured in cytosolic and nuclear fractions according to the 
colorimetric method of Bradford (Bradford, 1976). Briefly, the method involves the 
binding of Coomassie Brilliant Blue to protein and it is based on the observation that 
Coomassie Brilliant Blue exists in two different color forms, red and blue. The red 
form is converted to the blue form upon binding of the dye to protein. This binding 
causes a shift in the absorption maximum of the dye from 365 to 595 nm, and it is 
the increase in absorption at 595 nm which is monitored (Bradford, 1976). 
2.3.1.2 Membrane purification 
The cells were homogenized in PBS containing 9.0% sucrose with three freeze-
thaw cycles, 5 s sonication in ice and centrifugation at 700 × g for 10 min at 4 °C 
(Cecchi et al., 2008b). The membrane fractions were pelleted by a further superna-
tant centrifugation at 110,000 × g for 1 h at 4 °C. Protein content was measured by 
the method of Bradford (Bradford, 1976).  
2.3.1.3 Purification of DRMs 
The cells were washed twice with ice-cold PBS, scraped, and collected by centrif-
ugation at 1,000 × g. To purify detergent-resistant membrane fractions (DRMs), the 
cells were dispersed in a 10 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl, 
5.0 mM EDTA, 1.0 mM Na3VO4, 1.0% Triton X-100 (TNE buffer), protease inhibi-
tors (10 µg/ml leupeptin and 10 µg/ml aprotinin) and incubated in ice for 20 min 
(Romiti et al., 2001). The cells were disrupted in a Dounce homogenizer (80 strokes) 
and centrifuged at 1,500 × g for 5 min at 4 °C to obtain the post-nuclear fraction. 
The post-nuclear lysate was adjusted to 40% (w/v) sucrose by 1:1 addition of 80% 
sucrose prepared in TNE buffer, placed at the bottom of an ultracentrifuge tube and 
overlaid with two layers of 30% and 5.0% sucrose in TNE buffer. The sucrose gradi-




ent was centrifuged at 170,000 × g for 22 h at 4 °C using a Beckman SW50 rotor. 
Fractions were then collected from the top of the gradient as follow: 0.5 ml for frac-
tion 1, 0.25 ml for fractions 2 to 11, 1 ml for fractions 12 and 13, while the pellet was 
dissolved in 0.08 ml of TNE buffer (fraction 14) (Cecchi et al., 2009). A representa-
tive amount of each fraction was subjected to immunoblot analysis of flotillin-1 
marker on a 12% (w/v) sodiumdodecylsulfate polyacrylamide gel electrophoresis 
(SDS/PAGE), blotted onto a polyvinylidene difluoride (PVDF) Immobilio-P transfer 
membrane, incubated with 1:500 diluted mouse monoclonal anti-flotillin-1 antibod-
ies (BD Biosciences, San Diego, CA) and 1:5000 anti-mouse antibodies. The flotillin-
1-rich fractions were pooled as DRMs and extensively dialyzed against TNE buffer 
to remove sucrose. The amount of sphingomyelin in lipid rafts was assayed using a 
photometric method with the Sphingomyelin Assay Kit (Cayman Chemical, Ann 
Arbor, MI, USA). Briefly, sample sphingomyelin was hydrolyzed by sphingomyelin-
ase to phosphorylcholine and ceramide for 60 min at 37 °C. The choline resulting 
from the subsequent incubation of phosphorylcholine with alkaline phosphatase was 
oxidized by choline oxidase with production of H2O2. The latter was reacted in the 
presence of peroxidase with N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-
dimethoxyaniline (DAOS) and 4-aminoantipyrine, yielding a blue color product 
with an optimal absorption at 595 nm (Hojjati and Jiang, 2006). Sphingomyelin was 
quantified by comparison with a reference curve built by assaying known amounts 
of sphingomyelin (25–800 ng). 
2.3.2 Differentiation of human mesenchymal stromal cells 
To induce differentiation towards a neuronal phenotype (hMSC-n), an aliquot 
of cultured hMSC cells was pre-incubated for 24 h in NBM containing 1.0 mM β-
mercaptoethanol (BME) and 10 ng/ml basic fibroblast growth factor (bFGF), and 
subsequently cultured for a further 48 h in NBM containing 10% FBS, 10 mM 
BME. To assess the differentiated phenotype, cells were photographed using a 
phase contrast microscope (Nikon, Diaphot TMD-EF). hMSCs and hMSC-n cells 
were assessed for the expression of neuronal specific markers by quantitative real 
time RT-PCR. Total RNA isolation, cDNA synthesis and real time PCR conditions 
were as previously reported (Dal Pozzo et al., 2010). Primers and probes were 
TaqMan gene expression assays: for tau protein assay ID Hs00902193_m1; for mi-
crotubule associated protein 2 (MAP2) assay ID Hs00159041_m1; for synaptophy-
sin assay ID Hs00300531_m1 (Applied Biosystems, Foster City, CA, USA). Each 
measurement was carried out in triplicate. mRNA quantification was carried out 
using a comparative Ct method according to the manufacturer’s instructions (Ap-
plied Biosystems). Data was normalized to ribosomal 18S RNA expression (assay 
ID Hs99999901_s1; Applied Biosystems) and reported as a fold increase vs. 
hMSCs. Immunostaining for neurofilament M (NF-M) was performed as previ-
ously reported (Benvenuti et al., 2006), using 1:500 diluted polyclonal primary an-







2.3.3 Modulation of membrane cholesterol levels 
The increase in membrane cholesterol content was also achieved by supplement-
ing SH-SY5Y cell and FAD fibroblasts culture media with 0.1 mM PEG-cholesterol 
for 1 h at 37 °C or with 0.2 mg/ml soluble cholesterol (Chol) for 3 h at 37 °C, respec-
tively. In a series of experiment, the increase of membrane cholesterol content was 
achieved by supplementing SH-SY5Y cell culture media with Chol at three different 
concentrations (0.05; 0.2; 0.5 mg/ml) for 3 h at 37 °C. Membrane cholesterol deple-
tion was obtained by incubating SH-SY5Y cells with 1.0 mM β-CD for 30 min at 
37°C in serum-free media. Membrane cholesterol depletion was also performed by 
incubating SH-SY5Y cells and fibroblasts with 10 µM Mev for 48 h at 37 °C in the 
presence of 1.0% FBS. Cells were then extensively washed with PBS and exposed to 
peptide oligomers. In a series of experiments cholesterol depletion was achieved SH-
SY5Y cells by supplementing the culture medium with β-CD at three different con-
centrations (0.2; 1.0; 2.0 mM) for 30 min at 37 °C in serum-free media (Yancey et al., 
1996) or with Mev at three different concentrations (1.0; 5.0; 10 μM) for 48 h at 37°C 
in the presence of 1.0% FBS (Endo et al., 1976). 
2.3.4 Modulation of membrane GM1 levels 
In fibroblasts and SH-SY5Y cells, an increase in membrane GM1 content was 
achieved by adding 32 µM bovine brain-derived GM1 to cell culture media for 48 h, 
while neurons were treated with 100 µM GM1 for 24 h. GM1 depletion was achieved 
by inhibiting cell glucosylceramide synthase with 25 µM D-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) for 48 h in fibroblasts and SH-
SY5Y cells or for 24 h in neurons. Hydrolysis of the sialic acid moiety from gangli-
osides was achieved by exposing cells to an NAA cocktail (117 mU/ml of V. cholerae 
NAA and 33 mU/ml of A. ureafaciens NAA, Sigma) for 1 h at 37 °C (Malchiodi-
Albedi et al., 2010).  
2.3.5 Cholesterol content measurements 
2.3.5.1 Microscope analysis  
A labeling of membrane cholesterol was achieved using the fluorescent probe fil-
ipin III. The cells seeded on glass coverslips were fixed in 4.0% buffered paraformal-
dehyde for 20 min at 0 °C and then were incubated with 0.25 mg/ml cholesterol 
binding agent (filipin III) in PBS for 24 h at 37 °C. After washing, the cells were fixed 
again in 4.0% buffered paraformaldehyde for 20 min at 0 °C. The distribution of 
membrane cholesterol was investigated by using confocal scanning microscopy. The 
emitted fluorescence was detected after excitation at 355 nm using a confocal Leica 
TCS SP5 scanning microscope (Mannheim, Germany) equipped with an argon laser 
source. A series of optical sections (1024 × 1024 pixels) 1.0 μm in thickness was tak-
en through the cell depth for each sample using a Leica Plan Apo 63× oil immersion 




objective and projected as a single composite image by superimposition (Pensalfini 
et al., 2011).  
2.3.5.2 Enzymatic assay 
The amount of cholesterol in membrane fractions and in purified lipid rafts 
was assessed using the sensitive fluorimetric Amplex Red Cholesterol Assay Kit 
(Molecular Probes). Sample cholesterol was oxidized by 1.0 U/ml cholesterol oxi-
dase for 30 min at 37 °C to yield H2O2 and the corresponding ketone product. In 
the presence of 1.0 U/ml horseradish peroxidase (HRP), H2O2 reacted with 150 
μM 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent) with a 1:1 stoichi-
ometry to generate the highly fluorescent resorufin (Mohanty et al., 1997). At the 
end of the incubation, sample fluorescence was measured at 544 nm excitation and 
at 590 nm emission. Cholesterol content was determined by comparison with a 
reference curve built by assaying various cholesterol amounts (0.05-1.0 µg) 
(Amundson and Zhou, 1999). 
2.3.6 GM1 content measurements 
2.3.6.1 Microscope analysis 
GM1 distribution in the plasma membrane was monitored in cells seeded on 
glass coverslips using 1:100 diluted rabbit polyclonal anti-GM1 antibodies (Calbio-
chem; EMD Chemicals Inc., Darmstadt, Germany) and with 1:1000 diluted Alexa 
Fluor 488-conjugated anti-rabbit antibody or with 4.5 μg/ml CTX-B. The emitted 
fluorescence was detected after excitation at 488 nm and 647 nm, respectively, by the 
confocal scanning system described above.  
2.3.6.2 Dot-blot analysis 
The GM1 content in membrane fractions was investigated by dot blot analysis 
using 20 μg membrane proteins spotted onto a PVDF membrane; the membrane 
was then incubated overnight at 4 °C with 1:500 rabbit polyclonal anti-GM1 anti-
bodies and with 1:1000 peroxidase-conjugated anti-rabbit antibodies (Pierce, Rock-
ford, IL, USA) for 1 h at room temperature and detected with a Super Signal West 
Dura (Pierce). All spot densities were measured as densitometric units using the im-
age analysis and densitometric program Quantity One (Biorad, Milan, Italy). For 
each spot of interest, values of treated cells were calculated as a percentage relative to 
cells with basal GM1 content taken to be as 100%. To exclude a potential cross-
reactivity of the anti-GM1 antibodies against other neuronal gangliosides, we carried 
out a dot-blot analysis. Briefly, 2.0 μl of a 0.05 mg/ml solution of GM1, GD1a and 
GT1b were spotted onto PVDF, and then incubated overnight at 4 °C with 1:500 
rabbit polyclonal anti-GM1 antibodies and the signals detected and quantified as de-






2.3.6.3 Flow cytometric analysis  
The membrane GM1 content was also monitored in cells loaded with 2.25 μg/ml 
CTX-B by using a FACSCanto flow cytometer (Beckton Dickinson Bioscences, San 
Jose, CA, USA). 
2.3.7 Cell exposure to peptide aggregates  
SH-SY5Y cells, FAD and wild-type fibroblasts with different cholesterol and GM1 
content, were exposed to 1.0 µM Aβ42 oligomers for 30 min. In a series of experiments 
SH-SY5Y cells were exposed to 12 µM Aβ42 prefibrillar aggregates obtained according 
to Lambert’s protocol as above reported (Lamber et al., 2001). Primary cortical neu-
rons, hMSC and their neuronally differentiated counterparts hMSC-n were exposed to 
5.0 µM or 10 µM Aβ42, respectively. In a set of experiments, hMSC and hMSC-n were 
treated with different final concentration of Aβ42 oligomers or with 50 µM PrP 106-
126 oligomers. Aliquots of solutions containing native or aggregated HypF-N in pre-
fibrillar forms (condition A and B) were centrifuged, dried under N2 to remove the 
TFE or TFA when necessary, dissolved in the appropriate cell media at 48 µM concen-
tration and immediately added to SH-SY5Y in basal condition or upon cholesterol or 
GM1 modulation at 12 µM final concentration. The cells were incubated in the pres-
ence of the aggregates for 1 h. In a set of experiments were used fluorescent oligomers 
obtained from HypF-N 5-FITC or Aβ-FAM. In some experiments, the oligomers were 
added to cell culture media to appropriate final concentrations for differing lengths of 
time. Neither disassembly nor microscopic differences in the aggregate structure were 
observed following dilution in the cell culture media. Aggregate concentration was cal-
culated as monomeric peptide concentration. In some experiments cells were also ex-
posed to Aβ42-1 reversed sequence peptide, as negative control, processed as above 
reported for Aβ42 peptides.  
2.3.8 Analysis of aggregate interaction with the cells  
The interaction of Aβ42 aggregates with plasma membranes was monitored in 
cholesterol-enriched, cholesterol-depleted SH-SY5Y cells, in hMSC and hMSC-n 
cells by confocal scanning microscopy. Briefly, SH-SY5Y and hMSC cells exposed 
for 30 min to 1.0 µM ADDLs, or for 0, 10, 30 and 60 min to 10 µM Aβ42 oligomers, 
respectively; were counterstained with fluorescein-conjugated WGA (5.0 µg/ml) for 
10 min to detect the plasma membrane profiles.	   In another set of experiments, 
hMSC and hMSC-n, cultured on glass coverslips, were pre-incubated for 20 min in 
the absence or in the presence of 1:100 diluted rabbit polyclonal antibodies against 
GM1, exposed to 10 μM Aβ42 aggregates for 1 h and then counterstained as above 
reported. After washing, the coverslips were incubated with mouse monoclonal anti-
Aβ antibodies 6E10 (Signet, DBA, Italy) 1:1000 diluted in PBS with 1.0% FBS for 60 
min. The immunoreaction was revealed by incubation for 90 min with Texas Red-
conjugated anti-mouse secondary antibodies (Vector Laboratories, DBA, Italy), 
1:1000 diluted in PBS containing 1.0% FBS. The emitted fluorescence was detected 




after double excitation at 488 nm and 633 nm using the confocal scanning micro-
scope described above and in all images, green and red fluorescence indicates cell 
profiles and aggregates, respectively. Aggregate-cell interactions were also analyzed 
by exposing SH-SY5Y cells with different cholesterol content to 3.0 µM Aβ42-FAM 
oligomers and counterstaining the plasma membranes with Alexa Fluor 633-
conjugated WGA (5.0 µg/ml), but without fixing cells in buffered paraformaldehyde, 
without permeabilizing the plasma membrane and without using antibodies. The 
emitted fluorescence was detected after double excitation at 488 nm and 633 nm us-
ing the confocal scanning microscope described above and in all images, red and 
green fluorescence indicates cell profiles and aggregates, respectively. The internali-
sation of HypF-N and Aβ42 oligomers into the cytosol of the exposed SH-SY5Y cells 
with different cholesterol or GM1 content was monitored by confocal scanning mi-
croscopy in cells seeded on glass coverslips. After aggregate exposure, the cells were 
counterstained with 5.0 μg/ml Alexa Fluor 633-conjugated WGA, fixed in 2.0% buff-
ered paraformaldehyde for 10 min at room temperature, permeabilized with a 3.0% 
glycerol solution for 5 min and then the aggregates were detected with 1:1000 diluted 
rabbit polyclonal anti-HypF-N antibodies and with 1:1000 diluted Alexa Fluor 488-
conjugated anti-rabbit antibodies; Aβ42 oligomers were detected with mouse mono-
clonal 6E10 antibodies and with 1:1000 diluted fluorescein-conjugated anti-mouse 
antibodies. The emitted fluorescence was detected after double excitation at 488 nm 
and 633 nm by the confocal scanning system. In all images, red and green fluores-
cence indicates cell profiles and aggregates (HypF-N or Aβ42), respectively. 
2.3.9 Analysis of aggregate interaction with GM1 
The colocalization of Aβ42 aggregates with the GM1, marker of lipid rafts, was 
monitored in fibroblasts and neuroblastoma cells with different cholesterol content 
seeded on glass coverslips using mouse monoclonal 6E10 anti-Aβ antibodies and 
with 1:1000 diluted fluorescein-conjugated anti-mouse antibodies and 4.5 µg/ml 
Alexa Fluor 647-conjugated CTX-B. The emitted fluorescence was detected by the 
confocal scanning system after double excitation at 488 nm and 647 nm for fluores-
cein and Alexa Fluor 647-conjugated CTX-B, respectively.  
2.3.9.1 FRET analysis 
The colocalization of Aβ42 oligomers with GM1 was also analyzed in cholester-
ol-enriched or cholesterol-depleted fibroblasts, hMSCs and hMSC-n, seeded on glass 
coverslips, by fluorescence resonance energy transfer (FRET) analysis. Cells were ex-
posed to Aβ42-FAM oligomers for 30 min and then fixed in 2.0% buffered para-
formaldehyde for 10 min at room temperature. After washing, cell surface GM1 was 
counterstained with 4.5 µg/ml Alexa Fluor 555-conjugated CTX-B, re-suspended in 
cell culture medium, for 20 min at room temperature. An acceptor bleaching proto-
col was employed to measure FRET efficiency, as previously described (Day, et al., 






plished using the TCS SP5 confocal system described above using the implemented 
FRET acceptor photobleaching wizard. Pre-bleach and post-bleach images were se-
rially recorded, with Aβ-FAM and cell surface GM1 excited at 488 nm (donor) and 
555 nm (acceptor), respectively, using an argon laser and appropriate emission 
bands. Low laser intensities were used to avoid acquisition bleaching. The acceptor 
was bleached at high intensity at 555 nm. FRET efficiency is displayed in pseudocol-
or for better visualization. 
2.3.10 Analysis of aggregate internalisation 
To investigate the mechanism of HypF-N oligomer internalization, cholesterol-
depleted SH-SY5Y cells were incubated with 12 μM 5-FITC-labelled oligomers and 
5.0 μg/ml FM4-64 for 1 h at 37 ºC as previously reported (Kaminski Schierle et al., 
2011). The images were recorded using the 488 nm laser line to excite 5-FITC-
labelled oligomers and the 543 nm laser line to excite FM4-64, a widely used marker 
for endocytotic vesicles. In all images, red and green fluorescence indicates vesicles 
and aggregates, respectively. 
2.3.11 Analysis of membrane permeability 
In order to assess whether Aβ42 or HypF-N aggregates disrupt cell membrane 
integrity, neuroblastoma cells and fibroblasts with different cholesterol or GM1 con-
tent were pre-treated for 20 min at 37 °C with 2.0 μM calcein-AM, dissolved in 
DMSO and re-suspended in cell culture medium (Cecchi et al., 2008b). The decay in 
fluorescence was analyzed by confocal microscopy after excitation at 488 nm in cell 
exposed to Aβ42 or HypF-N aggregates. In another set of experiments, fibroblasts 
were exposed to calcein-AM and then incubated for 20 min in the absence or in the 
presence of 4.5 µg/ml Alexa Fluor 647-conjugated CTX-B or 1:100 diluted rabbit 
polyclonal anti-GM1 antibodies, before treatment with Aβ42 aggregates.  
2.3.12 Analysis of cytosolic Ca2+ dyshomeostasis  
The effect of Aβ42 or HypF-N aggregates on cytosolic free Ca2+ levels was ana-
lyzed in fibroblasts and SH-SY5Y cells with different cholesterol or GM1 content, in 
GM1-enriched or depleted primary cortical neurons, hMSC and hMSC-n cells, plat-
ed on glass coverslips and loaded with Fluo3-AM, a Ca2+-specific fluorescent probe. 
The cells were first exposed to Aβ42 aggregates or to HypF-N aggregates for differ-
ing length of times at 37 °C. Cytosolic Ca2+ levels were also examined in fibroblasts 
and neurons pre-treated for 20 min in the absence or in the presence of 1:100 diluted 
rabbit polyclonal anti-GM1 antibodies, before treatment with Aβ42 aggregates. The 
cells were then loaded for 30 min at 37 °C with 10 μM Fluo3-AM, 0.01% (w/v) plu-
ronic acid F-127 in Hank’s Balanced Salt Solution (HBSS) and subsequently fixed in 
2.0% buffered paraformaldehyde for 10 min at room temperature. Fluorescence was 
detected after excitation at 488-nm by collecting the emitted fluorescence with the 
confocal scanning system described above. 




2.3.13 Evaluation of ROS production  
Intracellular ROS production was detected by using CM-H2DCFDA, a ROS-
sensitive fluorescent dye. CM-H2DCFDA esterified derivative is loaded more effec-
tively within the cytoplasm of the cells because it is more cell permeant before ester 
groups are hydrolyzed by the cellular esterases. Only a negligible leakage of the 
probe occurred, since chloromethyl-DCF is negatively charged at physiological in-
tracellular pH. Cholesterol-enriched, cholesterol-depleted and basal SH-SY5Y cells, 
hMSC and hMSC-n were first cultured on glass coverslips and exposed to Aβ42 or 
HypF-N aggregates for different times at 37 °C. The cells were then incubated with 
5.0 μM CM-H2DCFDA, dissolved in 0.1% DMSO and Pluronic acid F-127 (0.01% 
w/v), in the final 10 min of aggregate exposure. The cells were then fixed in 2.0% 
buffered paraformaldehyde for 10 min at room temperature and the emitted CM-
H2DCFDA fluorescence was detected after 488-nm excitation by the confocal scan-
ning microscope described above. 
2.3.14 Analysis of lipid peroxidation  
2.3.14.1 Measurement of lipid peroxidation products 
To assess the rate of lipid peroxidation after Aβ42 cell treatment, the levels of 
8-OH isoprostane were measured photometrically in fibroblasts and hMSC cell ly-
sates and in lipid rafts fraction purified from fibroblasts at 405 nm using the 8-
isoprostane EIA kit (Cayman Chemical Company, Ann Arbor, MI, USA) (Pensal-
fini et al., 2011).  
2.3.14.2 Confocal microscope analysis 
Lipid peroxidation after cell exposure to Aβ42 aggregates was also investigated 
in fibroblasts and neurons by confocal scanning microscope analysis, using the fluo-
rescent probe BODIPY 581/591 C11, which is intrinsically lipophilic thus mimicking 
the properties of natural lipids (Naguib, 1998). In particular, BODIPY 581/591 C11 
can be used to measure antioxidant activity in lipid environments since it behaves as 
a fluorescent lipid peroxidation reporter that shifts its fluorescence from red to green 
when challenged with oxidizing agents (Drummen et al., 2004). FAD, wild-type fi-
broblasts and neurons with differing GM1 content were cultured on glass coverslips 
and exposed to 1.0 µM (fibroblasts) or 5.0 µM (neurons) Aβ42 aggregates for 30 min 
at 37 °C. In a set of experiments, fibroblasts and neurons, cultured on glass co-
verslips, were pre-incubated for 20 min in the absence or in the presence of 4.5 
µg/ml Alexa Fluor 647-conjugated CTX-B or 1:100 diluted rabbit polyclonal anti-
bodies against GM1 and then exposed to Aβ42 aggregates for 1 h. Lipid peroxidation 
was also examined in fibroblast and neurons exposed to aggregates in Ca2+-free me-
dium. Dye loading was achieved by adding 5.0 µM fluorescent BODIPY, dissolved in 
0.1% DMSO, to the cell culture media for 30 min at 37 °C. The cells were fixed in 






measured by simultaneous acquisition of the green (ex 485nm/em 520nm) and red 
signal (ex 581nm/em 591nm), by confocal microscope analysis, as described above. 
2.3.15 Cytotoxicity assay and cell death analysis: apoptotic and necrotic markers 
2.3.15.1 MTT test 
The toxic effect of the differing aggregates on metabolic cell functions was 
assessed in cell models by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay in 96-well plates. Cholesterol-
enriched, cholesterol-depleted and basal neuroblastoma cells were exposed to 1.0 
µM Aβ42 oligomers for 24 h at 37 °C; fibroblasts and neurons following GM1 
modulation were exposed to 1.0 (fibroblasts) or 5.0 (neurons) µM Aβ42 oligo-
mers for 24 h at 37 °C. SH-SY5Y cell, upon membrane cholesterol and/or GM1 
modulation were treated with 12 µM HypF-N or Aβ42 oligomers. hMSC and 
hMSC-n were treated with Aβ42 oligomers (0.1, 1.0, 10, 25, 50 µM final concen-
tration), 10 µM Aβ42 fibrils, 10 µM Aβ42-1 reverse peptides and 50 µM PrP 106-
126 oligomers. As a negative control, neuroblastoma cells were pre-treated with 
100 µM Vit E for 24 h at 37 °C, before aggregate or H2O2 exposure. In a series of 
experiments, fibroblast, primary cortical neurons, hMSC and hMSC-n, were pre-
incubated for 20 min in the absence or in the presence of 4.5 µg/ml Alexa Fluor 
647-conjugated CTX-B or 1:100 diluted rabbit polyclonal antibodies against 
GM1 and then exposed to Aβ42 aggregates for 24 h. After cell treatments, 100 μl 
of 0.5 mg/ml MTT solution in PBS was added to the cell cultures and the sam-
ples were incubated for 4 h at 37 °C. Finally, 100 μl of cell lysis buffer (20% SDS, 
50% N,N-dimethylformamide, pH 4.7) was added to each well and the samples 
were incubated for at least 3 h at 37 °C in a humidified incubator, before deter-
mination of absorbance value of blue formazan at 590 nm with an ELISA plate 
reader. Cell viability was expressed as a percentage of MTT reduction in aggre-
gate or H2O2-exposed cells compared to untreated cells (assumed as 100%). 
2.3.15.2 Hoechst staining 
Nuclear alterations eventually induced by the amyloid aggregates were investi-
gated by Hoechst 33342 dye staining. Briefly, cholesterol-enriched cholesterol-
depleted and basal neuroblastoma cells were exposed to Aβ42 or HypF-N oligo-
mers for 24 h at 37 °C. Human mesenchymal stromal cells, cultured on glass co-
verslips, were pre-incubated for 20 min in the absence or in the presence of 1:100 
diluted rabbit polyclonal antibodies against GM1 and then exposed to Aβ42 aggre-
gates for 24 h. Then, the cells were incubated with 20 µg/ml Hoechst for 15 min at 
37 °C and fixed in 2.0% buffered paraformaldehyde for 10 min at room tempera-
ture. Blue fluorescence micrographs of cells were obtained under UV illumination 
in an epifluorescence inverted microscope (Nikon, Diaphot TMD-EF) with an ap-
propriate filter set.  




2.3.15.3 Caspase-3 activity 
The extent of the apoptotic program activation in SH-SY5Y and hMSC cells was 
evaluated by confocal microscope analysis of caspase-3 activity, which is the main 
effector caspase in apoptosis. Neuroblastoma cells upon cholesterol modulation and 
hMSC cells pre-incubated for 20 min in the absence or in the presence of 1:100 di-
luted rabbit polyclonal antibodies against GM1, were exposed to 12 µM HypF-N or 
10.0 µM Aβ42 oligomers, respectively for 24 h at 37 °C. In a series of experiments, 
neuroblastoma cells depleted in cholesterol following treatment with 2.0 mM β-CD 
were pre-treated with 10 µM BAPTA-AM for 30 min, extensively washed and then 
exposed for 3 h to either type of HypF-N oligomers in culture media with or without 
Ca2+. After the appropriate treatment, the culture media were removed and replaced 
with FAM-FLICA Caspases 3&7 solution (Caspase 3&7 FLICA kit; FAM-DEVD-
FMK; Immunochemistry Technologies, LLC, Bloomington, MN, USA) for 30 min, 
following the manufacturer's instructions. The cells were fixed on glass coverslips in 
2.0% buffered paraformaldehyde for 10 min at room temperature and then fluores-
cence was detected after 488 nm excitation, by the confocal scanning system, as de-
scribed above.  
2.3.15.4 LDH release 
The presence of necrotic cells was assessed by measuring the activity of lactate 
dehydrogenase (LDH), a typical necrotic marker released into the cell culture me-
dium after plasma-membrane rupture. LDH activity was measured in the culture 
media of cholesterol-enriched, cholesterol-depleted or basal SH-SY5Y cells after 
exposure to 1.0 µM Aβ42 aggregates for 48 h at 37 °C using a fluorimetric LDH as-
say kit (Roche Diagnostics, Mannheim, Germany) at 490 nm, after blank subtrac-
tion at 595 nm. 
2.3.16 Steady-state fluorescence anisotropy 
Fluorescence anisotropy (r) of DPH was used to measure the structural order of 
the hydrophobic region of the purified lipid rafts under steady-state conditions 
(Lentz, 1989; Shinitzky and Barenholz, 1974). Anisotropy measurements were per-
formed at 37 °C by a Perkin-Elmer LS 55 luminescence spectrometer equipped with 
manual polarisers with excitation and emission wavelengths set at 360 nm and 425 
nm, and with a slit-width of 2.5 nm and 4 nm, respectively. Our system was initially 
calibrated using DPH in mineral oil, which should give an anisotropy value of 1.0. 
The g factor was calculated using horizontally polarized excitation and subsequent 
comparison of the horizontal and vertical emissions. Lipid rafts purified from neu-
roblastoma cells or fibroblast were incubated for 10 min in the absence or in the 
presence of 1.0 µM Aβ42 aggregates or Aβ42-1 reverse peptide and then further in-
cubated for 30 min with DPH at a 1:250 probe-to-lipid ratio. In another set of exper-
iments, lipid rafts were incubated for differing times (10, 30, 60 min) in the presence 






with the excitation polariser in the vertical position and the analysing emission po-
lariser in both the vertical (IVV) and the horizontal (IVH) positions; the anisotropy 




2.3.17 Atomic force microscopy (AFM) 
AFM analyses were performed in collaboration with the group of Prof.ssa Ales-
sandra Gliozzi, of the Department of Physics of the University of Genoa. AFM anal-
ysis was carried out on 50 µl aliquots of the purified DRMs deposited on freshly 
cleaved mica, incubated for 1 h and then rinsed with Milli-Q water. AFM measure-
ments were performed using a Dimension 3100 scanning probe microscope (Digital 
Instruments, Veeco, Santa Barbara, CA, USA) equipped with a Nanoscope IIIa con-
troller and a “G” scanning head (maximum scan size 100 x 100 µm). Tapping mode 
AFM would be expected to minimize lateral forces and allow better imaging of soft 
samples. Raft membranes were an exception, as we could not image them in tapping 
mode, even using different cantilevers and solution conditions. It is possible that 
when operating in tapping mode an oscillation is also induced in the sample. This 
would explain why tapping mode imaging of DRMs was impossible. On the other 
hand, when operating in contact mode, a force is steadily applied to the sample, re-
sulting in an improved stability of the system. Thus images were acquired in contact 
mode in liquid by using V-shaped non-conductive silicon nitride cantilevers (type 
DNP, Veeco; 115 µm length, nominal spring constant 0.58 N/m) with pyramidal tips 
(nominal curvature radius in the 20-60 nm range) and scan rate in the 0.5-2.0 Hz 
range. Images were captured as 512 × 512 pixel images. The minimum force em-
ployed in contact mode imaging was 0.3 nN. The morphological features of the 
samples were analyzed in terms of height and width in cross section in the topo-
graphic AFM images. The heights of the steps associated either to membrane do-
mains or to cavities were measured with respect to the background. The sizes of each 
domain (or hollow) were the mean of the widths measured along the major diameter 
of the domain (or hollow) and the corresponding in-plane perpendicular direction. 
Due to tip size effects, which cause an apparent increase of the size of the imaged ob-
ject in the image plane, domain sizes are overestimated respect to the real ones. To 
evaluate the expected widths, w, we modelled the domain as a flat object with half-
spherical edges, using the equation: 
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where wapp and h are the measured width and height, respectively, and RT is the 
AFM tip radius. We used a silicon calibration grating with ultrasharp tips (NT-MDT 
TGT01, Silicon-MDT Ltd., Moscow, Russia) to measure the curvature radius RT for 
four tips of the same type and we obtained a mean value of 25±7nm. This value, 
which is within the range provided by the manufacturer, has been used to evaluate 
the correction for tip enlargement effects, according to the procedure quoted above. 
The possible changes in neuroblastoma or fibroblasts raft morphology induced by 
the interaction with Aβ42 oligomers were investigated in samples prepared as de-
scribed above incubated for 30 min in the presence of 1.0 µM ADDLs, rinsed with 
Milli-Q and imaged in liquid. To check the presence of the GM1 ganglioside, after 
deposition on the mica substrate the DRMs were incubated for 30 min with rabbit 
polyclonal anti-GM1 antibodies, diluted 1:1000. The presence of flotillin-1 in the 
samples deposited on the mica substrate was assessed by incubating the rafts with 0.5 
µg/ml mouse anti-flotillin-1 antibodies for 30 min. The domains imaged in the 
DRMs samples were better characterized by incubation with a mixture of carboxy-
peptidase Y from baker's yeast, thermolysin from Bacillus thermoproteolyticus rok-
ko Type X and α-chymotrypsin from bovine pancreas Type VII (Sigma; Milan, Ita-
ly), at final concentrations of 1.0 mg/ml, 5.0 mg/ml and 5.0 mg/ml, respectively. Pro-
tease digestion was carried out by incubating the rafts with the protease mixture for 
2 h either before or after sample deposition on the mica substrate. To characterize 
morphologically the Aβ42 aggregates, 20 µl aliquots of ADDLs, obtained as reported 
above, were deposited on freshly cleaved mica substrates and dried under mild vac-
uum. The images were acquired in tapping mode in air using a Dimension 3100 
AFM microscope (as detailed above) and a multimode scanning probe microscope 
equipped with an “E” scanning head (maximum scan size 10 µm). Single beam un-
coated silicon cantilevers (type OMCL-AC, Olympus, Japan) were used. The drive 
frequency was around 300 kHz and the scan rate was in the 0.3-0.8 Hz range. 
2.3.18 Measurements of the fluorescence intensities 
To quantify the signal intensity of each fluorescent probe, a variable number of 
cells (10 to 22) were analyzed in each experiment using ImageJ software (NIH, Be-
thesda, MD, USA), and the fluorescence intensities expressed as fractional changes 
above the resting baseline, ΔF/F, where F is the average baseline fluorescence in con-
trol cells (assumed as 100%) and ΔF represents the fluorescence changes over the 
baseline in cells exposed to different treatments. In the quantification of the fluores-
cence intensity of intracellular Aβ42 oligomers in human mesenchymal stromal 
cells, fluorescence signals are expressed as ΔF (F1 - F0), where F1 represents the fluo-
rescence in Aβ42 oligomer-treated cells and F0 the fluorescence in untreated cells. 
GM1-Aβ42 aggregates and endocytotic vesicles-HypF-N oligomers colocalizazion 
was estimated for regions of interest (in 12–13 cells), in three different experiments, 
using the ImageJ (NIH, Bethesda, MD, USA) and JACOP plugin (rsb.info.nih.gov) 






2.3.19 Statistical analysis 
Except the AFM and hMSC-n neuronal markers expression data, which are ex-
pressed as mean ± standard error (SE), all other data are expressed as mean ± stand-
ard deviation (SD). Comparisons between the different groups were performed by 
ANOVA followed by Bonferroni’s t-test. A p value < 0.05 was considered statistically 
significant. AFM data concerning sample morphological features are over an ensem-
ble of at least 100 measurements. All the statistical analyses had a confidence level 
≥ 95%. 
  





3.1 Results I 
3.1.1 A protective role for lipid raft cholesterol against amyloid-induced mem-
brane damage in human neuroblastoma cells 
Increasing evidence supports the idea that the initial events of Aβ oligomerization 
and cytotoxicity in Alzheimer’s disease involve the interaction of amyloid Aβ-derived 
diffusible ligands (ADDLs) with the cell membrane. This also indicates lipid rafts, or-
dered membrane microdomains enriched in cholesterol, sphingolipids and gangliosides, 
as likely primary interaction sites of ADDLs. To shed further light on the relation be-
tween ADDL-cell membrane interaction and oligomer cytotoxicity, in the first part of 
the result section was investigated the dependence of ADDLs binding to lipid rafts on 
membrane cholesterol content in human SH-SY5Y neuroblastoma cells. Confocal laser 
microscopy showed that Aβ42 oligomers markedly interact with membrane rafts and 
that a moderate enrichment of membrane cholesterol prevents their association with the 
monosialoganglioside GM1. Moreover, anisotropy fluorescence measurements of flotil-
lin-1-positive rafts purified by sucrose density gradient suggested that the content of 
membrane cholesterol and membrane perturbation by ADDLs are inversely correlated. 
Finally, contact mode atomic force microscope images of lipid rafts in liquid showed that 
ADDLs induce changes in raft morphology with the appearance of large cavities whose 
size and depth were significantly reduced in similarly treated cholesterol-enriched rafts. 
Our data suggest that cholesterol reduces amyloid-induced membrane modifications at 
the lipid raft level by altering raft physicochemical features. 
3.1.2 Aβ42 oligomer binding to the cell surface and its cytotoxic effect are modu-
lated by membrane cholesterol content 
In previous studies we showed that the interaction of amyloid aggregates of dif-
ferent peptides and proteins with the plasma membranes of several types of cultured 
cells is significantly inversely correlated to the membrane content of cholesterol 
(Cecchi et al., 2005; Cecchi et al., 2008b; Cecchi et al., 2008c; Pensalfini et al., 2011). 
Here, we modulated the cholesterol content in human neuroblastoma cells by incu-
bating the cells in the presence of polyoxyetanyl-cholesteryl sebacate (PEG-
cholesterol), methyl-β-cyclodextrin (β-CD) or mevastatin (Mev). Cell treatment 
with PEG-cholesterol significantly increased the content of cholesterol in the cell 
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membrane (13.55 ± 0.68 µg/mg protein, p ≤ 0.05) versus control cells (10.84 ± 0.54 
µg/mg protein) as assayed by the Amplex Red Cholesterol Assay Kit. Conversely, 
membrane cholesterol content was significantly reduced by cell treatment with β-
CD (7.26 ± 0.73 µg/mg protein, p ≤ 0.05) and Mev (9.71 ± 0.46 µg/mg protein, p ≤ 
0.05) versus control cells. These data were confirmed by confocal analysis of the sen-
sitive fluorescent probe filipin III (Fig. 11A).  
Then, we evaluated the ability of our ADDLs to bind to the plasma membrane of 
neuroblastoma cells after a 30 min period of exposure by qualitative confocal micro-
scope analysis of anti-Aβ42 antibody fluorescence (Fig. 11B). To exclude any possi-
ble interference of the cell fixation favoring the intracellular uptake of ADDLs, the 
distribution of fluorescein-labeled Aβ42-FAM aggregates was analyzed in unfixed 
neuroblastoma cells. Green fluorescence signal confirmed the different membrane 
distribution of ADDLs at our experimental conditions (Fig. 11B).  
 
 
Figure 11. (A) Representative confocal microscope analysis of membrane cholesterol content 
in SH-SY5Y neuroblastoma cells probed by the fluorescent dye filipin III. (B) Representative 
confocal microscope images showing aggregates penetrating into the plasma membrane of 
neuroblastoma cells treated with 1.0 μM Aβ42 ADDLs (top) or with 3.0 µM Aβ42-FAM ag-
gregates (middle) for 30 min. Representative blue fluorescence micrographs of Hoechst 33342 
stained cells, after exposure to 1.0 μM ADDLs for 24 h (bottom). (C) MTT and assays after 
exposure to 1.0 µM Aβ42 aggregates  




We also evaluated whether an increased content of membrane-cholesterol was 
able to prevent amyloid toxicity at our experimental conditions. As shown in Fig. 
11C, the quantitative analysis of the ability of the treated cells to reduce MTT and 
the morphological evaluation of Hoechst 33342 stained cells revealed no marked 
characteristics of apoptosis in cells enriched in cholesterol after their exposure to 
ADDLs for 24 h. On the other hand, the loss of membrane cholesterol in cells treated 
with β-CD or Mev before exposure to the aggregates resulted in a marked increase in 
the number of cells displaying nuclear condensation and a significant impairment of 
viability respect to similarly exposed cells with basal cholesterol content. Finally, we 
investigated whether neuroblastoma cells exposed to ADDLs for 48 h underwent a 
necrotic cell death. As shown in Fig. 11C, a significant release of LDH in the cell cul-
ture media was observed in cells with basal and, to a greater extent, reduced choles-
terol content exposed to ADDLs. Also in this case, cholesterol enriched cells dis-
played a higher resistance to amyloid toxicity, as compared to control cells, as re-
vealed by the significant reduction of LDH release in the culture media. 
3.1.3 Aβ42 oligomers colocalize with lipid rafts  
Cholesterol is not uniformly distributed into the plasma membrane. In fact, it is 
concentrated in lipid rafts, which appear to exist in a liquid-ordered phase contrib-
uting to their partitioning from the surrounding liquid-disordered glycerophospho-
lipid-rich environment. Lipid rafts are considered primary interaction sites of AD-
DLs (Williamson et al., 2008). Therefore, we sought to assess whether the modified 
ability of our ADDLs to interact with normal, cholesterol-enriched or depleted cells 
implied the participation of lipid rafts. Confocal laser microscopy showed a marked 
colocalization of Aβ42 oligomers with GM1, a well known lipid raft marker, on the 
plasma membranes of neuroblastoma cells (Fig. 12). In particular, when the images 
were merged, a number of yellow areas representing the colocalization of mem-
brane-bound ADDL with GM1 were seen. The scatter plots of fluorescence signals 
over the highlighted areas are shown in Fig. 12 (right). Two different algorithms, the 
Pearson’s correlation coefficient and the overlap coefficient according to Manders 
gave similar results. In particular, the analysis over three different experiments yield-
ed a colocalization of 43% between GM1 and ADDLs in control cells. Interestingly, a 
moderate enrichment of membrane cholesterol in PEG-chol treated cells appeared 
to reduce the ADDLs interaction with the monosialoganglioside GM1 as supported 
by the low degree of colocalization (19%), while an increased colocalization was 
found in β-CD (69%) and Mev (67%) treated cells. 
Overall, our colocalization data show that Aβ oligomers interact with the plasma 
membrane preferentially at the raft domains and that any structural modification of 
the latter following increase or decrease of cell cholesterol results in alterations of 
ADDL-raft interaction. These findings agree with previously reported data, showing 
that the content of cholesterol in cell membranes or in synthetic lipid vesicles modu-
lates membrane-aggregate interaction (Arispe and Doh, 2002; Cecchi et al., 2008b), 








Figure 12. Representative confocal microscope images showing ADDL colocalization with 
GM1 (yellow), a typical marker of lipid rafts in neuroblastoma cells. Top, control cells; second 
row, PEG-chol treated cells; third and fourth row, β-CD and Mev treated cells, respectively. 
Aβ42 oligomers were labelled with monoclonal mouse 6E10 anti-Aβ antibodies and fluores-
cein-conjugated anti-mouse antibodies (green), while GM1 was stained with fluorescent 
CTX-B conjugate as a probe (red). The scatter plots indicate the colocalization pattern over 
the selected area of each panel; the sampled pixels were plotted as a function of red (x axis) 
and green (y axis) fluorescence intensity, resulting in a partial (top), low (second row) or high 
(third and fourth row) GM1-ADDL colocalization. 
 
3.1.4 Isolation and characterization of DRMs 
After having analyzed the ADDL-raft interaction in normal, cholesterol-
enriched, or depleted SH-SY5Y cells, we investigated by confocal microscopy the 
modification of lipid raft morphology and distribution in the plasma membranes of 
cells enriched or depleted in cholesterol by labelling the cell surface GM1. GM1-
positive membrane domains did not appear uniformly distributed on the plasma 
membranes and some more brightly stained domains were observed in control cells 
(Fig. 13). PEG-cholesterol treatment apparently increased the brightness of GM1-
rich domains, without any evident alteration of their surface distribution. On the 




other hand, a substantially reduced CTX-B fluorescence was evident in cholesterol-
depleted cells, confirming that the content of membrane cholesterol is crucial for li-
pid raft organization, possibly by regulating in a dose-dependent manner both their 




Figure 13. Representative immunoblot analysis of flotillin-1 levels in 14 sucrose gradient frac-
tions collected from the top (low density) through the bottom (high density) of the gradient 
tube. An aliquot from each fraction was run on 12% SDS/PAGE, transferred onto a PVDF 
membrane and then incubated with mouse anti-flotillin-1 monoclonal antibodies. The 
amount of cholesterol in the DRM pools was determined by a fluorimetric assay and ex-
pressed as ratio to sphingomyelin content. On the right side of the figure, representative con-
focal analysis of the cell surface GM1 distribution in SH-SY5Y cells probed by the fluorescent 
CTX-B conjugate.  
 
Next, we investigated the effects of the same treatments directly on lipid raft 
fractions isolated from treated or control neuroblastoma cells. Due to their insolu-
bility in non-ionic detergents at low temperatures, lipid rafts have been defined as 
detergent-resistant membranes (DRMs). Because of their high lipid-to-protein ra-
tio, DRMs display a low density and can be isolated by cell lysis with Triton X-100 
and flotation on sucrose-density gradients. Sucrose gradient fractions, purified 
from human neuroblastoma cells untreated or treated with PEG-cholesterol or 
with β-CD or Mev, were analyzed by Western blot for the presence of flotillin-1, a 
lipid raft protein marker. As shown in Fig. 13, flotillin-1 was localized in low den-






enrichment did not affect remarkably the DRM density distribution. On the con-
trary, in β-CD and Mev treated cells most of the flotillin-1 immunoreactivity was 
shifted to fractions 12-14. However, a minor flotillin-1 immunoreactivity was still 
present in fractions 2-5, suggesting that β-CD or Mev treatment led to a partial, 
not complete, disruption of the organization and/or the number of lipid rafts in 
our cell model. After extensive dialysis to remove sucrose, the amount of choles-
terol was quantified in the pooled flotillin-1-positive fractions (2-5) purified from 
cells enriched or depleted in cholesterol or from control cells. The amount of cho-
lesterol in the plasma membrane microdomains was significantly increased (+20% 
vs control cells) or reduced (-40% vs control cells) upon cell treatment with PEG-
cholesterol or with β-CD and Mev, respectively (Fig. 13). No significant difference 
was observed in the total sphingomyelin levels among DRMs pools obtained from 
control cells (2.17 ± 0.32 ng/µl), cholesterol-enriched cells (2.09 ± 0.23 ng/µl) and 
cholesterol-depleted cells (1.94 ± 0.45 ng/µl). 
3.1.5 Effects of ADDLs on lipid raft structural order 
The effect of cholesterol on membrane fluidity is known to be complex; choles-
terol can either enhance or decrease membrane fluidity depending on temperature, 
cholesterol concentration and bilayer composition (Wood et al., 1999). However, 
under physiological conditions cholesterol is known to increase membrane rigidity. 
Thus, we evaluated the effect of cholesterol content on the structural order of the 
hydrophobic regions of lipid rafts by measuring the fluorescence anisotropy of 1,6-
diphenyl-1,3,5-hexatriene (DPH) under steady-state conditions at 37 °C. The rela-
tive motion of the DPH dye molecule within the fatty acid acyl chain space of the li-
pid bilayer was determined by polarized fluorescence and expressed as r, the anisot-
ropy constant, whose value is inversely proportional to the degree of membrane flu-
idity (Lentz, 1989; Shinitzky and Barenholz, 1974). In raft-enriched samples pre-
pared from neuroblastoma cells a moderate cholesterol enrichment significantly in-
creased the raft structural order, whereas cholesterol depletion resulted in a higher 
fluidity (Fig. 14).  
We also investigated whether the content of cholesterol in lipid rafts modified 
the membrane perturbing effect of ADDLs. We found a rapid reduction of fluidity in 
control lipid rafts exposed to 1.0 µM Aβ42 oligomers for various lengths of time 
(Fig. 14, inset). As the most ordered structure was reached in less than 10 min of ex-
posure to the oligomers, we chose this incubation time for subsequent experiments. 
No evident difference in DPH fluorescence anisotropy was detected by exposing li-
pid rafts to Aβ42-1, suggesting that this effect is specific of the β-sheet structure 
found in ADDLs.  
Cholesterol-enriched lipid rafts did not display any significant change of the ani-
sotropy upon exposure to Aβ42 oligomers or to the reverse Aβ42-1 peptide, suggest-
ing that cholesterol enrichment protects lipid rafts from perturbation by Aβ42. On 
the contrary, cholesterol loss resulted in increased rigidity of rafts exposed not only 
to Aβ42 ADDLs, as expected, but also to Aβ42-1 monomers, suggesting that the lat-









Figure 14. DPH fluorescence anisotropy, r, measured before and after DRM treatment with 
Aβ42 ADDLs or the reverse Aβ42-1 peptide. The measurements were performed on control, 
cholesterol-enriched and cholesterol-depleted samples. DPH fluorescence anisotropy, r, 
measured by incubating rafts for 2, 10, 30 and 60 min in the presence of 1.0 µM Aβ42 oligo-
mers. All the data are means ± S.D. of six independent experiments. *p≤0.05, significant dif-
ference vs untreated microdomain fluidity. 
3.1.6 AFM imaging of supported DRMs purified from cells exposed to ADDLs 
AFM analyses were performed in collaboration with the group of Prof.ssa Ales-
sandra Gliozzi, of the Department of Physics of the University of Genoa. The deposi-
tion of purified DRMs on mica substrates for AFM inspection resulted in the spon-
taneous formation of membrane multilayers, similarly to the behaviour observed 
when supported bilayers are formed from liposome deposition (Canale et al., 2006; 
Egawa and Furusawa, 1999). The DRM multilayers completely covered the imaging 
field and there was no mica substrate exposed. However they did not appear homo-
geneous, with membrane domains sprouting from a uniform background (Fig. 15A). 
The background thickness with respect to the mica surface, measured by indenting 
the background in different points, corresponded to up to four double layers (each 
about 5 nm thick). The domains were stable upon scanning (Fig. 15B) and had a typ-
ical lateral size of a few hundred of nm. Their height with respect to the background 
was less than 2 nm (Table III). To check whether the sprouting domains had the 
same chemical nature of the background, we performed antibody labelling experi-
ments to detect the presence of GM1 and flotillin-1, typical components of mem-









Figure 15. (A) Contact mode AFM image in liquid (height data) of DRMs extracted from 
control cells; (B) a subsequent scan of the same area showing reproducibility of domain imag-
ing. The image in (B) was taken 15 min after that in (A); (C) height profile obtained from an 
image section along the horizontal line indicated in (A); (D) imaging of DRMs labeled with 
anti-GM1 antibodies. Scan size 2.5 µm; Z range (A, B) 10 nm, (D) 5 nm. 
 
A uniform distribution of granular structures located in the background is ob-
served, indicating the presence of GM1 in this region. As the DRM multilayers com-
pletely covered the imaging field, we can rule out the possibility of any non-specific 
interaction of anti-GM1 antibodies with the mica. No granular structures were ob-
served on the domain surface, although incubation with anti-GM1 antibodies resulted 
in domain fragmentation. To check whether proteins were the main component of 
these domains, we incubated the DRMs with a cocktail of proteases, as described in 
Materials and Methods section. DRM treatment with the proteases before deposition 
on the mica substrate resulted in the disappearance of membrane domains and the 
presence of a homogeneous sample surface. Conversely, when DRMs were incubated 
with proteases after deposition on the mica substrate, the domains originally present 




Figure 16. Contact mode AFM images in liquid (height data) showing the disrupting effect of 
proteases on DRM lipid domains (A, B): (A) first scan after a 2 h sample incubation in the 
presence of proteases; (B) second scan (about 15 min later); (C) DRMs purified from cells 
pretreated with Aβ42 oligomers. The white arrows indicate some of the cavities resulting 
from DRM interaction with ADDLs. (D) DRMs purified from cells pre-treated with Aβ42-1 
oligomers. Scan size 2.5 µm; Z range 10 nm. 
As mentioned above, successive scans performed in the absence of proteases 
(Fig. 15A,B) showed that the domains can be reproducibly imaged and therefore 
their instability observed in the presence of proteases can actually result from the ac-
tion of the latter. These results suggest that the background is composed by DRMs, 
while the slightly higher domains are formed by fluid phase-separated proteins or 
lipid-protein complexes present in the DRM preparations.  




DRMs purified from cholesterol–enriched and cholesterol-depleted cells were 
also imaged by AFM. In samples purified from cholesterol-enriched cells the lateral 
size of the membrane domains appeared reduced as compared with that measured in 
control samples which, in turn, was reduced with respect to that measured in DRMs 
purified from cholesterol-depleted cells (Table III). This finding could be explained 
by the effect of cholesterol on membrane fluidity, resulting in decreased mobility, 
and therefore reduced coalescence, of fluid domains, in agreement with the fluores-




Table III. Interaction with ADDLs affects the morphological features of DRMs. Each pore (or 
domain) size figure was the mean of the widths measured along the pore (or domain) major 
diameter and the corresponding in-plane perpendicular direction. Domain heights were 
measured with respect to the image background. The data are expressed as mean±standard 
error over an ensemble of at least 100 measurements. 
Next, we investigated the effect of cell exposure to ADDLs on DRM morphology. 
DRMs purified from cells treated with Aβ42 oligomers before raft extraction (Fig. 
16C) displayed the presence of cavities, or hollows (white arrows), whose depth and 
size are reported in Table III. Corral-like structures (1.7 ± 0.1) nm high and (260 ± 10) 
nm in diameter were also observed (Fig. 16C). Both cavities and corral-like structures 
were absent in DRMs purified from cells treated with Aβ42-1 oligomers before raft ex-
traction (Fig. 16D), suggesting a non generic interaction of Aβ42 with lipid rafts. Fig. 
17 compares the morphologies of DRMs extracted from control (Fig. 17A), cholester-
ol-enriched (Fig. 17B) and cholesterol-depleted (Fig. 17C) cells before (−) and after (+) 
exposure to ADDLs. The latter are imaged in the inset in Fig. 17B. The presence of the 
peptide clearly altered DRM morphology, giving rise to the formation of cavities in all 
samples. The quantitative analysis of the images showed that the depth and size of the 
cavities observed in cholesterol-enriched samples were significantly reduced with re-
spect to those displayed by cholesterol-depleted samples. All DRMs treated with Aβ42 
oligomers after purification displayed cavities with depths and sizes significantly in-
creased as compared to those found in DRMs purified from cells previously exposed to 
the same oligomers. In particular, a four-fold increase in the cavity sizes was observed 
(Table III). These results indicate that a reduced raft damage was caused by ADDLs in 







Figure 17. Contact mode AFM images in liquid (height data) of DRMs before (−) and after 
(+) 30 min incubation with 1.0 µM Aβ42 ADDLs. (A+, A−) DRMs prepared from control 
cells; (B+, B−) cholesterol-enriched DRMs; (C+, C−) cholesterol-depleted DRMs. The white 
arrows indicate some of the cavities formed as a consequence of DRM interaction with AD-
DLs. Scan size 2.5 μm; Z range 10 nm. The inset in (B+) is a tapping mode AFM image of 
ADDLs. Scan size 1.0 μm; Z range 5.0 nm. 
In addition to cavity formation, DRM exposure to ADDLs resulted in changes of 
domain morphology. In fact, exposure of DRMs purified from control and choles-
terol-enriched cells to ADDLs resulted in a remarkable reduction of domain heights 
(as measured with respect to the image background) to values similar to those ob-
served in DRMs purified from cells previously exposed to Aβ oligomers. On the con-
trary, domain height was substantially unchanged in DRMs purified from cholester-
ol-depleted cells (Table III).  
The domain lateral size in DRM preparations from control and cholesterol-
depleted cells exposed to Aβ oligomers was reduced, while that of DRMs from cho-
lesterol-enriched cells was substantially unchanged, suggesting that cholesterol hin-
ders the ADDL-DRM (and possibly raft) interaction. Furthermore, the domain size 
in DRMs purified from cells treated with Aβ1-42 oligomers was the same as that of 
the DRMs purified from control, not exposed, cells suggesting a possible recovery of 
the membrane structure in vivo. 
3.2 Results II 
3.2.1 Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative 
stress in Alzheimer’s disease 
Several lines of evidence suggest that the initial events of Aβ oligomerization and 
deposition in AD involve the interaction of soluble oligomers with neuronal mem-
branes. In this second part of the result section, was shown that Aβ42 oligomers are 
recruited to lipid rafts, which are ordered membrane microdomains rich in choles-
terol and gangliosides, resulting in lipid peroxidation, Ca2+ dyshomeostasis and 
greater membrane permeability in primary fibroblasts from familial AD patients 
(FAD) bearing APP Val717Ile, PS1 Leu392Val or PS1 Met146Leu gene mutations. 




Moreover, the presence of significantly higher levels of lipid peroxidation correlated 
with greater structural modification in detergent resistant domains (DRMs) isolated 
from APP and PS1 fibroblasts, compared to WT fibroblasts obtained from healthy 
subjects. The modulation of specific raft physicochemical properties, such as moder-
ate increases in cholesterol content, modest depletion of GM1 content and interfer-
ence with GM1 exposure or negative charge, precluded the interaction of amyloid 
aggregates with the plasma membrane and the resulting cell damage in FAD fibro-
blasts and cortical neurons from rat brains. These findings suggest a specific role for 
raft domains as primary mediators of amyloid toxicity in AD neurons. 
3.2.2 Lipid rafts are primary interaction sites for Aβ42 oligomers at the plasma 
membrane 
Mutations in PS1, PS2 or APP genes have been shown to increase production of 
42-residue amyloid peptides, i.e. the most amyloidogenic form of Aβ (Hardy and 
Selkoe, 2002). Accordingly, higher levels of Aβ42 peptide were found in the culture 
media of PS1 Leu392Val, PS1 Met146Leu and APPVal717Ile fibroblasts from FAD 
patients compared to WT fibroblasts from healthy subjects (Fig.18A left). APP fi-
broblasts, in particular, released significantly more Aβ42 than PS1 cells. Thus, we 
investigated whether FAD fibroblasts with altered proteolytic APP processing dis-
play increased oxidative damage. 8-OH isoprostane levels were significantly higher 
in PS1 and APP fibroblasts with respect to WT fibroblasts (Fig. 18A right). 
 
Figure 18. (A) Aβ42 levels in the cell culture media of WT, PS1 and APP fibroblasts were meas-
ured using a commercial ELISA kit. 8-OH isoprostane levels were quantified both in cell lysates 
and in the pooled flotillin-1-positive fractions (DRMs) purified from WT, PS1 and APP fibro-
blasts. (B) Representative confocal microscope images of lipid peroxidation in WT, PS1 and 
APP fibroblasts were achieved using the fluorescent probe BODIPY. Representative confocal 







Figure 19 Aβ42-GM1 interactions induce structural modification of DRMs. (A) Representa-
tive Western blot analysis of flotillin-1 levels in WT, PS1 and APP fibroblasts, determined 
from 14 sucrose gradient fractions collected from the top (low density) to the bottom (high 
density) of the gradient tube. An aliquot from each fraction was run on 12% SDS/PAGE, 
transferred onto a PVDF membrane and then incubated with mouse monoclonal anti-
flotillin-1 antibodies. Flotillin-1-positive fractions (DRMs) enriched in lipid raft microdo-
mains (from 3 to 5) were pooled and analyzed using contact mode AFM in liquid with a scan 
size of 5 μm. Steps or cavities were present in PS1 and APP DRMs (white arrows). (B) DPH 
fluorescence anisotropy, r, measured by incubating rafts from WT, PS1 and APP fibroblasts 
for 0, 5, 10, 30 and 60 min in the presence of 1.0 µM Aβ42 oligomers, and then for 30 min 
with DPH. All data is mean ± S.D. of four independent experiments. *p ≤ 0.05, significant 
difference vs WT fibroblasts. AFM image of DRMs purified from WT fibroblasts after 30 min 
incubation with 1.0 µM Aβ42 oligomers. Scan size 5 μm. 
Confocal microscope analysis confirmed the presence of enhanced cell-surface 
oxidation in FAD fibroblasts displaying greater basal Aβ production, as assessed us-
ing the fluorescent probe BODIPY 581/591C11 (Fig. 18B). Moreover, the increase in 
lipid peroxidation was higher in detergent-resistant membranes (DRMs) (Fig. 19A, 
left) compared to the entire membrane component (Fig. 18A, right), pointing to lipid 
rafts as a preferential site for Aβ42 interaction at the cell surface. Accordingly, we 
observed marked colocalization of Aβ42 oligomers with gangliosides in fibroblast 
membranes following exposure to Aβ42 aggregates (Fig. 18B). In particular, where 
green and red fluorescent signals were merged, a number of yellow areas, represent-
ing Aβ42-GM1 colocalization, were evident in PS1 and APP fibroblasts. Scatter plots 
of fluorescence signals, analyzed using Pearson’s correlation coefficient and the 
overlap coefficient according to Manders, yielded about 65% Aβ42-GM1 colocaliza-
tion in PS1 and APP fibroblasts and 50% in WT fibroblasts obtained from healthy 
subjects. Greater Aβ42-GM1 colocalization in FAD fibroblasts was associated with 
evident alteration of DRM morphology, as observed by contact mode AFM (Fig. 
19A). In particular, steps/cavities (white arrows), which were absent in WT DRMs, 
were found in PS1 and, to a greater extent, in APP DRMs. Disruption of the plasma 
membrane is evident from its granular appearance, where multiple small defects are 




formed. The greater membrane damage observed in APP samples correlates well 
with their increased release of Aβ42, compared to PS1 samples. Furthermore, expo-
sure of DRMs purified from WT fibroblasts to Aβ42 oligomers for 30 min generated 
extensive small lesions in lipid rafts (Fig. 19B, white arrows). Similar behaviour was 
observed in DRMs extracted from SH-SY5Y cells (Cecchi et al., 2009). Accordingly, 
the fluorescence anisotropy constant (r) of 1,6-diphenyl-1,3,5-hexatriene (DPH), 
which is inversely proportional to the degree of membrane fluidity, was higher in 
DRMs from PS1 and APP fibroblasts than that in corresponding lipid rafts from WT 
fibroblasts (Fig. 19B). Moreover, DRMs obtained from PS1 and, to a greater extent, 
APP fibroblasts showed a greater increase in stiffness when exposed to Aβ42 oligo-
mers, with respect to rafts purified from WT fibroblasts. 
3.2.3 Cholesterol and GM1 mediate Aβ42 accumulation at the plasma membrane  
Cholesterol and monosialoganglioside GM1 are two key components of lipid 
rafts, which are increasingly accepted as playing an important role in stimulating 
protein aggregation and forming interactions with protein oligomers (Ariga et al., 
2008; Ehehalt et al., 2003; Malchiodi-Albedi et al., 2010; Matsuzaki et al., 2010). 
Hence, we investigated whether cholesterol may modulate Aβ42 interaction with 
these liquid-ordered structures in FAD and WT fibroblasts. Moderate enrichment of 
membrane cholesterol, as assessed by filipin staining (Fig. 20), reduced the interac-
tion of Aβ42 oligomers with GM1, resulting in about 34% colocalization in PS1 and 
APP fibroblasts and 28% colocalization in WT cells, compared to similarly treated 
cells with basal cholesterol content (Fig. 18B and 21A). 
 
Figure 20. Modulation of membrane cholesterol in fibroblast cultures. Representative confo-
cal microscope analysis of membrane cholesterol in WT and FAD fibroblasts displaying PS1 
and APP gene mutations, probed using the fluorescent dye filipin III. Membrane cholesterol 
enrichment and depletion were achieved by supplementing fibroblast culture media with 0.2 
mg/ml βCD-Chol (Chol) for 3 h at 37 °C, or with 10 µM mevastatin (Mev) for 48 h at 37°C in 
the presence of 1% FBS, respectively. Filipin III fluorescence is expressed as a fractional 
change above the resting baseline, ΔF/F, where F is the average baseline fluorescence in con-
trol cells (assumed to be 100%) and ΔF represents the change in fluorescence with respect to 
baseline levels. The values shown are means ± S.D. of three independent experiments. 






In contrast, an increase in Aβ42-GM1 colocalization (about 80%) in PS1 and 
APP and, to a lesser extent, in WT fibroblasts (59%), was observed after cholesterol 
depletion. Accordingly, robust FRET between Aβ42 oligomers and GM1 was ob-
served in cholesterol-depleted fibroblasts (Fig. 21B), indicating that these two mole-
cules directly interact with each other at the cell surface (Day, et al., 2001; Kenwor-
thy et al., 2000). In particular, FRET was more detectable in FAD fibroblasts than in 
WT cells treated with mevastatin for 48 hours. In contrast, moderate enrichment of 
membrane cholesterol appeared to reduce Aβ42-GM1 interactions, as supported by 
the low intensity of colocalization signals (Fig. 21B). Accordingly, treatment with 
neuraminidase (NAA), which removes the sialic acid moiety from GM1, reduced the 
interaction of Aβ42 oligomers with GM1, resulting in about 20% colocalization in 




Figure 21. Cholesterol and GM1 mediate Aβ42 accumulation at the plasma membrane. (A) 
Representative confocal microscope images showing Aβ42 colocalization with GM1 (yellow). 
WT, PS1 and APP fibroblasts were treated with 1.0 µM Aβ42 for 30 min and then labeled 
with mouse monoclonal 6E10 anti-Aβ42 and fluorescein-conjugated anti-mouse antibodies 
(green), while GM1 was stained with fluorescent CTX-B conjugate (red). Scatter plots com-
pare Aβ42-GM1 colocalization in WT, PS1 and APP fibroblasts following treatment with 
Chol and Mev. Pixels were plotted as a function of red (x axis) and green (y axis) fluorescence 
intensity, resulting in little (top) or marked (bottom) Aβ42-GM1 colocalization. (B) Repre-
sentative FRET images showing Aβ42-GM1 colocalization in fibroblasts exposed to 1.0 µM 
Aβ42-FAM for 30 min following treatment with Chol and Mev. FRET efficiency images are 
presented using a pseudocolor scale for better visualization. The color of the bar represents 
the pixel density of the image and thus the intensity of interaction. (C) Representative confo-
cal microscope images showing Aβ42-GM1 colocalization in fibroblasts depleted of sialic acid 
(by addition of NAA) and then exposed to 1.0 μM Aβ42 for 30 min. Aβ42 oligomers were la-
beled with 6E10 antibodies (green), while GM1 was stained with Alexa Fluor 647-conjugated 
CTX-B (red). Pixels were plotted as above reported, resulting in little Aβ42-GM1 colocaliza-
tion.  




3.2.4 Cholesterol and GM1 mediate Ca2+ dyshomeostasis and extensive mem-
brane permeabilization induced by Aβ42 oligomers 
Perturbation of ion distribution across the plasma membrane is one of the earli-
est modifications displayed by cells exposed to toxic amyloid aggregates (Arispe et 
al., 2007; Decker et al., 2010; Demuro et al., 2010). Accordingly, a sharp increase in 
cytosolic Ca2+ was observed in FAD and WT fibroblasts exposed to Aβ42 oligomers 
(Fig. 22A). In particular, kinetic analysis revealed that the increase in intracellular 
Ca2+ levels in PS1 and APP fibroblasts, with rate constants (k1, k2) of 5.23(±0,10) x 
10-3 seconds-1, 5.86(±0,11) x 10-3 seconds-1, was greater compared to WT cells (k3) of 
2.07(±0,77) x 10-3 seconds-1. Furthermore, the increase in cytosolic Ca2+ content was 
much smoother and milder in cholesterol-enriched fibroblasts exposed to amyloid 
oligomers with respect to similarly treated control cells with basal cholesterol con-
tent (Fig. 22A,B). In contrast, membrane cholesterol depletion, following cell treat-
ment with mevastatin, triggered a greater increase in cytosolic Ca2+ levels. 
 
Figure 22. Cholesterol enrichment reduces Aβ42-induced Ca2+ dyshomeostasis. (A) Repre-
sentative confocal microscope images of cytosolic Ca2+ levels in WT, PS1 and APP fibro-
blasts, under basal conditions or following treatment with Chol and Mev, treated with 1.0 μM 
Aβ42 oligomers for 0, 10, 30 and 60 min at 37 °C. Cells were then treated for 30 min with 8.8 
μM fluo-3-AM. (B) Quantitative analysis of fluo-3 fluorescence. The values shown are means 
± S.D. of three independent experiments. *p≤0.05, significant difference vs relative control 






On the other hand, significant GM1 enrichment (Fig. 23A) induced a sharper 
rise in cytosolic Ca2+ levels than that observed in similarly exposed cells with basal 
GM1 levels (Fig. 23B). In contrast, a decrease in membrane GM1, following cell 
treatment with the glucosylceramide synthase inhibitor PDMP (Fig. 23A), prevented 
the Ca2+ spikes induced by Aβ42 oligomers (Fig. 23B). The binding of anti-GM1 an-
tibodies (AbGM1) to raft monosialoganglioside and sialic acid hydrolysis by NAA also 
precluded the increase in intracellular Ca2+. In any case, no change in Ca2+ levels was 
observed when fibroblasts were treated with GM1 or PDMP in the absence of Aβ42 
oligomers (Fig 23C). 
 
 
Figure 23. Depletion of GM1 reduces Aβ42-induced Ca2+ dyshomeostasis. (A) Representative 
confocal microscope images of GM1 content in WT, PS1 and APP fibroblasts under basal con-
ditions, or following treatment with 50 µg/ml GM1 or 25 µM PDMP for 48 h at 37°C. Semi-
quantitative values of the green fluorescent signal (rabbit polyclonal anti-GM1 antibodies) are 
shown on the left of each image. The values shown are means ± S.D. of three independent ex-
periments. *p≤0.05, significant difference vs relative control cells with basal GM1 levels. (B, C) 
Representative confocal microscope images of cytosolic Ca2+ levels in WT, PS1 and APP fibro-
blasts, under basal conditions or following treatment with GM1, PDMP, AbGM1 or a cocktail 
of NAA, exposed to 1.0 μM Aβ42 aggregates for 0 and 30 min at 37 °C (B), or not treated with 
aggregates (C). Cells were then treated for 30 min with 8.8 μM fluo-3-AM. 
Moreover, the presence of Aβ42 aggregates in the cell culture media triggered a 
sharp decrease in cell calcein fluorescence, suggesting extensive Aβ42 oligomer-
induced alteration of membrane permeability in fibroblasts (Fig. 24). The decrease 
in calcein fluorescence was less marked in Aβ42-exposed fibroblasts enriched in 




membrane cholesterol, while greater calcein leakage was observed in APP and PS1 
fibroblasts compared to WT controls, suggesting greater Aβ42 aggregate-induced 
alteration of membrane permeability in the former. Indeed, calcein-loaded APP and 
PS1 fibroblasts fluoresced less compared to WT fibroblasts, even prior to the exoge-
nous addition of Aβ42 aggregates, perhaps reflecting greater amyloid-induced mem-
brane damage in FAD cells displaying enhanced basal Aβ production (Fig. 24). No 
decrease in calcein fluorescence was observed in Aβ42-exposed, GM1-depleted fi-
broblasts. In contrast, in cholesterol-depleted or GM1-enriched fibroblasts, marked 




Figure 24. Cholesterol enrichment and GM1 depletion prevent membrane permeabilization 
induced by Aβ42 oligomers. Representative confocal microscope images showing cholesterol-
enriched (Chol), cholesterol-depleted (Mev), GM1-enriched (GM1) or GM1-depleted 
(PDMP) fibroblasts loaded with 2.0 μM calcein-AM for 20 min and then exposed to 1.0 µM 
Aβ42 aggregates for 30 min at 37 °C. 
3.2.5 GM1 modulates lipid peroxidation and cytotoxicity induced by Aβ42 oli-
gomers 
Aβ42 has been found to be tightly associated with monosialoganglioside GM1, 
implicating lipid rafts in the process of Aβ aggregation and deposition (Ariga et al., 
2001; Ehehalt et al., 2003). Accordingly, the binding of anti-GM1 antibodies (AbGM1) 
and cholera toxin (CTX-B) to raft GM1 reduced the alteration of membrane perme-
ability (as shown by decreased calcein leakage) and prevented the sharp increase in 
membrane oxidation (Fig. 25A,B). Calcein leakage was also prevented by treating 
fibroblasts with NAA (Fig. 25A). Moreover, BODIPY-loaded FAD fibroblasts 
showed a greater shift to green fluorescence than did WT cells when exposed to 
Aβ42 aggregates (Fig. 25B). However, this fluorescence shift was precluded by cul-
turing cells in a Ca2+-free medium, suggesting that the influx of extracellular Ca2+ is 







Figure 25 GM1 modulates membrane permeabilization, lipid peroxidation induced by Aβ42 
oligomers. (A) Representative confocal microscope images of WT, PS1 and APP fibroblasts 
loaded with 2.0 μM calcein-AM for 20 min. Cells were incubated in the absence or presence of 
AbGM1, CTX-B or NAA, as reported above, and subsequently exposed to 1.0 μM Aβ42 oligo-
mers for 30 min. (B) Representative confocal microscope images of lipid peroxidation in fibro-
blasts pre-incubated for 20 min with AbGM1 or CTX-B and subsequently exposed to 1.0 μM 
Aβ42 oligomers for 30 min. As a control, cells were also exposed to Aβ42 aggregates in a Ca2+-
free medium. Lipid peroxidation was analyzed using the fluorescent probe BODIPY 581/591C11.  
The MTT assay was then performed in fibroblasts previously modulated in GM1 
content, structure or accessibility, following 24 h exposure to 1.0 μM Aβ42 oligo-
mers. As shown in Fig. 26, the increase in GM1 content triggered a slight increase in 
Aβ42 toxicity relative to that observed in fibroblasts with basal GM1 content. In 
contrast, membrane GM1 depletion, membrane binding with anti-AbGM1 or CTX-B, 
and GM1 charge modification improved fibroblast viability, suggesting a major role 
for GM1 raft domains in amyloid-induced cytotoxicity. 
 
 
Figure 26 GM1 modulates Aβ42-induced cytotoxicity. Aggregate cytotoxicity in FAD and 
WT fibroblasts was assessed using the MTT assay. Cells were GM1-enriched (GM1), GM1-
depleted (PDMP) or incubated for 20 min in the absence or presence of AbGM1, CTX-B or 
NAA, prior to treatment with 1.0 μM Aβ42 aggregates for 24 h at 37 °C. Cell viability was ex-
pressed as a percentage of MTT reduction in treated cells compared to corresponding un-
treated cells, where it was assumed to be 100%. 




3.2.6 GM1 mediates Aβ42-induced Ca2+ dyshomeostasis, lipid peroxidation and 
cytotoxicity in rat cortical neurons 
We next investigated the effects of Aβ42 oligomers on intracellular Ca2+ content 
and membrane lipoperoxidation in cultured rat cortical neurons with varying GM1 
content. A moderate increase in membrane GM1 content, as assessed by confocal 
microscopy using AbGM1 antibodies (Fig. 27A), resulted in a sharper increase in cyto-
solic Ca2+ (Fig. 27B) and membrane oxidation (Fig. 27C) in neurons, compared to 
that observed in Aβ42-exposed cells with basal GM1 content (Fig. 27B,C). In con-
trast, following GM1 depletion by PDMP treatment, the binding of AbGM1 to raft 
monosialoganglioside and sialic acid hydrolysis by NAA precluded the increase in 
intracellular Ca2+ (Fig. 27B) and lipoperoxidation of the cell membrane (Fig. 27C). 
No change in cytosolic Ca2+ levels was observed when rat neurons, in the absence of 
Aβ42 oligomers, were pre-treated so as to modulate GM1 content, exposure or 
charge. Moreover, membrane oxidation was prevented by culturing cells in a Ca2+-
free medium, suggesting that the influx of extracellular Ca2+ is involved in Aβ42 oli-




Figure 27. GM1 depletion reduces Aβ42-induced Ca2+ dyshomeostasis and membrane 
lipoperoxidation in rat cortical neurons. (A) Representative confocal microscope images of 
GM1 content in neurons under basal conditions, or following treatment with 100 µM GM1 or 
25 µM PDMP for 24 h at 37 °C. (B) Representative confocal microscope images of cytosolic 
Ca2+ levels in neurons, under basal conditions or following treatment with GM1, PDMP, 
AbGM1 or NAA, exposed to 5.0 μM Aβ42 aggregates for 0 (-) and 30 (+) min at 37°C. (C) 
Representative confocal microscope images of lipid peroxidation in cells under basal condi-
tions or pre-incubated with GM1, PDMP, AbGM1 or NAA, and subsequently exposed to 5.0 
μM Aβ42 oligomers (+) for 30 min. As a control, cells were also exposed to Aβ42 aggregates 
in a Ca2+-free medium. 
Next, we investigated whether changes in cytosolic calcium levels and mem-
brane lipoperoxidation also resulted in neurotoxicity. As shown in Fig. 28, Aβ42 oli-
gomers triggered a substantial decrease in MTT reduction, compared to untreated 






icity relative to that observed in neurons with basal GM1 content. In contrast, mem-
brane GM1 depletion and GM1 charge modification improved neuron viability, 
confirming for the role of GM1 raft domains in amyloid-induced cytotoxicity. 
 
 
Figure 28. GM1 depletion reduces Aβ42-induced cytotoxicity in rat cortical neurons. MTT 
reduction assay carried out in cells pre-treated with GM1, PDMP, AbGM1 or NAA, prior to 
treatment with 5.0 μM Aβ42 aggregates for 24 h at 37 °C. The reported values are means ± 
S.D. of three independent experiments. *p≤0.05, significant difference vs relative control cells. 
 
3.3 Results III 
3.3.1 Membrane lipid composition and its physicochemical properties define cell 
vulnerability to aberrant protein oligomers 
Increasing evidence suggests that the interaction of misfolded protein oligomers 
with cell membranes is a primary event resulting in the cytotoxicity associated with 
many protein misfolding diseases, including neurodegenerative disorders.  
In the third part of the result section are describe the relative contributions to 
toxicity of the physicochemical properties of both protein oligomers and the cell 
membrane with which they interact. We modulated the membrane content of cho-
lesterol and the ganglioside GM1 in SH-SY5Y cells exposed to two types of oligo-
mers of the prokaryotic protein HypF-N displaying different ultrastructural and cy-
totoxicity properties, and to oligomers formed by Aβ peptide associated with Alz-
heimer’s disease. The data reveal that the degree of toxicity of the oligomeric species 
results from a complex interplay between the structural and physicochemical fea-
tures of both the oligomers and the cellular membrane. 
3.3.2 Membrane cholesterol content modulates oligomer cytotoxicity 
We increased or decreased the membrane cholesterol content in human SH-
SY5Y neuroblastoma cells by incubating the latter in solutions containing three dif-
ferent concentrations of either soluble cholesterol (Chol), methyl-β-cyclodextrin (β-
CD) or mevastatin (Mev) (Fig. 29); β-CD and Mev are known to remove cholesterol 
from the plasma membrane of cultured cells and to inhibit cholesterol biosynthesis, 
respectively (Endo et al., 1976; Yancey et al., 1996). Cell treatment with 0.2 or 0.5 




mg/ml Chol significantly increased the content of membrane cholesterol (to 
13.01±0.92 and 15.66±1.53 μg/mg protein respectively) relative to untreated cells 
(9.85±1.13 μg/mg protein). Conversely, membrane cholesterol was significantly re-
duced by treatment with 1.0 or 2.0 mM β-CD (to 6.75±0.49 and 5.78±0.23 μg/mg 
protein respectively) or with 5.0 or 10 μM Mev (to 7.82±0.42 and 6.58±0.35 μg/mg 
protein respectively) (Fig. 29A). These data were confirmed by confocal microscopy 
using the fluorescent probe filipin, whose fluorescence increases upon binding to 
cholesterol (Fig. 29B) (Drabikowski et al., 1973).  
 
 
Figure 29. Modulation of cholesterol levels in human SH-SY5Y neuroblastoma cells. (A) The 
quantity of membrane cholesterol was determined by a fluorimetric assay. The asterisk indi-
cates a significant difference relative to cells with basal cholesterol levels (p≤0.05). (B) Repre-
sentative confocal microscopy images showing the quantity of membrane cholesterol in SH-
SY5Y cells, probed by the fluorescent dye filipin. The green fluorescence intensity in the im-
ages correlates with the amount of membrane cholesterol. In both panels the values reported 
are means ± S.D. of four independent experiments.  
Our recent results have shown that oligomers generated from the small prokaryot-
ic protein HypF-N under different destabilising conditions (A or B) differ significantly 
in their sub-microscopic structural properties and cytotoxicities, though displaying 
similar morphological and tinctorial properties (Campioni et al., 2010; Zampagni et 
al., 2011). To assess the effects of the alteration of membrane cholesterol on the cyto-
toxicity of either form of HypF-N oligomer, we first evaluated their effects on cell via-
bility parameters describing mitochondrial status and chromatin condensation using 
the MTT and Hoechst 33342 assays, respectively. As revealed by the MTT assay, Chol-
enriched SH-SY5Y cells exposed to type A oligomers, which have been found to be 
highly toxic to cells with basal cholesterol content, showed significantly improved via-
bility (Fig. 30), whereas similarly treated cells remained fully viable upon exposure to 







Figure 30. Cytotoxicity caused by type A and type B HypF-N oligomers in cells enriched with, 
or depleted in, cholesterol. MTT reduction assay carried out on basal, cholesterol-enriched 
(Chol) and cholesterol-depleted (β-CD or Mev) SH-SY5Y cells treated for 24 h with type A 
(light grey) or type B (dark grey) HypF-N oligomers (12 µM monomer concentration). Cell 
viability was expressed as the percentage of MTT reduction in treated cells as compared to 
corresponding cells not exposed to the oligomers but treated with corresponding amounts of 
Chol, β-CD or Mev. The values reported are means ± S.D. of six independent experiments. 
The symbols * and § indicate significant differences relative to basal cells exposed to type A 
and B HypF-N oligomers, respectively (p≤0.05). 
By contrast, loss of membrane cholesterol following cell treatment with β-CD or 
Mev resulted not only resulted in a greater loss of cell viability in the presence of 
type A oligomers, but also in the appearance of significant cytotoxicity following the 
exposure to type B oligomers (Fig. 30). A similar modulation of oligomer cytotoxici-
ty was observed for the cells with different cholesterol content when treated with 
Aβ42 oligomers (Fig. 31). Furthermore, we found that membrane cholesterol con-
tent did not influence the toxicity of H2O2. Indeed cholesterol-enriched, cholesterol-
depleted or cells with basal content of cholesterol displayed the same degree of tox-
icity upon exposure to 150 µM H2O2, suggesting that toxicity modulation by choles-
terol is specific for protein oligomers (Fig. 31). By contrast, cell pre-incubation with 
100 μM vitamin E for 24 h induced a complete suppression of cytotoxicity following 
treatment with Aβ42 oligomers or H2O2 (Fig. 31). 
Taken together, these observations indicate that, in our system, oligomer toxicity 
depends not only on the type of oligomer but also on the amount of cholesterol in 
the cell plasma membrane.  
The cells treated with Chol, β-CD and Mev were also stained with Hoechst 
33342, a fluorescent marker that binds to the highly condensed chromatin present 
in the nuclei of apoptotic cells (Weisblum and Haenssler, 1974). Fluorescence mi-
croscopy images show that type A oligomers increased the apoptotic status of the 
SH-SY5Y cells, whereas neither type B oligomers nor the native protein had any 
effect, thus mirroring the data obtained with the MTT test (Fig. 32A,B). The imag-
es show that cholesterol modulates the apoptotic response induced by exposure to 
HypF-N oligomers; indeed, the cells enriched in cholesterol were resistant to type 
A oligomers, whereas the cells depleted in cholesterol by treatment with β-CD or 
Mev not only increased their apoptotic status when exposed to type A oligomers 
but also became apoptotic even in the presence of type B oligomers (Fig. 32C).  





Figure 31. Cytotoxicity of Aβ42 oligomers and H2O2 in cells enriched with, or depleted in, cholester-
ol. MTT reduction assay carried out on basal cells or on cells treated with 0.5 mg/ml Chol, 2.0 mM β-
CD or 10 µM Mev and then exposed for 24 h to 12 µM Aβ42 or to 150 µM H2O2 or pretreated for 48 
h with 100 µM vitamin E prior to Aβ42 or H2O2 exposure. The values reported are means ± S.D. of 
four independent experiments. Cell viability was expressed as the percentage of MTT reduction in 
treated cells as compared to corresponding cells not exposed to the oligomers but treated with corre-
sponding amounts of Chol, β-CD, Mev. The symbols § and * indicate significant differences relative 
to basal untreated cells and basal cells treated with Aβ42, respectively (p≤0.05). 
 
Figure 32. Chromatin condensation caused by type A or type B HypF-N oligomers in cells with dif-
ferent cholesterol content. Hoechst staining (A) and MTT reduction assay (B) carried out on basal 
cells exposed for 24 h to 12 µM type A or type B HypF-N oligomers or to native monomeric HypF-N. 
The blue fluorescence arises from Hoechst 33342 dye bound to apoptotic nuclei. The MTT values 
reported are means ± S.D. of six independent experiments. The symbol * indicates significant differ-
ences relative to untreated cells (p≤0.05). (C) Hoechst staining test showing apoptotic pathway activa-
tion induced by type A and B HypF-N oligomers in cells enriched with cholesterol (Chol) or depleted 







Figure 33. Caspase-3 activation caused by type A and type B HypF-N oligomers in cells enriched 
with, or depleted in, cholesterol. Representative confocal scanning microscopy images of basal, 
cholesterol-enriched and cholesterol-depleted cells showing caspase-3 activation following 
treatment for 24 h with type A (upper images) or type B (lower images) HypF-N oligomers (12 
µM). Caspase-3 activity was assessed using the fluorescent probe FAM-FLICA™ Caspase 3&7 
(green). The presence and concentrations of Chol, β-CD and Mev, and the corresponding semi-
quantitative values of the green fluorescence signal, are shown below each confocal image for 
type A (light grey) and type B (dark grey) oligomers. The values reported are means ± S.D. of 
three independent experiments. The symbols * and § indicate significant differences relative to 
basal cells exposed to type A and B HypF-N oligomers, respectively (p≤0.05). 
A similar trend was observed by measuring caspase-3 activity, a well recognised 
apoptotic marker. Indeed, when cells significantly enriched in membrane cholesterol 
were exposed to type A oligomers, a reduced caspase-3 activation was observed with 
respect to similarly treated cells with basal cholesterol content (Fig. 33). Under these 
conditions, type B oligomers induce no change in caspase-3 activity.  
By contrast, type A oligomers triggered a significant increase in the activation of 
the apoptotic pathway in cells significantly depleted in membrane cholesterol rela-
tive to cells with basal cholesterol content (Fig. 33). In addition, similarly treated 
cells exposed to type B oligomers showed significant increases in caspase-3 activity, 
with respect to cells with basal cholesterol levels. 
3.3.3 Membrane cholesterol modulates oligomer-induced alteration of intracellu-
lar Ca2+ homeostasis and ROS levels 
It is widely accepted that disruption of intracellular Ca2+ homeostasis and impair-
ment of redox status are among the earliest biochemical consequences of the interac-
tion of prefibrillar amyloid assemblies with cell membranes (Butterfield et al., 2001; 
Hyun et al., 2002; Kourie, 2001). We therefore investigated the effects of the two dis-
tinct types of HypF-N oligomers on the intracellular Ca2+ content and reactive oxygen 




species (ROS) production in SH-SY5Y neuroblastoma cells with different cholesterol 
levels using confocal microscopy. When cells significantly enriched in membrane cho-
lesterol content were exposed to type A oligomers, a smaller rise in cytosolic Ca2+ (Fig. 
34A) and ROS (Fig. 34B) levels was observed with respect to cells with basal cholester-
ol content that were treated similarly. Under these conditions, type B oligomers do not 
induce any change in free Ca2+ or ROS, although type A oligomers were found to cause 
significant increases in the levels of both these species (Fig. 34A,B) in cells depleted in 
membrane cholesterol by treatment with 1.0 or 2.0 mM β-CD or with 5.0 or 10 µM 
Mev relative to cells with basal cholesterol content. In addition, cells treated similarly 
exposed to type B oligomers showed significant increases in intracellular Ca2+ (Fig. 
34A) and ROS (Fig. 34B), with respect to cells with basal cholesterol levels. 
 
 
Figure 34. Cytosolic Ca2+ spikes and ROS production in cells with different cholesterol con-
tent exposed to type A and type B HypF-N oligomers. (A) Representative confocal scanning 






Mev) cells showing levels of intracellular free Ca2+ (A) or intracellular ROS production (B) 
following treatment for 1 h with type A (upper images) or type B (lower images) HypF-N oli-
gomers (12 µM). The corresponding semi-quantitative values of the green fluorescence signal, 
are shown below each confocal image for type A (light grey) and type B (dark grey) oligo-
mers. The symbols * and § indicate significant differences relative to basal cells exposed to 
type A and B HypF-N oligomers, respectively (p≤0.05).  
To investigate whether or not the alteration of Ca2+ levels triggered the apoptotic 
pathway, we measured caspase-3 activation in cholesterol-depleted cells exposed to 
aggregates either in the presence of the intracellular Ca2+ chelator BAPTA-AM or in 
Ca2+-free medium. The early (3 h) increase in caspase-3 activity, following the addition 
of both types of oligomers, was prevented when the cells were pre-treated for 30 min 
with 10 µM BAPTA-AM or cultured in a Ca2+-free medium, suggesting a primary 
causative role for the influx of extracellular Ca2+ in the apoptotic pathway (Fig. 35). 
 
 
Figure 35. Ca2+-dependent capase-3 activation induced by type A and type B HypF-N oligo-
mers. Representative confocal scanning microscopy images showing caspase-3 activation in 
cholesterol-depleted cells (2.0 mM β-CD) exposed for 3 h to no oligomers, 12 µM type A or 
type B HypF-N oligomers after pre-treatment with 10 µM BAPTA-AM for 30 min or in cul-
ture media with or without free Ca2+. The corresponding semi-quantitative values of the sig-
nals, are shown below each confocal image. The values reported are means ± S.D. of three in-
dependent experiments. The symbol * indicates significant differences relative to cholesterol-
depleted cells treated with no oligomers (p≤0.05). 
3.3.4 Cholesterol levels modulate membrane permeability to the oligomers  
Next, we sought to assess whether the modulation of membrane cholesterol lev-
els affected the ability of either oligomer type to interact with the plasma membrane 
of SH-SY5Y cells, triggering loss of membrane integrity and inducing membrane 




permeabilization. We found that the previously reported ability of SH-SY5Y cells 
with basal content of cholesterol to internalise type A oligomers (Campioni et al., 
2010; Zampagni et al., 2011) was significantly increased when SH-SY5Y cells were 
treated with the highest concentrations of β-CD or Mev; conversely, oligomer inter-
nalisation was significantly reduced in cells most enriched in membrane cholesterol 
(Fig. 36). In contrast, type B oligomers, found to be unable to cross the plasma 
membrane of basal SH-SY5Y cells, became increasingly internalised in cells treated 
with β-CD or Mev, but not with Chol, as assessed by confocal microscope analysis 
(Fig. 36).  
 
 
Figure 36. Interaction of type A and B HypF-N oligomers with the plasma membrane of cells 
enriched with, or depleted in, cholesterol. Representative confocal scanning microscopy z-
stacks images of basal, cholesterol-enriched (Chol) and cholesterol-depleted (β-CD and Mev) 
cells treated for 1 h with 12 µM type A (upper images) or type B (lower images) HypF-N oli-
gomers. In all images, red and green fluorescence indicates cell profiles and HypF-N oligo-
mers, respectively. The presence and concentrations of Chol, β-CD and Mev, and the corre-
sponding semi-quantitative values of the green fluorescence signal arising from HypF-N oli-
gomers inside the cells, are shown below each confocal image for type A (light grey) and B 
(dark grey) oligomers. The values reported are means ± S.D. of three independent experi-
ments. The symbols * and § indicate significant differences relative to basal cells exposed to 
type A and B HypF-N oligomers, respectively (p≤0.05).  
The imaging of different optical sections (including basal, intermediate median 
and apical planes) of cholesterol-depleted cells revealed not only the presence of 








Figure 37. Aggregate internalisation by endocytosis, in cholesterol depleted cells. (A) Repre-
sentative optical sections taken through 2.0 mM β-CD treated cells by confocal scanning mi-
croscopy after exposure for 1 h to HypF-N oligomers at basal, median and apical focal 
lengths, as indicated. (B) Representative confocal microscope images of live cells with re-
duced content of cholesterol incubated for 1 h with 5.0 μg/ml FM4-64 (red) and with 5-FITC 
type A (upper images) and B (lower images) HypF-N oligomers (green). The overlay image 
shows that oligomers uptake is concomitant with the internalization of FM4-64, a lipophilic 
dye widely used as a marker of endocytotic vesicles. The scatter plots indicate the oligomers-
vesicle colocalization pattern; the sampled pixels were plotted as a function of red (x axis) and 
green (y axis) fluorescence intensity. (C) Representative optical sections taken through 2.0 
mM β-CD treated cells by confocal scanning microscopy after exposure for 1 h to Aβ42 oli-
gomers at basal, median and apical focal lengths, as indicated.  
Futher experiments showed that both type A and B oligomers appeared to be in-
ternalized and sorted into endocytotic vesicles in live cells (Fig. 37B). Indeed, confo-
cal laser microscopy showed a marked colocalization (by ∼ 85%) of HypF-N 5-FITC-
labelled oligomers with FM4-64, a widely used marker for endocytotic vesicles. In 
particular, when the images were merged, a large number of yellow areas represent-
ing the colocalization of endocytotic vesicles (red) with fluorescent oligomers 




(green) was seen. The analysis over three different experiments yielded a similar de-
gree of colocalization between endocytotic vesicles and type A or type B oligomers in 
cholesterol depleted cells following treatment with 2.0 mM β-CD (Fig. 37B), as as-
sessed by two different algorithms, the Pearson's correlation coefficient and the 
overlap coefficient according to Manders.  
The modulation of the ability to internalise the oligomers by differently treated 
cells was also examined by measuring membrane permeability using calcein as a fluo-
rescent probe. Analysis by confocal microscopy of SH-SY5Y cells pre-loaded with the 
calcein-AM fluorescent probe showed that cell exposure to type A oligomers resulted 
in a clear decrease of fluorescence intensity in cells with a high reduction of cholesterol 
content relative to those with basal cholesterol levels, indicating increased membrane 
permeabilization in the former (Fig. 38). By contrast, the reduction of calcein fluores-
cence was significantly less evident in cells that were enriched in cholesterol when ex-
posed to type A oligomers, suggesting a reduced permeabilization. Moreover, mem-
brane permeabilization was not observed in cells with normal or increased cholesterol 
content exposed to type B oligomers, whereas cells with a decreased cholesterol con-
tent exposed to the same oligomers showed a significant increase in membrane per-
meabilization with respect to cells with basal cholesterol levels (Fig. 38). Taken togeth-
er, these results suggest that oligomer recruitment across the plasma membrane and 
the permeability of the membrane to cytosolic molecules are closely related to each 
other, and that membrane cholesterol modulation strongly affects the extent to which 
the different types of oligomers are able to induce both effects. 
 
 
Figure 38. Membrane permeability induced by type A and B HypF-N oligomers in cells en-
riched with, or depleted in, cholesterol. Representative confocal scanning microscopy images 
showing basal, cholesterol-enriched (Chol) and cholesterol-depleted (β-CD and Mev) cells 






ages) HypF-N oligomers (12 µM). The presence and concentrations of Chol, β-CD and Mev, 
and the corresponding semi-quantitative values of the calcein fluorescence intensity, are 
shown below each confocal image for type A (light grey) and B (dark grey) oligomers. The 
values reported are means ± S.D. of three independent experiments. The symbols * and § in-
dicate significant differences relative to basal cells exposed to type A and B HypF-N oligo-
mers, respectively (p≤0.05).  
3.3.5 Membrane GM1 affects the cytotoxic and permeabilizing effects of HypF-N 
oligomers 
Several studies have indicated that monomeric and oligomeric Aβ bind prefer-
entially to GM1, a monosialoganglioside that is abundant in neuronal cell mem-
branes, particularly in lipid rafts. Binding to GM1 has also been found to stimulate 
fibril formation by Aβ peptides (Ariga et al., 2001; Kakio et al., 2002; Malchiodi-
Albedi et al., 2010; Matsuzaki et al., 2010; McLaurin et al., 1998; Wakabayashi and 
Matsuzaki, 2007; Wang et al., 2005); similar effects have been reported for other 
peptides such as amylin (Wakabayashi and Matsuzaki, 2009) and salmon calcitonin 
(sCTO) (Diociaiuti et al., 2006). In addition, treatment with neuraminidase (NAA), 
which removes the sialic acid moiety from gangliosides, has been reported to inhibit 
sCTO neurotoxicity and its associated biochemical modifications (Malchiodi-Albedi 
et al., 2010). Here, we studied the effects of membrane GM1 modulation on the cyto-
toxicity of either type of HypF-N oligomers. To this end, we incubated separate 
batches of SH-SY5Y cells with GM1 from bovine brain or with D-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP), a glucosylceramide synthase 
inhibitor that blocks the natural synthesis of GM1 (Tamboli et al., 2005). Treatment 
of SH-SY5Y cells with GM1 significantly increased the GM1 content in the cell 
membrane, whereas PDMP treatment significantly reduced the membrane GM1 lev-
el, as assessed by dot blot, flow cytometry and confocal microscopy analyses using 
anti-GM1 antibodies and cholera toxin subunit B (CTX-B) (Fig. 39). The specificity 
of our antibodies to GM1 was confirmed by the lack of cross-reactivity with GD1a 
and GT1b neuronal gangliosides, as shown by dot blot analysis (Fig. 39, top right). 
In our cell model, we found that the increase in membrane GM1 did not modify 
substantially the toxicity of type A oligomers, whereas it caused type B oligomers to 
become significantly toxic and able to induce caspase-3 activation (Fig. 40A,B). 
Conversely, a decrease in GM1 by cell treatment with PDMP or NAA did not modi-
fy cell resistance to type B oligomers, but suppressed cell vulnerability to type A oli-
gomers (Fig. 40A;B). 
A similar trend was observed when cells with different GM1 content were treat-
ed with Aβ42 aggregates (Fig. 41), suggesting that amyloid cytotoxicity generically 
depends on the GM1 content in the cell plasma membrane. By contrast, the modula-
tion of membrane GM1 did not affect the toxicity of 150 µM H2O2, supporting a 
specific involvement of membrane GM1 in amyloid oligomer cytotoxicity (Fig. 41).  
 





Figure 39. Dot-blot and the corresponding densitometric analysis (top, left) of the GM1 con-
tent in the membrane fraction of untreated cells or of cells pre-treated with 32 µM GM1 or 25 
µM PDMP. The specificity of the antibodies to GM1 is shown by the lack of cross-reactivity 
to GD1a and GT1b gangliosides (dot-blot on the right). Flow cytometric analysis (top, right) 
of membrane GM1 content in untreated cells (blue) or in cells pre-treated with GM1 (red) or 
PDMP (green). After GM1 modulation, single-cell suspensions were incubated with the fluo-
rescent probe CTX-B. The confocal microscopy images (bottom) show the cell surface GM1 
distribution probed by anti-GM1 antibodies (green) or the CTX-B conjugate (red).  
 
Figure 40. Cytoxicity and caspase-3 activation caused by type A and type B HypF-N oligo-
mers in cells enriched with, or depeted in, GM1. (A) MTT reduction assay carried out on un-
treated (basal), GM1-enriched (GM1), GM1-depleted (PDMP) and sialic-acid-depleted 






(12 µM). Cell viability was expressed as the percentage of MTT reduction in treated cells as 
compared to corresponding cells not exposed to the oligomers but treated with correspond-
ing amounts of GM1, PDMP or NAA. The values reported are means ± S.D. of three inde-
pendent experiments. The symbols * and § indicate significant differences relative to basal 
cells exposed to type A and B HypF-N oligomers, respectively (p≤0.05). (B) Representative 
confocal scanning microscopy images and the corresponding semi-quantitative values of the 
fluorescent signals showing caspase-3 activation in untreated (basal), GM1-enriched (GM1) 
or GM1-depleted (PDMP) cells. Caspase-3 activity was assessed using the fluorescent probe 
FAM-FLICA™ Caspase 3&7 (green). 
 
 
Figure 41. Cytotoxicity of Aβ42 oligomers and H2O2 in cells enriched with, or depleted in 
GM1. MTT reduction assay carried out on GM1-enriched (GM1), GM1-depleted (PDMP) 
and sialic-acid-depleted (NAA) cells exposed for 24 h to 12 µM Aβ42 or 150 µM H2O2. The 
values reported are means ± S.D. of four independent experiments. Cell viability was ex-
pressed as the percentage of MTT reduction in treated cells as compared to corresponding 
cells not exposed to the oligomers but treated with corresponding amounts of GM1, PDMP 
or NAA. The symbols § and * indicate significant differences relative to basal untreated cells 
and basal cells treated with Aβ42, respectively (p≤0.05). 
As with the results obtained by modulating the content of membrane cholester-
ol, these findings were confirmed by cell permeability data. Indeed, SH-SY5Y cells 
with increased GM1 content showed a significantly higher internalisation of type B 
oligomers into the cells and an enhanced membrane permeability to calcein with re-
spect to cells with basal levels of GM1 (Fig. 42A,B). By contrast, cells pre-treated 
with PDMP or NAA displayed a significantly reduced entry of type A oligomers into 
the cells and a reduced membrane permeability to calcein with respect to cells with 
basal levels of GM1 (Fig. 42A,B). 





Figure 42. Penetration of, and membrane permeability induced by, type A and type B HypF-
N oligomers in cells with altered GM1 content. (A) Representative confocal scanning micros-
copy images of basal, GM1-enriched (GM1), GM1-depleted (PDMP) and sialic-acid-depleted 
(NAA) cells exposed for 1 h to type A (upper images) or type B (lower images) HypF-N oli-
gomers (12 µM). In all images, red and green fluorescence indicates cell profiles and HypF-N 
oligomers, respectively. The semi-quantitative values of the green fluorescence intensity aris-
ing from HypF-N oligomers inside the cells are shown below each confocal image for type A 
(light grey) and type B (dark grey) oligomers. The values reported are means ± S.D. of three 
independent experiments. (B) Representative confocal microscopy images showing basal, 
GM1-enriched (GM1), GM1-depleted (PDMP) and sialic-acid-depleted (NAA) cells pre-
loaded with calcein-AM and then exposed to type A (upper images) or type B (lower images) 
HypF-N oligomers (12 µM). The semi-quantitative values of the calcein fluorescence are 
shown below each confocal image for type A (light grey) and type B (dark grey) oligomers. 
The values reported are means ± S.D. of three independent experiments. In both panels the 
symbols * and § indicate significant differences relative to basal cells exposed to type A and 
type B HypF-N oligomers, respectively (p≤0.05). 
3.3.6 GM1, rather than cholesterol,  plays a dominant role in oligomer cytotoxici-
ty and membrane permeability 
The observation of the opposite effects of membrane cholesterol and GM1 on 
the cytotoxicity of oligomers, and on their ability to interact with, and to permea-
bilize, the cell membrane, prompted us to explore the relative contributions of the 
two lipids to the overall effects described above. Initially, we modified the content of 
membrane cholesterol by incubating the cells in the presence of the different con-






evaluated the GM1 content in their plasma membrane. Cholesterol enrichment re-
sulted in a dose-dependent decrease of membrane GM1 with respect to untreated 
cells, as assessed by flow cytometry analysis (Fig. 43A). In accord with these findings, 
confocal microscopy and dot-blot analyses showed a marked decrease in the mem-
brane content of GM1 (by ~ 30%) in cells with the highest Chol concentration rela-
tive to basal cells (Fig. 43B,C). 
 
Figure 43. (A) Flow cytometric analysis of membrane GM1 content in basal, cholesterol-
enriched (Chol) and cholesterol-depleted (β-CD or Mev) cells. (B) Representative confocal 
microscopy analysis of the cell surface GM1 distribution probed by anti-GM1 antibodies 
(green) or by the fluorescent CTX-B conjugate (red). (C) Dot blot analysis of the GM1 con-
tent in the membrane fraction of untreated cells (basal) or of cells treated with 0.5 mg/ml 
Chol, 2.0 mM β-CD, 10 µM Mev, 32 µM GM1 or with a mixture of 0.5 mg/ml Chol and 32 
µM GM1. (D) Membrane cholesterol in untreated cells (basal) or in cells pre-treated with 32 
µM GM1, 25 µM PDMP, 0.5 mg/ml Chol and 32 µM GM1 or 0.5 mg/ml Chol. The symbols *, 
§, ° indicate a significant difference relative to basal, GM1 and Chol treated cells, respectively 
(p≤0.05). 
Conversely, cholesterol depletion following cell treatment with β-CD or Mev de-
termined an inverse modulation of GM1, whose levels were significantly increased 
after exposure to the highest concentrations of β-CD (by ~ 30%) or Mev (by ~ 40%) 
(Fig. 43A,B,C). In a separate set of experiments, we measured the levels of cholester-
ol in cells with different GM1 content following treatment with GM1 or PDMP. We 
found that the increase in the GM1 level significantly decreased the content of cho-
lesterol in the cell membrane (by ~ 25%) as compared to that measured in untreated 
cells; conversely, the cholesterol content was found to be slightly increased (by ~ 
15%) in cells depleted in GM1 (Fig. 43D). These data indicate that the apparent bio-
logical effects of the perturbation of the levels of either lipid could be the result, at 
least in part, of the alteration of the other. 




We therefore sought to assess the effect of the modification of both cholesterol 
and GM1 levels in the same cells. Cell exposure to both Chol and GM1 resulted in a 
remarkable increase of the GM1 content (by ~ 55%), as assessed by densitometric 
analysis of dot-blots (Fig. 43C) and a slight increase in cholesterol levels (by ~ 10%), 
as assessed by the fluorimetric assay (Fig. 43D). In particular, in cells treated with 
both lipids, the cholesterol content was significantly higher or lower relative to cells 
treated only with GM1 or Chol, respectively. These cells were significantly more sus-
ceptible to, and permeabilised by, type B oligomers with respect to basal cells (Fig. 
44A,B); by contrast, loss of membrane cholesterol and sialic acid upon treatment 
with both Mev and NAA resulted in a significant decrease of cell vulnerability to, 
and permeabilisation by, type A oligomers versus basal cells (Fig. 44A,B). According-
ly, cholesterol and GM1 depletion following treatment with both Mev and PDMP, 
respectively, suppressed type A oligomer toxicity (Fig. 44A). Taken together, the two 
sets of data indicate that GM1, rather than cholesterol, plays a dominant role in me-
diating HypF-N oligomer cytotoxicity and that the effects observed by modifying the 
cholesterol content in the cell membrane can, at least in part, be the result of the as-
sociated inverse modulation of GM1. 
 
Figure 44. Cytoxicity and penetration of type A and type B HypF-N oligomers in cells with 
altered content of both cholesterol and GM1. (A) MTT reduction assay in untreated cells (ba-
sal), in cells treated with both 0.5 mg/ml cholesterol and 32 µM GM1 (Chol+GM1), in cells 
depleted both in cholesterol and in sialic acid using 10 µM Mev, 117 mU/ml of V. cholerae 
NAA and 33 mU/ml of A. ureafaciens NAA (Mev+NAA), or in cells depleted both in choles-
terol and in GM1 using 10 µM Mev and 25 µM PDMP (Mev+PDMP) and then exposed for 
24 h to type A (light grey) or type B (dark grey) HypF-N oligomers (12 µM). Cell viability was 






cells not exposed to the oligomers but treated with corresponding amounts of Chol and GM1, 
Mev and NAA, Mev and PDMP. The values reported are means ± S.D. of six independent 
experiments. (B)	  Representative confocal scanning microscopy images of untreated (basal), 
cholesterol- and GM1-enriched (Chol+GM1), or cholesterol- and sialic acid-depleted 
(Mev+NAA) cells exposed for 1 h to type A (upper images) or type B (lower images) HypF-N 
oligomers (12 µM). In all images, red and green fluorescence indicates cell profiles and HypF-
N oligomers, respectively. The presence of additives and the corresponding semi-quantitative 
values of the green fluorescence intensity arising from HypF-N oligomers inside the cells are 
shown below each confocal image for type A (light grey) and type B (dark grey) oligomers. 
The values shown are means ± S.D. of three independent experiments. In both panels the 
symbols * and § indicate significant differences relative to basal cells exposed to type A and B 
HypF-N oligomers, respectively (p≤0.05). 
3.4 Results IV 
3.4.1 Neuronal differentiation of human mesenchymal stromal cells increases 
their resistance to Aβ42 aggregate toxicity 
Cell therapy is a promising approach for the treatment of neurodegenerative 
conditions such as Alzheimer’s and Parkinson’s diseases. However, the presence of 
toxic aggregates in tissue raises the question of whether grafted stem cells are suscep-
tible to amyloid toxicity before they differentiate into mature neurons. To address 
this question, in this fourth part of the result section has been investigated the rela-
tive vulnerability of human mesenchymal stromal cells and their neuronally differ-
entiated counterparts to Aβ42 oligomers and whether susceptibility correlates with 
membrane GM1 content, a key player in oligomer toxicity. Our cell model was high-
ly susceptible to aggregate toxicity, whereas neuronal differentiation induced re-
sistance to amyloid species. This data correlated well with the content of membrane 
GM1, levels of which decreased considerably in differentiated cells. These findings 
extend our knowledge of stem cell vulnerability to amyloid species, which remains a 
controversial issue, and confirm that amyloid-GM1 interactions play an important 
role in cell impairment. 
3.4.2 Neuronal differentiation of hMSCs results in reduced levels of membrane 
GM1 
A neuronally differentiated phenotype (hMSC-n) was induced in human mesen-
chymal stromal cells (hMSCs) isolated from iliac crest aspirates of young volunteers, 
as previously reported (Benvenuti et al., 2006). Following cell treatment, hMSCs un-
derwent a morphological shift from a flat, fibroblast-like phenotype to a neuronal-
like one characterized by prominent process-like extensions and positive staining for 
neurofilament M (NF-M) (Fig. 45A).  
Expression of the neuronal markers synaptophysin, tau and microtubule associ-
ated protein 2 (MAP 2) was also significantly increased in hMSC-n compared to 
hMSCs (Fig. 45B). Numerous studies have shown that different gangliosides and 
their expression levels are cell type-specific and tightly controlled during cell devel-




opment and differentiation (Ariga et al., 2008). To this end, we investigated the 
membrane content of monosialoganglioside GM1 during stromal cell differentia-
tion. Dot blot analysis revealed a significant decrease in membrane GM1 (by ~ 75%) 
in hMSC-n with respect to hMSCs (Fig. 45C). This finding was confirmed by confo-
cal microscope analysis using anti-GM1 antibodies or cholera toxin subunit B (CTX-
B) (Fig. 45C). 
We previously demonstrated that membrane cholesterol content is significantly 
higher in retinoic-acid-differentiated SH-SY5Y neuroblastoma cells compared to 
undifferentiated controls (Cecchi et al., 2008a). Accordingly, neuronal differentia-
tion of hMSCs results in a significant increase in membrane cholesterol content 
(from 34.24 ± 5.75 to 55.92 ± 7.87 μg/mg protein).  
 
 
Figure 45. Neuronal differentiation reduces membrane GM1 levels in hMSC-n. A Left, Repre-
sentative images of hMSCs and hMSC-n obtained by inverted phase contrast microscopy. 
Right, representative immunocytochemical staining of neurofilament M (NF-M) in hMSCs 
and hMSC-n. B Expression of neuronal markers in hMSC-n. The reported values (mean ± 
s.e.) are representative of four independent experiments and indicate the increase in expres-
sion (fold) vs hMSCs, which was taken to be 1. * Significant difference (p≤0.05) vs. untreated 
cells. C Left, representative dot blot analysis and relative densitometric quantification of 
membrane GM1 content in hMSCs and hMSC-n. Right, representative confocal images 
showing cell surface distribution of GM1, probed with anti-GM1 antibodies (green) or with 
CTX-B conjugate (red). The reported values (mean ± s.d.) are representative of three inde-






3.4.3 Neuronal differentiation of hMSCs reduces the interaction of Aβ42 oligo-
mers with the cell surface  
The interaction between amyloid aggregates and neuronal membranes is thought to 
play an important role in AD neuropathology (Stefani and Dobson, 2003; Stefani, 2007). In 
general, the idea that lipid bilayers affect protein/peptide aggregation, aggregate interaction 
with exposed cells and amyloid cytotoxicity has gained widespread acceptance (Ariga et al., 
2008; Arispe and Doh, 2002; Cecchi et al., 2005). Similarly, recent evidence suggests that 
GM1 content plays a key role in modulating the interaction of amyloid oligomers with the 
cell membrane. Accordingly, different levels of membrane GM1 in undifferentiated 
hMSCs and differentiated hMSC-n prompted us to examine the effect of neuronal differ-
entiation on the ability of exogenous Aβ42 oligomers to bind the cell surface. We used 
FRET microscopy to determine the intermolecular proximity of Aβ42 oligomers to mem-
brane GM1 at the cell surface of hMSCs and hMSC-n (Kinoshita et al., 2003). Interestingly, 
a stronger FRET signal was detected in hMSCs than in hMSC-n, suggesting greater prox-
imity of Aβ42 oligomers to GM1 in the former compared to the latter (Fig. 46A). In line 
with this finding, the amount of Aβ42 oligomers inside cells increased quickly following 
addition of 10 µM Aβ42 oligomers to the cell medium, reaching maximum levels after 30 
min (Fig. 46B). Moreover, quantitative analysis of intracellular Aβ42 fluorescence showed 
that Aβ42 oligomers were internalized to a greater extent by undifferentiated cells than by 
neuronally differentiated counterparts (Fig. 46B). Imaging of different optical sections, in-
cluding basal, apical and median planes of hMSCs and hMSC-n exposed to oligomers for 
60 min, confirmed that more Aβ42 aggregates were present inside (median planes) hMSCs 
than in hMSC-n (Fig. 46C, left panel). We also found that Aβ42 internalization could be 
prevented by pre-incubating cells with anti-GM1 antibodies (Anti-GM1 Ab) (Fig. 46C, 
right panel). These findings tally with the recognized importance of GM1 as a key interac-
tion site for amyloid oligomers at the membrane level. 
3.4.4 Neuronal differentiation of hMSCs reduces Aβ42 oligomer-induced intra-
cellular Ca2+ dyshomeostasis and oxidative stress 
The influx of Ca2+ ions from the extracellular space into the cytosol and the gen-
eration of intracellular ROS are recognized as early biochemical modifications in 
cells exposed to amyloid oligomers (Canale et al., 2006; Cecchi et al., 2005; Demuro 
et al., 2005; Orrenius et al., 2003). Accordingly, we found that Aβ42 aggregates trig-
gered a significant increase in intracellular Ca2+ levels and ROS production in both 
hMSCs and hMSC-n, compared to unexposed control cells (Fig. 47A and B).  
However, the increase in cytosolic Ca2+ and ROS was significantly greater in un-
differentiated cells than in neuronally differentiated counterparts. Moreover, the in-
crease in 8-OH isoprostane levels was much greater in hMSCs than in hMSC-n, fol-
lowing cell exposure to Aβ42 oligomers for 3 h (Fig. 47C). Overall, these findings 
suggest that neuronal differentiation of our stem cell model, which causes a decrease 
in membrane GM1, is associated with reduced susceptibility to Ca2+ dyshomeostasis 
and lipid peroxidation upon exposure to toxic Aβ42 oligomers.  






Figure 46. A Examples of FRET efficiency images, reflecting the colocalization of Aβ42 oli-
gomers with GM1 in hMSCs and hMSC-n exposed to 10 µM Aβ42-FAM for 30 min. B 
Representative confocal microscope images showing insertion of Aβ42 oligomers into the 
plasma membrane of hMSCs and hMSC-n exposed for differing lengths of time (0, 10, 30 
and 60 min) to 10 μM ADDLs. The plasma membrane profile was stained with fluorescein-
conjugated WGA (green); Aβ42 aggregates were labelled with monoclonal anti-mouse 
6E10 antibodies (red). The fluorescent intensity of intracellular Aβ42 oligomers was quan-
tified and is shown below the images. C Left Optical sections (basal, median and apical fo-
cal lengths) of cells exposed for 60 min to 10 μM Aβ42 oligomers. Right Representative 
confocal microscope images showing insertion of aggregates into the plasma membrane of 
hMSCs and hMSC-n pre-incubated for 20 min with 1:100 diluted polyclonal anti-GM1 an-
tibodies prior to 30-min aggregate exposure. The reported values (mean ± s.d.) are repre-
sentative of three independent experiments. The symbols * and § indicate significant dif-
ferences vs. respective untreated cells and hMSC-n cells, respectively (p≤0.05). A variable 








Figure 47 A Representative confocal microscope images showing intracellular Ca2+ levels in 
hMSCs and hMSC-n before and after exposure to 10 μM Aβ42 oligomers for 10 min. B Rep-
resentative confocal microscope images showing intracellular ROS levels in hMSCs and 
hMSC-n before and after exposure to 10 μM Aβ42 oligomers for 10 min. C Lipid peroxida-
tion was quantified by measuring 8-OH isoprostane levels in hMSCs and hMSC-n exposed to 
10 μM Aβ42 aggregates for 3 h. The values reported are mean ± s.d. of three independent ex-
periments. The symbols * and § indicate significant differences (p≤0.05) vs. untreated cells 
and hMSC-n, respectively. 
3.4.5 Neuronal differentiation of hMSCs increases cell resistance to Aβ42 aggre-
gates 
It is widely accepted that impairment of function and viability in cells exposed to 
toxic amyloid aggregates results from early changes in membrane permeability and 
intracellular redox state. We therefore assessed the effect of neuronal differentiation 
and changes in membrane GM1 content on Aβ42 oligomer cytotoxicity, by analyz-
ing cell viability parameters including mitochondrial status, chromatin condensation 
and activation of apoptosis. As revealed by the MTT assay, hMSC-n were more re-
sistant than hMSCs when exposed to a wide range (0.1–50 μM, monomer concentra-
tion) of Aβ42 oligomer concentrations (Fig. 48). The use of MTT data to plot a dose-
response curve, which reached a plateau at the highest Aβ42 oligomer concentra-
tions, allowed us to calculate the Aβ42 oligomer concentrations responsible for 50% 
of the observed effect (IC50). The IC50 for hMSC-n was fifty fold higher (3.34 μM) 
than for hMSCs (0.06 μM). In addition, undifferentiated cells, but not their neu-
ronally differentiated counterparts, displayed partial susceptibility to Aβ42 fibrils (10 




μM, monomer concentration), confirming the remarkable resistance of differentiat-
ed cells to Aβ42 aggregate-induced stress (Fig. 48). Furthermore, the absence of any 
cytotoxic effect in cells treated with the Aβ42-1 reverse peptide highlights the selec-
tivity of the cellular response to Aβ42 aggregates. This differential susceptibility to 
amyloid oligomers was also observed by treating cells with 50 μM PrP 106-126 (Fig 
48). Moreover, treating cells with anti-GM1 antibodies prior to 10 μM Aβ42 oligo-
mer exposure improved cell viability, suggesting an important role for GM1 raft 
domains in amyloid-induced cytotoxicity (Fig. 48).  
 
Figure 48. Neuronal differentiation of hMSCs protects against aggregates toxicity. Viability of 
hMSCs and hMSC-n exposed for 24 h to different concentrations of Aβ42 oligomers (0.1-50 
μM), 10 μM fibrils, 10 μM Aβ42-1 reverse peptide or 50 μM PrP 106-126. Values were calcu-
lated with respect to control experiments, which were carried out by culturing the same cells 
under the same conditions except that aggregates were replaced by vehicle. The reported val-
ues (mean ± s.d.) are representative of three independent experiments carried out in tripli-
cate. The symbols * and § indicate significant differences vs. untreated cells and hMSC-n 
cells, respectively (p≤0.05). 
In contrast with 10 μM Aβ42 oligomer-exposed hMSCs, negligible chromatin 
condensation was found in aggregate-exposed hMSC-n upon staining with Hoechst 
33342, a fluorescent marker that binds to the highly condensed chromatin found in 
the nuclei of apoptotic cells (Figure 49B upper panel) (Cecchi et al., 2008b). Treat-
ment with anti-GM1 antibodies precluded apoptotic responses in both cell types 
(Figure 49B, right). Cells displayed a similar response with regards caspase-3 activity 
– a more specific apoptotic marker – when treated with 10 μM Aβ42 oligomers or 
pre-treated with anti-GM1 antibodies prior to Aβ42 exposure (Fig 49B, lower panel). 
This data confirms that differentiated neuronal cells display greater resistance to 
Aβ42 oligomer toxicity and indicates that, in our model, cell impairment eventually 
culminates in apoptotic cell death, in agreement with previous findings in other cell 







Figure 49. Neuronal differentiation of hMSCs increases cell resistance to Aβ42 aggregates. 
Left Hoechst staining (upper panel) and caspase-3 activation (lower panel) in hMSCs and 
hMSC-n, either untreated or exposed to 10 μM Aβ42 oligomers for 24 h. Right Hoechst stain-
ing (upper panel) and caspase-3 activation (lower panel) in hMSCs and hMSC-n pre-
incubated for 20 min with 1:100 diluted polyclonal anti-GM1 antibodies prior to 24-h oligo-
mer exposure. All images were obtained using the same magnification. 
  




4.1 A protective role for lipid raft cholesterol against amyloid-induced membrane 
damage in human neuroblastoma cells  
In the present study we investigated whether membrane cholesterol can influ-
ence ADDL cytotoxicity to human neurotypic SH-SY5Y cells by modulating either 
the physical state of the cell membrane, mainly at the lipid raft level, or oligomer 
binding to the membrane itself, in most cases a key step in amyloid cytotoxicity. In 
PEG-cholesterol supplemented cells, the increase of plasma membrane cholesterol 
resulted in a reduced ADDL binding to the plasma membrane, as compared to con-
trol cells. Conversely, the same oligomers appeared to accumulate mostly at the cell 
plasma membrane when they were added to the culture medium of cells depleted in 
membrane cholesterol following treatment with β-CD or Mev. These results suggest 
that, in our neuronal cell model, the cholesterol content of the cell membrane is in-
versely correlated with the membrane perturbing effects of Aβ42 oligomers. These 
data agree with our previous findings, which show that neuroblastoma cells enriched 
in membrane cholesterol display higher resistance to Aβ42 oligomer toxicity than 
untreated or cholesterol-depleted cells (Cecchi et al., 2008b). They are also con-
sistent with previous reports showing that disruption of cholesterol homeostasis can 
be detrimental to cells because toxic Aβ aggregates interact more easily with choles-
terol-poor membranes (Arispe and Doh, 2002; Cecchi et al., 2005; Cecchi et al., 
2008a; Yip et al., 2001). In particular, our data agree with several reports indicating 
that the cholesterol content affects membrane physical features such as fluidity and 
density of lipid packing, hindering both aggregate recruitment at the cell membrane 
and membrane permeabilization (Arispe and Doh, 2002). In particular, the results 
we obtained in the presence of mevastatin -a specific inhibitor of cholesterol synthe-
sis- support a cholesterol-dependent effect, rather than a generic lipid density-
dependent effect at the plasma membrane level. 
Previous reports suggest that Aβ binding and aggregation, as detected by ThT or 
Congo Red staining, occur in lipid raft domains where it is favoured by clusters of 
the key component GM1 ganglioside (Yanagisawa, 2007; Williamson et al., 2008). It 
has also been hypothesized that Aβ42 adopts an altered conformation upon binding 
to GM1 and that in such an altered conformation it can act as a seed for Aβ fibrillo-
genesis in AD brain (Yanagisawa, 2007). Finally, previous findings indicate that 
GM1 clusters are affected by membrane cholesterol depletion (Fujita et al., 2007). 
Actually, our confocal laser microscope analysis showed a marked ADDL-GM1 col-
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ocalization on plasma membrane rafts in neuroblastoma cells. Furthermore, in our 
cell model, cholesterol-depleted lipid rafts displayed enhanced ADDL-GM1 colocali-
zation with respect to control cells, whereas we found a significantly reduced ADDL 
binding to cholesterol-enriched rafts, as compared to control cells. Our data on 
ADDL-GM1 colocalization in cholesterol-enriched or -depleted cells agree with pre-
viously reported findings on the effect of cholesterol on amyloid aggregate binding 
to the cell membrane (Arispe and Doh, 2002; Kawahara et al., 2000; Yip et al., 2001) 
and suggest that a mild loss of neuronal membrane cholesterol results in an in-
creased binding of ADDLs to neuronal lipid rafts.  
There is no consensus on the steady state fraction of rafts in the cell membranes, 
their size, location and lipid/protein composition, which might reflect rapid raft dy-
namics accounting for intrinsic raft heterogeneity in different cultured or tissue cells. 
There are several procedures described in the literature allowing purification of lipid 
rafts and caveolae membranes, and the variability of the experimental result can de-
pend on the method used. In this study we choose a widely used method to prepare 
membrane domains enriched in sphingolipids, monosialogangliosides and choles-
terol (DRMs). This experimental approach provides a more appropriate mimic of 
the lipid rafts found in vivo than synthetic raft-like vesicles. However, whether, and 
to what extent, these isolated DRMs reflect the physical, chemical and biochemical 
organization of lipid rafts in vivo remains to be elucidated. Taking into account these 
caveats, we investigated the ability of ADDLs to interact with purified DRMs and the 
effect of such interaction on physical and morphological features of the latter.  
Our anisotropy fluorescence measurements of sucrose density gradient-purified 
and flotillin-1-positive DRMs confirmed that there is an inverse relation between 
cholesterol content and membrane perturbing effects of ADDLs. The DPH probe 
partitions equally between the ordered and the disordered phases of membrane lipid 
domains (Lentz, 1989). It is evenly distributed throughout all the lipidic regions in 
the plasma membrane of a living cell (Companyó et al., 2007; Lentz, 1993) and its 
location is similar in membranes with different content of cholesterol (Kaiser and 
London, 1998). Therefore, the cholesterol-induced effects on DPH fluorescence po-
larization here reported reflect differences in DPH motion, rather than in DPH dis-
tribution (Kaiser and London, 1998). By using such technique, we found that DRMs 
microdomains purified from cholesterol-enriched cells are less susceptible to the de-
crease of fluidity caused by Aβ oligomers as compared to comparable preparations 
of DRMs purified from control cells. Conversely, the loss of cholesterol resulted in a 
higher susceptibility of disassembled lipid rafts, not only to Aβ42 oligomers but also 
to the Aβ42-1 reverse monomeric peptide. These results suggest that the more fluid 
the lipid raft membrane, the greater its ability to bind non-specifically Aβ42 and, 
possibly, other peptides. We therefore conclude that the presence of β-sheet struc-
ture appears to be required for the membrane perturbing properties of Aβ oligomers 
only in DRMs mimicking raft microdomains with basal cholesterol content, but not 
in DRMs purified from cholesterol depleted plasma membranes, in agreement with 
previously reported evidences in synaptosomal plasma membranes (Eckert et al., 
2005).  




AFM imaging in liquid, obtained in collaboration with the group of Prof.ssa Gli-
ozzi, showed that treatment of DRMs with ADDLs resulted in the formation of large 
cavities, or hollows. The ADDL-lipid interaction may result in lipid depletion from 
the bilayer, with the formation of steps reflecting differences between the thickness 
of a standard bilayer and that of a thinner phase. Similar effects have been observed 
previously in supported lipid bilayers exposed to prefibrillar amyloid aggregates 
(Canale et al., 2006). A thinner phase may result from lipid interdigitation, as ob-
served in supported lipid bilayers interacting with transmembrane peptides (Rinia et 
al., 2000). Alternatively, oligomer interaction with the bilayer may induce trans-
gauche conformational changes of the lipids, giving rise to a reduced bilayer thick-
ness (Teller et al., 2000). The size and depth of the cavities were significantly reduced 
in DRMs purified from cholesterol-enriched cells, suggesting cholesterol may pro-
tect against amyloid-induced cell membrane damage at the lipid raft level. Overall, 
our results on DRM morphology agree with previous experimental data indicating a 
protective effect of cholesterol against membrane disassembly by prefibrillar aggre-
gates of proteins and peptides (Arispe and Doh, 2000). The formation of cavities was 
observed also in DRMs purified from cells pre-treated with Aβ42 oligomers. Howev-
er, in this case the depth and size of the cavities were significantly reduced, suggest-
ing that living cells are able to resist, at least in part, ADDL-induced membrane 
damage. 
A typical feature of DRM samples observed by AFM was the presence of do-
mains protruding from the lipid surface. These domains were shown to consist of 
fluid protein or lipoprotein complexes. In fact, they disappeared in the presence of 
proteases and displayed higher adhesion forces than the background. We exploited 
the presence of these fluid domains to characterize the differences between samples 
with varying cholesterol content and to check the changes induced by their interac-
tion with ADDLs. The domain size increased with decreasing cholesterol content 
(Table III), reflecting increased environment fluidity. Actually, increased mobility 
can favour fluid domain coalescence. On the contrary, domain height decreased with 
decreasing cholesterol content. The latter finding might be interpreted as the result 
of an increased compliance of the cholesterol-depleted DRM environment. Treat-
ment of DRMs with ADDLs induced changes in domain morphology that appeared 
to depend on the content of cholesterol and suggested domain disassembly. In par-
ticular, in cholesterol-enriched samples the domain size was almost unaffected by 
treatment with ADDLs, while in control and cholesterol-depleted samples the do-
main size after raft treatment with ADDLs was almost half of that measured before 
treatment.  
Domain heights were similar in DRMs purified from control cells and subse-
quently exposed to ADDLs and in DRMs purified from cells previously exposed to 
the same Aβ oligomers, suggesting that domain modifications are similar when they 
occur in the whole intact plasma membrane or in purified membrane fractions. 
However, pre-treatment with Aβ oligomers did not affect the domain size, which 






Overall, our data on DRM domains provide information on the structural and 
morphological features of the cell plasma membrane and its cholesterol- and GM1 
ganglioside-enriched raft domains. In particular, we showed that the content of cho-
lesterol affects the ability of ADDLs to interact with the cell membrane by modulat-
ing membrane physical features at the raft level. In addition, as far as we know, we 
imaged for the first time by AFM the morphological features of raft domains puri-
fied from the plasma membrane of neurotypic model cells previously enriched or 
depleted in cholesterol and the different effects on their structure caused by expo-
sure to ADDLs. 
4.2 Lipid rafts mediate amyloid-induced calcium dyshomeostasis and membrane 
permeabilization in Alzheimer’s fibroblasts 
The pathogenesis of FAD, with regards to PS and APP mutations, has been at-
tributed to toxic effects associated with the overproduction and aggregation of Aβ 
peptides, particularly the more hydrophobic Aβ42 (Hardy and Selkoe, 2002). This 
hypothesis was originally based on the premise that pathogenic mutations increase 
the production of Aβ42 by favoring proteolytic processing of APP by β- or γ-
secretase and by heightening the self-aggregation of Aβ into amyloid fibrils (Selkoe 
and Wolfe, 2007; Steiner et al., 2008). In the present study, fibroblasts from FAD pa-
tients carrying APP Val717Ile, PS1 Leu392Val or Met146Leu gene mutations, secret-
ed elevated amounts of Aβ42 peptide and showed greater membrane permeability 
and lipid peroxidation with respect to WT fibroblasts from healthy subjects, suggest-
ing partial disruption of membrane integrity and chronic oxidative stress associated 
with enhanced Aβ production. These findings are in agreement with several other 
studies, which also provide evidence for excess lipid peroxidation associated with Aβ 
deposits in APP/PS1-mutant AD brains and mice (Abdul et al., 2008; Varadarajan et 
al., 2000). Oxidative damage may further increase Aβ binding to the cell surface. In-
deed, Aβ is reported to accumulate faster in membranes containing oxidatively 
damaged phospholipids than in membranes containing only unoxidized or saturated 
phospholipids (Murray et al., 2007). Our results also showed that the lipoperoxida-
tion was higher in detergent-resistant membranes (DRMs) compared to the entire 
cell membrane, pointing to lipid rafts as preferential sites for Aβ42 interaction at the 
cell surface. Indeed, as observed by contact mode AFM, the increased release of 
Aβ42 in FAD fibroblasts was associated with evident alteration of lipid raft mor-
phology, resulting in the formation of steps/cavities in PS1 and, to a greater extent, 
in APP DRMs. Our observations are in agreement with AFM data obtained in re-
constituted planar lipid bilayers, in which Aβ42 treatment resulted in the formation 
of multimeric channel-like structures (Lin et al., 2001). On the other hand, other 
AFM studies have suggested that the amyloidogenic human amylin peptide induces 
small defects that spread across the lipid surface and result in lipid loss, rather than 
formation of discrete protein pores (Green et al., 2004). Moreover, Aβ treatment in-
duced greater aggregate-ganglioside colocalization and DRM structure perturbation 




in FAD fibroblasts, with respect to WT controls. Our approach allowed us to study 
the role of lipid rafts in Aβ-induced cytotoxicity in living cells displaying genetic de-
fects in tissues where AD lesions occur. Indeed, mutated fibroblasts displayed en-
hanced raft damage, suggesting that modified molecular structure is a common fea-
ture of cells displaying these genetic mutations. This evidence strengthens the claim 
that lipid rafts are key cell membrane targets for Aβ42 oligomers. In agreement with 
our observations, Aβ has been shown to be highly concentrated in lipid rafts in the 
brains of Tg2576 transgenic mice (Kawarabayashi et al., 2004). Moreover, the pre-
sent study provides evidence that two lipidic raft components, that is cholesterol and 
GM1, affect the susceptibility of FAD fibroblasts to Aβ42 oligomers in opposite 
ways, by modulating amyloid binding to lipid rafts and its subsequent toxic effects. 
In particular, immunofluorescence and FRET analysis revealed that cholesterol-
depleted membranes displayed enhanced Aβ42-GM1 colocalization with respect to 
cholesterol-enriched lipid rafts. Furthermore, fibroblast treatment with NAA, an en-
zyme that leaves the content and structure of GM1 unchanged except for the remov-
al of the negatively charged sialic acid moiety, almost completely precluded Aβ42 
binding to the cell surface. In agreement with our observations, a decrease in choles-
terol, resulting from downregulated seladin-1 gene expression, and an increase in 
GM1 have been found in cell membranes purified from AD patients, relative to 
healthy controls (Greeve et al., 2000; Molander-Melin et al., 2005). Other results in-
dicate that cholesterol depletion promotes the formation of membrane GM1 clus-
ters, which may in turn favor greater interaction of Aβ with the cell membrane (Fu-
jita et al., 2007; Yanagisawa, 2011).  
The idea that calcium overload might be the final toxic insult to brain neurons in 
AD fits with numerous observations. The three major mechanisms of Aβ interaction 
with cell membranes that have been proposed involve binding to endogenous calci-
um-permeable channels, disruption of membrane lipid integrity, and the formation 
of calcium-permeable channels by Aβ (Arispe et al., 2007; Decker et al., 2010; 
Demuro et al., 2010). We found a sharp increase in cytosolic Ca2+ levels and exten-
sive alteration of membrane permeability in FAD and WT fibroblasts when exposed 
to Aβ42 oligomers. The increase in cytosolic Ca2+ content and alteration of mem-
brane permeability was much smoother and milder in cholesterol-enriched or GM1-
depleted fibroblasts exposed to amyloid oligomers with respect to similarly treated 
control cells with basal cholesterol or GM1 content. In contrast, membrane choles-
terol depletion or GM1 enrichment triggered a greater increase in cytosolic Ca2+ lev-
els and membrane permeability. Even in rat cortical neurons membrane GM1 con-
tent influences Aβ42 toxicity and intracellular Ca2+ homeostasis, corroborating our 
hypothesis at the neuronal level. Moreover, fibroblasts pre-treated with anti-GM1 
antibodies, cholera toxin subunit B –a specific GM1 ligand– or with NAA complete-
ly suppressed Aβ-induced Ca2+ spikes and membrane damage, suggesting that the 
negative charge on GM1 is a key factor determining calcium dyshomeostasis and 
membrane permeabilization, which results in cell vulnerability to Aβ oligomers. In 
agreement with our observations, pre-treatment of neurons with either anti-GM1 






on calcitonin oligomer-induced neurotoxicity, probably modifying the plasma 
membrane region that is susceptible to the formation of pore-like structures (Mal-
chiodi-Albedi et al., 2010). On the other hand, other studies report that GM1 may 
protect against Aβ25-35 toxicity in hippocampal slices (Kreutz et al., 2011). Altered 
ganglioside metabolism, resulting in increased GM1 content, has also been reported 
in the AD brain (Yamamoto et al., 2008). In addition, an age-dependent local in-
crease in ganglioside density and loss of cholesterol has been reported, showing that 
high-density GM1 clustering at presynaptic neuritic terminals is a critical step for Aβ 
deposition in AD (Yamamoto et al., 2008) and for the subsequent increase in mem-
brane lateral pressure (Lin M.S. et al., 2008). Our data also showed that Aβ42-
induced lipoperoxidation is inhibited by depletion of extracellular calcium, suggest-
ing that oligomer-induced membrane oxidation is supported by Ca2+ uptake, which 
ultimately disrupts calcium homeostasis and activates signaling cascades that lead to 
cellular degeneration. It can therefore be hypothesized that oligomers first increase 
Ca2+ uptake, possibly via amyloid channel formation, resulting in membrane pore 
formation and/or generalized thinning of the phospholipid bilayer that eventually 
leads to non-specific alteration of membrane permeability. From this point of view, 
one might suggest that raft cholesterol and GM1, by modulating membrane fluidity 
and charge, respectively, may specifically influence the binding of Aβ42 oligomers, 
their insertion into the phospholipid bilayer and their ability to disrupt membrane 
structure, which ultimately triggers cell death. However, the possibility that intracel-
lular calcium overload is in part due to the interaction of oligomers with endogenous 
calcium-permeable channels cannot be ruled out. Greater knowledge of neuronal 
calcium dysregulation is needed, as calcium signaling modulators are targets of po-
tential AD therapeutics. Despite using few patients in this study, our findings strong-
ly suggest that the binding of Aβ42 oligomers to the plasma membrane and the re-
sulting dysregulation of membrane permeability is significantly mediated by lipid 
raft microdomains. 
4.3 Membrane lipid composition and its physicochemical properties define cell 
vulnerability to aberrant protein oligomers 
A number of previous studies have provided considerable insight into the mo-
lecular basis of the structure-toxicity relationship for aberrant protein oligomers, re-
vealing the significance of flexibility, hydrophobic exposure, and overall instability, 
as determinants of their ability to interact with the plasma membrane of cells dis-
rupting their normal function (Bolognesi et al., 2010; Campioni et al., 2010; Lee et 
al., 2007). An increasing body of data also highlights the roles of biological surfaces, 
notably the cell membrane, in promoting protein binding, misfolding, aggregation 
and fibril disassembly, thereby influencing the morphology, structure and biological 
activity of the resulting aggregates (Demuro et al., 2005; Gorbenko and Kinnunen, 
2006; Koffie et al., 2009; Martins et al., 2008; Xue et al., 2009). Interestingly, howev-
er, the ability of protein oligomers to cause cell dysfunction has primarily been relat-




ed simply to the inherent properties of the oligomers, formed either in the presence 
or in the absence of a range of biological factors.  
In the present study we show that the nature of the cell membrane can influence 
profoundly the degree of toxicity of specific forms of misfolded protein oligomers. 
To this aim we set out to explore the cytotoxicity to cultured neuroblastoma cells 
with a normal or a rationally altered content of membrane lipids, of two types of 
pre-formed HypF-N oligomers that we previously found to display different struc-
tural features and toxicities (Campioni et al., 2010; Zampagni et al., 2011). For com-
parison, we also used Aβ42 oligomers, whose cytotoxicity is well known (Kayed et 
al., 2003; Stefani and Dobson, 2003). In particular, we modulated the structural ri-
gidity and/or charge density of the plasma membrane by altering in a variety of ways 
the levels of either cholesterol or GM1, or of both at one time. Cholesterol and GM1 
are two key components of lipid rafts (Lingwood and Simons, 2010), whose im-
portance as sites stimulating peptide and protein misfolding and aggregation, and 
also as regions where oligomers interact preferentially with membranes, is increas-
ingly recognized (Ehehalt et al., 2003; Malchiodi-Albedi et al., 2010; Molander-
Melin et al., 2005). 
Our results show that both type A and B oligomers were internalized and sorted 
into endocytotic vesicles in the exposed cells. However, interaction of oligomer with 
the cell membrane and internalisation were significantly decreased in cells enriched 
in membrane cholesterol or with a reduced content of GM1; in particular, type B ol-
igomers, that were unable to cross the plasma membrane of SH-SY5Y cells with a 
basal lipid content, became increasingly internalised in cells with a reduced content 
of cholesterol. Moreover, the cytotoxicities of Aβ42 oligomers and of the two types of 
misfolded HypF-N oligomers used in this study were dramatically affected by the 
physicochemical features of the cell membrane. In particular, the oligomers found to 
be toxic to the cells with basal lipid content became increasingly significantly less 
toxic as the membrane cholesterol level was increased or that of GM1 was decreased, 
whereas the opposite effect was found with cells treated so as to reduce their content 
of membrane cholesterol. Conversely, the oligomers that were not toxic to untreated 
cells remained harmless to cells with an increased content of cholesterol or a reduced 
content of GM1, but became increasingly harmful as the content of cholesterol in the 
membrane was decreased or that of GM1 was increased, reaching levels of toxicity 
comparable to those shown by the toxic oligomers with untreated cells. A number of 
characteristic features known to underlie oligomer cytotoxicity were also found to be 
modified in the cells with an altered membrane lipid composition, including cell 
membrane permeability, the levels of intracellular Ca2+ and ROS, and the apoptotic 
response.  
The data obtained using cells with an altered content of both membrane choles-
terol and GM1 show that the alteration in the GM1 levels plays a dominant role in 
determining the resulting effects. The importance of GM1 relative to cholesterol in 
determining oligomer-mediated cytotoxicity is also supported by our findings of an 
inverse relationship between the content of cholesterol and of GM1 in the plasma 






tem studied here the effects on oligomer cytotoxicity of the modulation of mem-
brane cholesterol results predominantly from the concomitant inverse modification 
of the content of GM1. In particular, the higher increase of GM1 content induced by 
cell treatment with 10 µM Mev compared to cells exposure to 2.0 mM β-CD 
correlates well with the greater cytotoxicity of both types of oligomers under the 
former condition, although the cholesterol content was similar under both 
conditions. In addition, we found that cells treated with NAA, an enzyme that re-
move the negatively charged sialic acid from gangliosides (Malchiodi-Albedi et al., 
2010), behaved similarly to those treated with an inhibitor of GM1 synthesis, sug-
gesting that the negative charge carried by the head group of GM1 is one of the key 
chemical factors determining cell vulnerability to aberrant protein oligomers.  
In agreement with our observations, a decrease in cholesterol and an increase in 
GM1 have been found in cell membranes purified from AD patients relative to 
healthy controls (Fujita et al., 2007; Molander-Melin et al., 2005). An altered gangli-
oside metabolism resulting in an increase in GM1 has also been reported in AD 
brains (Yamamoto et al., 2008). In addition, membrane alterations associated with 
age-dependent local increases in the density of gangliosides and the loss of choles-
terol have been reported, suggesting that high-density GM1 clustering at presynaptic 
neuritic terminals is a critical step for Aβ deposition in AD (Yamamoto et al., 2008) 
and for the consequent increase of the membrane lateral pressure (Lin M.S et al., 
2008). Finally, GM1-containing membranes have been reported to induce polymor-
phisms of Aβ fibrils favouring the growth of more cytotoxic species than those 
formed in solution (Okada et al., 2008).  
The data reported here, therefore, lead us to conclude that the level of cytotoxici-
ty of a specific type of protein oligomer, or indeed of other amyloid-related struc-
tures, is the result of a complex interplay between two critical factors: the specific 
properties of the aberrant protein assemblies (e.g., relative stability, disorder, flexibil-
ity and exposure of hydrophobic surface) (Bolognesi et al., 2010; Campioni et al., 
2010; Lee et al., 2007; Olzsha et al., 2011) and the physicochemical features of the in-
teracting cell membranes that are associated with their lipid composition (e.g. fluidi-
ty, electrostatic potential, curvature, lateral pressure) (Martins et al., 2008; McLaurin 
et al., 1998; Sethuraman and Belfort, 2005; Stefani, 2008). Accordingly, our data can 
contribute to rationalize the variable susceptibility to deleterious protein oligomers 
(Nekooki-Machida et al., 2009) of different cell types (Cecchi et al., 2005) or differ-
ent regions of the same tissue (Demuro et al., 2005) where cells with distinctive 
membrane characteristics are present (Cecchi et al., 2005). Finally, these results also 
shed new light on the molecular determinants of protein misfolding and deposition 
diseases and expand the spectrum of molecular strategies for therapeutic interven-
tion, ranging from those aimed at the inhibition of protein aggregation itself to those 
designed to increase the resistance of cellular targets to the misfolded forms of pro-
teins. 
 




4.4 Neuronal differentiation of human mesenchymal stromal cells increases their 
resistance to Aβ42 aggregate toxicity 
Multipotent neural stem cells are the most primordial, least committed cells of 
the central nervous system, and their transplantation holds the promise of regenera-
tive therapy for a number of neurodegenerative diseases (Lee et al., 2008). However, 
the propagation efficiency of these cells is often limited, making it difficult to estab-
lish large-scale cultures. Moreover, once grafted, these cells may be inefficient at 
generating the neuronal cells required for reconstruction of the damaged tissue 
(Pearson et al., 2008). Among other problems, the possible therapeutic use of em-
bryonic or adult neural, or hematopoietic stem cells in AD, Parkinson’s disease and 
other neurodegenerative conditions also raises the question of whether they, like 
neuronal cells, are susceptible to endogenous amyloid deposits, which would jeop-
ardize their survival in vivo. The potential relevance of this issue is further highlight-
ed by recent data showing that amyloid fibrils are not entirely stable entities; rather, 
they can ‘leak’ toxic oligomers in the presence of phospholipid bilayers (Martins et 
al., 2008) and, possibly, other surfaces found in tissue (Koffie et al., 2009). The ques-
tion of stem cell susceptibility to amyloid species arises from a wealth of data show-
ing that different cells display differential susceptibility to the same amyloid species, 
not only in culture (Cecchi et al., 2005; Cecchi et al., 2008b; Cecchi et al., 2008c) but 
also in vivo. This is supported by the finding that in neurological disorders with 
amyloid deposition, only specific neuronal cell populations present in distinct brain 
areas are functionally impaired and eventually die. 
In this study we investigated whether, and to what extent, undifferentiated hu-
man mesenchymal stromal cells (hMSCs) and their neuronally differentiated coun-
terparts (hMSC-n) were affected by the of Aβ42 oligomer toxicity. Our data show 
that the two cell types displayed differential susceptibility to Aβ aggregate-induced 
toxicity. We found that undifferentiated cells were much more vulnerable to Aβ42 
oligomers than their differentiated counterparts, in agreement with previous find-
ings in a number of stem cell models (Cecchi et al., 2008a). Actually, several recent 
studies on the toxic effects of prefibrillar amyloid species on undifferentiated cells 
have yielded contrasting results, with different stem cell types displaying variable 
susceptibility to amyloid cytotoxicity. A report published in 1990 showed that Aβ 
peptides were neurotrophic to undifferentiated neurogenic cells, but neurotoxic to 
their differentiated counterparts (Yankner et al., 1990). It has also been reported that 
rat neural stem cells can resist micromolar concentrations of Aβ peptides (Eucher et 
al., 2007; López-Toledano and Shelanski, 2004). More recently, murine embryonic 
stem cells and hematopoietic progenitor cells have been shown to be highly resistant 
to concentrations of Aβ42 oligomers previously shown to be cytotoxic to several 
other cell types (Neri et al., 2010). However, other investigations working on neu-
ronal progenitor cells reached opposite conclusions (Haughey et al., 2002; Mazur-
Kolecka et al., 2006). A possible explanation for these discrepancies is that, like dif-
ferentiated cells (Cecchi et al., 2005), even different types of undifferentiated stem 






Some of the earliest and most common biochemical modifications seen in cells 
exposed to toxic amyloid oligomers are the result of oligomer-cell membrane inter-
actions, which result in bilayer disassembly, loss of selective membrane permeability, 
uptake of free Ca2+ and the appearance of oxidative stress (Butterfield et al., 2001; 
Demuro et al., 2005). In this chain of events, the cell membrane, particularly lipid 
rafts, plays a dominant role in the binding of amyloid oligomers, favoring oligomer 
insertion into the phospholipid bilayer (Cecchi et al., 2009). Indeed, an increasing 
number of studies point to the importance of lipid rafts and their cholesterol- and 
ganglioside-rich composition (Ariga et al., 2008; Arispe and Doh, 2002). However, 
we previously found that, by modulating both cholesterol and GM1 content in neu-
roblastoma cell membranes, the overriding contribution to amyloid cytotoxicity is 
that of GM1 (Evangelisti et al., 2012). In particular, gangliosides are thought to play 
a key role in recruiting amyloid species, possibly via electrostatic interactions due to 
their net negative charge (Malchiodi-Albedi et al., 2010). We therefore assessed 
whether the differential susceptibility of undifferentiated and neuronally differenti-
ated stem cells to Aβ42 oligomers is determined by the content of monosialogangli-
oside GM1, the most abundant ganglioside in lipid rafts. The more vulnerable, un-
differentiated cells displayed significantly higher membrane GM1 content, thus ex-
plaining, at least in part, their ability to bind and to be permeabilized by Aβ42 oli-
gomers, together with the resulting increase in Ca2+ and ROS and loss of cell viabil-
ity. Equally, new functional ion channel features in hMSC-n could increase their re-
sistance to amyloid toxicity (Benvenuti et al., 2006). Yanagisawa et al. (Yanagisawa 
et al., 2010) found that the toxicity of Aβ40, which is considerably less cytotoxic than 
Aβ42 (Jan et al., 2008), increased markedly in the presence of a 4-fold molar excess 
of GM1 in a murine embryonic neural stem cell model. In contrast, another report 
found that Aβ40 exerted a toxic effect on neural progenitor cells even in the absence 
of gangliosides (Mazur-Kolecka et al., 2006). It is likely that the use of different cells 
and different experimental conditions are responsible for these conflicting findings.  
We report for the first time that a neuronally differentiated cell model is intrin-
sically more resistant to Aβ42 oligomer-induced cytotoxicity than the undifferenti-
ated, cognate cell line, and that the molecular basis of this differential susceptibility 
can be traced, at least in part, to the GM1 content of the plasma membrane. Subse-
quent biochemical studies should address the molecular basis of this resistance, such 
that potential cell therapies can be implemented in the treatment of amyloid diseas-
es, particularly neurodegenerative pathologies such as AD and Parkinson’s disease. 
4.5 Concluding remarks 
Taken together, these results provide information useful to depict a mechanism 
of cell impairment and death that can be common to prefibrillar aggregates of most 
peptides and proteins. Some of the earliest and most common biochemical modifica-
tions induced by amyloid species are the result of oligomer-cell membrane interac-
tions, which result in bilayer disassembly, loss of selective membrane permeability, 




uptake of free Ca2+ and the appearance of oxidative stress. In this chain of events, the 
cell membrane, particularly lipid rafts, plays a dominant role in the binding of amy-
loid oligomers, favoring oligomer insertion into the phospholipid bilayer (Cecchi et 
al., 2009). In particular, our data suggest that raft cholesterol and GM1, by modulat-
ing membrane fluidity and charge, respectively, may specifically influence the bind-
ing of oligomers, their insertion into the phospholipid bilayer and their ability to 
disrupt membrane structure, which ultimately triggers cell death. Moreover, the ef-
fects on oligomer cytotoxicity of the modulation of membrane cholesterol results 
predominantly from the concomitant inverse modification of the content of GM1. 
These results implement the recently published data on the role of membrane cho-
lesterol and GM1 in AD pathogenesis. Furthermore, the data lead us to conclude 
that the degree of toxicity of the oligomeric species results from a complex interplay 
between the structural and physicochemical features of both the oligomers (e.g., 
relative stability, disorder, flexibility and exposure of hydrophobic surface) and 
physicochemical features of the interacting cell membranes that are associated with 
their lipid composition (e.g. fluidity, electrostatic potential, curvature, lateral pres-
sure). Moreover, we report that a neuronally differentiated human mesenchymal 
stromal cells are intrinsically more resistant to Aβ42 oligomer-induced cytotoxicity 
than the undifferentiated, cognate cell line, and that the molecular basis of this dif-
ferential susceptibility can be traced, at least in part, to the GM1 content of the plas-
ma membrane. Finally, these results also shed new light on the molecular determi-
nants of protein misfolding and deposition diseases and expand the spectrum of mo-
lecular strategies for therapeutic intervention, ranging from those aimed at the inhi-
bition of protein aggregation itself to those designed to increase the resistance of cel-












Aβ  amyloid-β peptide; AD Alzheimer’s disease; ADDL amyloid β-derived dif-
fusible ligands; AFM atomic force microscopy; AICD APP intracellular C-terminal 
domain fragment; AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor; ApoE apolipoprotein E; APP amyloid precursor protein; Aβ42-FAM Aβ42 
amine-reactive succinimidyl esters of carboxyfluorescein; BACE beta site APP cleav-
ing enzyme or β-secretase; BAPTA-AM 1,2-bis(2-aminophenoxy)ethane-
N,N,N’,N’-tetraacetic acid acetoxymethylester; BBB blood brain barrier; bFGF basic 
fibroblast growth factor;BME β-mercaptoethanol; BODIPY 4,4-difluoro-3’,4adiaza-
s-indacene; BSA bovine serum albumin; β-CD methyl-β-cyclodextrin; Calcein-AM 
calcein-acetoxymethyl ester; Chol water-soluble cholesterol balanced with methyl-β-
cyclodextrin; CM-H2DCFDA 2’-7’ dichlorodihydrofluorescein diacetate, acetyl es-
ter; CNS central nervous system; CR congo red; CSF cerebro spinal fluid; CTX-B 
cholera toxin subunit B; DMEM Dulbecco’s modified Eagle’s medium; DMSO di-
methylsulfoxide; DPH 1,6-diphenyl-1,3,5-hexatriene; DRMs detergent-resistant 
membranes; DTT dithiothreitol; ECL enhanced chemiluminescence; EDTA eth-
ylenediaminetetraacetc acid; EGTA ethylene glycol-bis(β aminoethylether) 
N,N,N’,N’-tetraacetc acid; ELISA enzyme-linked immunosorbent assay; FAD famil-
ial Alzheimer’s disease; FBS fetal bovine serum; Fluo3-AM fluo3-acetoxymethyl es-
ter; FM4-64 N-(3-triethylammoniumpropyl)-4-(6-(4-
(diethylamino)phenyl)hexatrienyl)pyridinium dibromide; FRET fluorescence reso-
nance energy transfer; GD1a disialoganglioside; GM1 monosialotetrahexosylgangli-
oside; GT1b trisialoganglioside; HBSS hank’s balanced saline solution; HEPES N-
(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid); HFIP hexafluoro-2-
isopropanol; HMGCoAR 3-hydroxy-3-methylglutarylCoA reductase; HRP horse-
radish peroxidase; HypF-N N-terminal domain of the prokaryotic hydrogenase 
maturation factor HypF; HypF-N 5-FITC HypF-N labelled with fluorescein-5-
isothiocyanate; IAPP islet amyloid polypeptide; LDH lactate dehydrogenase; MAP2 
Microtubule associated protein 2; Mev mevastatin; MSCs bone marrow-derived 
mesenchymal stromal cells; MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NAA neuroaminidase; NBM neurobasal medium; 
NF-M neurofilament M; NMDA N-methyl d-aspartate receptors; PBS phosphate 
buffer saline; PDMP D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol; PEG-cholesterol polyoxyetanyl-cholesteryl sebacate; PI3-SH3 SH3 do-
main from bovine phosphatidyl-inositol-3’ –kinase; PMSF phenylmethylsulpho-
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nylfluoride; PrP prion protein; PS1 Presenilin-1; PS2 Presenilin-2; PVDF polyvinyl-
idene difluoride; RAGE receptor for advanced glycation end products; ROS reactive 
oxygen species; SDS-PAGE sodiumdodecylsulfate polyacrylamide gel electrophore-
sis; TEM transmission electron microscopy; TFA trifluoroacetic acid; TFE trifluoro-
ethanol; ThT thioflavin T; TNE Tris-HCl, NaCl, EGTA and Triton X-100 containing 
buffer; Vit E Vitamin E; WGA wheat germ agglutinin. 
 
  






Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., 
Dingwall C., De Strooper B., Dotti C.G. (2004). Neuronal membrane cholesterol loss en-
hances amyloid peptide generation. J. Cell. Biol. 167, 953-960.  
Abdul H.M., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. (2008). Oxidative 
damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. 
Free Radic Biol. Med. 45, 1420-1425.  
Abrous D.N., Koehl M., Le Moal M. (2005). Adult neurogenesis: from precursors to network 
and physiology. Physiol. Rev. 85, 523–569. 
Adamczyk A. and Strosznajder J.B. (2006). Alpha-synuclein potentiates Ca2+ influx through 
voltage-dependent Ca2+ channels. NeuroReport 17, 1883–1886. 
Adler M.J., Coronel C., Shelton E., Seegmiller J.E., Dewji N.N. (1991). Increased gene expres-
sion of Alzheimer disease β-amyloid precursor protein in senescent cultured fibroblasts. 
Proc. Natl. Acad. Sci. USA 88, 16–20. 
Allen J.A., Halverson-Tamboli R.A., Rasenick M.M. (2007). Lipid raft microdomains and 
neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128–140. 
Alvarez A., Toro R., Cáceres A., Maccioni R.B. (1999). Inhibition of tau phosphorylating pro-
tein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459, 421-
426. 
Alvarez-Buylla A., Garcia-Verdugo J.M., Tramontin A.D. (2001). A unified hypothesis on the 
lineage of neural stem cells. Nat. Rev. Neurosci. 2, 287–293. 
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disor-
ders. 4th Ed., Washington DC. 
Amundson D.M. and Zhou M. (1999). Fluorometric method for the enzymatic determination 
of cholesterol. J. Biochem. Biophys. Methods 38, 43-52. 
Anderton B.H., Dayanandan R., Killick R., Lovestone S. (2000). Does dysregulation of the 
Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer’s disease? 
Mol. Med. Today 6, 54–59. 
Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., Miyatake T. (2001). Characteriza-
tion of high-affinity binding between gangliosides and amyloid β-protein. Arch. Biochem. 
Biophys. 388, 225–230. 
Ariga T., McDonald M.P., Yu R.K. (2008). Role of ganglioside metabolism in the pathogenesis of 
Alzheimer's disease--a review. J. Lipid Res. 49, 1157-1175.  
Arispe N., Pollard H.B., Rojas E. (1993). Giant multilevel cation channels formed by Alzheimer 
disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. 
USA 90, 10573-10577. 
Arispe N. and Doh M. (2002). Plasma membrane cholesterol controls the cytotoxicity of Alz-
heimer’s disease Abeta(1-40) and (1-42) peptides. FASEB J. 16, 1526–1536. 
Elisa Evangelisti, Structural and functional aspects of membranes : the involvement of lipid rafts in Alzheimer’s 
disease pathogenesis : the interplay between protein oligomers and plasma membrane physicochemical features in 





Arispe N., Diaz, J.C., Simakova O. (2007). Abeta ion channels. Prospects for treating Alzhei-
mer's disease with Abeta channel blockers. Biochim. Biophys. Acta 1768, 1952-1965. 
Baglioni S., Casamenti F., Bucciantini M., Luheshi L.M., Taddei N., Chiti F., Dobson C.M., 
Stefani M. (2006). Prefibrillar amyloid aggregates could be generic toxins in higher or-
ganisms. J. Neurosci. 26, 8160-8167. 
Benvenuti S., Saccardi R., Luciani P., Urbani S., Deledda C., Cellai I., Francini F., Squecco R., 
Rosati F., Danza G., Gelmini S., Greeve I., Rossi M., Maggi R., Serio M., Peri A. (2006). 
Neuronal differentiation of human mesenchymal stem cells: changes in the expression of 
the Alzheimer's disease-related gene seladin-1. Exp. Cell Res. 312, 2592–2604. 
Berson J.F., Theos A.C., Harper D.C., Tenza D., Raposo G., Marks M.S. (2003). Proprotein con-
vertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate 
melanosome biogenesis. J. Cell. Biol. 161, 521-533.  
Bezprozvanny I. and Hayden M.R. (2004). Deranged neuronal calcium signaling and Hun-
tington disease. Biochem. Biophys. Res. Comm. 322, 1310–1317. 
Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. (2005). Intraneuronal Aβ 
causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. 
Neuron 45, 675-688. 
Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Müller F.J., Loring J.F., Ya-
masaki T.R., Poon W.W., Green K.N., LaFerla F.M. (2009). Neural stem cells improve cog-
nition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 
106, 13594–13599. 
Bokvist M., Lindström F., Watts A., Gröbner G. (2004). Two types of Alzheimer’s β-amyloid 
(1-40) peptide membrane interactions: aggregation preventing transmembrane anchor-
ing versus accelerated surface fibril formation. J. Mol. Biol. 335, 1039–1049. 
Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., Crowther D.C., Wilson 
M.R., Dobson C.M., Favrin G, Yerbury J.J. (2010). ANS binding reveals common features 
of cytotoxic amyloid species. ACS Chem. Biol. 5, 735-740. 
Bradford M.M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 
248-254. 
Brandt M.D. and Storch A. (2008). Neurogenesis in the adult brain: from bench to bedside? 
Fortschr. Neurol. Psychiatr. 76, 517–529 
Bravo R., Arimon M., Valle-Delgado J.J., Garcia R. Durany N., Castel S., Cruz M., Ventura S., 
Fernandez-Busquets X. (2008). Sulfated polysaccharides promote the assembly of amy-
loid β1-42 peptide into stable fibrils of reduced cytotoxicity. J. Biol. Chem. 283, 32471-
32783. 
Brunelle P. and Rauk A. (2002). The radical model of Alzheimer’s disease: specific recogni-
tion of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: an ONIOM study. J. 
Alzheimers Dis. 4, 283–289. 
Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi 
G., Dobson C.M., Stefani M. (2002). Inherent cytotoxicity of aggregates implies a com-
mon origin for protein misfolding diseases. Nature 416, 507–511. 
Bucciantini M., Rigacci S., Berti A., Pieri L., Cecchi C., Nosi D., Formigli L., Chiti F., Stefani M. 
(2005). Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar 
aggregates. FASEB J. 19, 437-439.  
Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. (2000). Tau protein isoforms, 
phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 
95–130. 




Butterfield A.D., Drake J., Pocernich C., Castegna A. (2001). Evidence of oxidative damage in 
Alzheimer’s disease brain: central role for amyloid β-peptide. Trends Mol. Med. 7, 548–
554.  
Butterfield S.M. and Lashuel H.A. (2010). Amyloidogenic protein-membrane interactions: 
mechanistic insight from model systems. Angew. Chem. Int. Ed. Engl. 49, 5628-5654.  
Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner 
B.J., Cerretti D.P., Black R.A. (1998). Evidence that tumor necrosis factor a converting 
enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein 
precursor. J. Biol. Chem. 273, 27765–27767. 
Cai X.D., Golde T.E., Younkin S.G. (1993). Release of excess amyloid beta protein from a mu-
tant amyloid beta protein precursor. Science 259, 514–516. 
Campioni S., Mannini B., Zampagni M., Pensalfini A., Parrini C., Evangelisti E., Relini A., Stefani 
M., Dobson C.M., Cecchi C., Chiti F. (2010). A causative link between the structure of ab-
errant protein oligomers and their toxicity. Nat. Chem. Biol. 6, 140-147.  
Canale C., Torrassa S., Rispoli P., Relini A., Rolandi R., Bucciantini M., Stefani M., Gliozzi A. 
(2006). Natively folded HypF-N and its early amyloid aggregates interact with phospho-
lipid monolayers and destabilize supported phospholipid bilayers. Biophys. J. 91, 4575-
4588.  
Casalot L. and Rousset M. (2001). Maturation of the [NiFe] hydrogenases. Trends Microbiol. 9, 
228-237. 
Cecchi C., Baglioni S., Fiorillo C., Pensalfini A., Liguri G., Nosi D., Rigacci S., Bucciantini M., 
Stefani M. (2005). Insights into the molecular basis of the differing susceptibility of vary-
ing cell types to the toxicity of amyloid aggregates. J. Cell Sci. 118, 3459-3470.  
Cecchi C., Pensalfini A., Baglioni S., Fiorillo C., Caporale R., Formigli L., Liguri G., Stefani M. 
(2006). Differing molecular mechanisms appear to underlie early toxicity of prefibrillar 
HypF-N aggregates to different cell types. FEBS J. 273, 2206-2222. 
Cecchi C., Pensalfini A., Liguri G., Baglioni S., Fiorillo C., Guadagna S., Zampagni M., For-
migli L., Nosi D., Stefani M. (2008a). Differentiation increases the resistance of neuronal 
cells to amyloid toxicity. Neurochem. Res. 33, 2516-2531.  
Cecchi C., Rosati F., Pensalfini A., Formigli L., Nosi D., Liguri G., Dichiara F., Morello M., 
Danza G., Pieraccini G., Peri A., Serio M., Stefani M. (2008b). Seladin-1/DHCR24 protects 
neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. J. 
Cell. Mol. Med. 12, 1990-2002.  
Cecchi C., Pensalfini A., Stefani M., Baglioni S., Fiorillo C., Cappadona S., Caporale R., Nosi 
D., Ruggiero M., Liguri G. (2008c). Replicating neuroblastoma cells in different cell cycle 
phases display different vulnerability to amyloid toxicity. J. Mol. Med. 86, 197-209. 
Cecchi C., Nichino D., Zampagni M., Bernacchioni C., Evangelisti E., Pensalfini A., Liguri G., 
Gliozzi A., Stefani M., Relini A. (2009). A protective role for lipid raft cholesterol against 
amyloid-induced membrane damage in human neuroblastoma cells. Biochim. Biophys. 
Acta 1788, 2204-2216. 
Chafekar F.M., Hoozemans J.J., Zwart R., Baas F., Scheper W. (2007). Abeta 1-42 induces 
mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid. 
Redox Signal. 9, 2245-2254. 
Chafekar S.M., Baas F., Scheper W. (2008). Oligomer-specific Aβ toxicity in cell models is 
mediated by selective uptake. Biochim. Biophys. Acta 1782, 523-531. 
Chapman M.R., Robinson L.S., Pinkner J.S., Roth R., Heuser J., Hammar M., Normark S., Hult-
gren S.J. (2002). Role of Escherichia coli curli operons in directing amyloid fiber for-






Chen F., David D., Ferrari A., Götz J. (2004). Posttranslational modifications of tau — role in 
human tauopathies and modeling in transgenic animals. Curr. Drug Targets 5, 503–515. 
Chen Y. and Kokholyan N. (2005). A single disulfide bond differentiates aggregation path-
ways of β2-microglobulin. J. Mol. Biol. 354, 473-482. 
Chen S., Yadav S.P., Surewicz W.K. (2010). Interaction between human prion protein and 
amyloid-beta (Abeta) oligomers: role of N-terminal residues. J. Biol. Chem. 285, 26377–
26383. 
Cheon M., Chang I., Mohanty S., Luheshi L.M., Dobson C.M., Vendruscolo M., Favrin G. (2007). 
Structural reorganisation and potential toxicity of oligomeric species formed during the 
assembly of amyloid fibrils. PLoS Comput. Biol. 3, 1727-1738. 
Cherny D., Hoyer W., Subramaniam V., Jovin T.M. (2004). Double-stranded DNA stimulates 
the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an 
electron microscopy study. J. Mol. Biol. 344, 929–938. 
Chevallier N.L., Soriano S., Kang D.E., Masliah E., Hu G., Koo E.H. (2005). Perturbed neuro-
genesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am. J. 
Pathol. 167, 151–159. 
Chi E.Y., Frey S.L., Lee K.Y. (2007). Ganglioside G(M1)-mediated amyloid-β fibrillogenesis 
and membrane disruption. Biochemistry 46, 1913–1924. 
Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. (1999). De-
signing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. 
Natl. Acad. Sci. USA. 96, 3590–3594. 
Chiti F., Bucciantini M., Capanni C., Taddei N., Dobson C.M., Stefani M. (2001). Solution 
conditions can promote formation of either amyloid protofilaments or mature fibrils 
from the HypF N-terminal domain. Protein Sci. 10, 2541–2547. 
Chiti F. and Dobson C.M. (2006). Protein misfolding, functional amyloid, and human dis-
ease. Annu. Rev. Biochem. 75, 333-366. 
Choi D.W. (1992). Excitotoxic cell death. J. Neurobiol. 23, 1261-1276. 
Choi Y.G., Kim J.L., Lee H.P., Jin J.K., Choi E.K., Carp R.I., Kim Y.S. (2000). Induction of 
heme oxygenase-1 in the brain of scrapie-infected mice. Neurosci. Lett. 11, 173–176. 
Choo-Smith L., Garzon-Rodriguez W., Glabe C.G., Surewicz W.K. (1997). Acceleration of 
amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-
containing membrane  vesicles. J. Biol. Chem. 272, 22987-22990. 
Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., 
Lieberburg I., Selkoe D.J. (1992). Mutation of the beta-amyloid precursor protein in famil-
ial Alzheimer’s disease increases beta-protein production. Nature 360, 672–674. 
Citron M., Vigo-Pelfrey C., Teplow D.B., Miller C., Schenk D., Johnston J., Winblad B., Venize-
los N., Lannfelt L., Selkoe D.J. (1994). Excessive production of amyloid beta-protein by pe-
ripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial 
Alzheimer disease mutation. Proc. Natl. Acad. Sci. USA 91, 11993–11997. 
Claessen D., Rink R., de Jong W., Siebring J., de Vreugd P., Boersma F.G., Dijkhuizen L., Wosten 
H.A. (2003). A novel class of secreted hydrophobic proteins is involved in aerial hyphae 
formation in Streptomyces coelicolor by forming amyloid-like fibrils. Genes. Dev. 17, 
1714-1726.  
Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M., Selkoe D.J., Ashe K.H. 
(2005). Natural oligomers of the amyloid-β specifically disrupt cognitive function. Nat. 
Neurosci. 8, 79-84.  
Colbeau A., Elsen S., Tomiyama M., Zorin N.A., Dimon B., Vignais P.M. (1998). Rhodobacter 
capsulatus HypF is involved in regulation of hydrogenase synthesis through the HupUV 
proteins. Eur. J. Biochem. 251, 65-71. 




Colucci-D’Amato L., Bonavita V., di Porzio U. (2006). The end of the central dogma of neu-
robiology: stem cells and neurogenesis in adult CNS. Neurol. Sci. 27, 266–270. 
Companyó M., Iborra A., Villaverde J., Martínez P., Morros A. (2007). Membrane fluidity 
changes in goat sperm induced by cholesterol depletion using beta-cyclodextrin. Bio-
chim. Biophys. Acta 1768, 2246-2255. 
Conway K.A., Harper J.D., Lansbury P.T. Jr. (2000). Fibrils formed in vitro from alpha-
synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Bio-
chemistry 39, 2552-2563. 
Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses 
A.D., Haines J.L., Pericak-Vance M.A. (1993). Gene dose of apolipoprotein E type 4 allele 
and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923. 
Crameri A., Biondi E., Kuehnle K., Lütjohann D., Thelen K.M., Perga S., Dotti C.G., Nitsch 
R.M., Ledesma M.D., Mohajeri M.H. (2006). The role of seladin-1/DHCR24 in cholesterol 
biosynthesis, APP processing and Abeta generation in vivo. EMBO J. 25, 432-443. 
Crowther R.A. and Wischik C.M. (1985). Image reconstruction of the Alzheimer paired heli-
cal filament. EMBO J. 4, 3661–3665. 
Curtain C.C., Ali F.E., Smith D.G., Bush A.I., Masters C.L., Barnham K.J. (2003). Metal ions, 
pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with 
membrane lipid. J. Biol. Chem. 278, 2977-2982.  
Dahlgren K.N., Manelli A.M., Stine W.B.Jr., Baker L.K., Krafft G.A., LaDu M.J. (2002). Oli-
gomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal via-
bility. J. Biol. Chem. 277, 32046-32053. 
Dal Pozzo S., Urbani S., Mazzanti B., Luciani P., Deledda C., Lombardini L., Benvenuti S., Pe-
ri A., Bosi A., Saccardi R. (2010). High recovery of mesenchymal progenitor cells with 
non-density gradient separation of human bone marrow. Cytotherapy 12, 579-586. 
Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., Kretzschmar H., 
Hengerer B., Kostka M. (2007). Different species of α-synuclein oligomers induce calci-
um influx and seeding. J. Neurosci. 271, 9220-9232. 
Day R., Periasamy A., Schaufele F. (2001). Fluorescence resonance energy transfer microscopy of 
localized protein interactions in the living cell nucleus. Methods 25, 4–18. 
De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. 
(2007). Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate 
receptordependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. 
Chem. 282, 11590-11601. 
De Ferrari G.V. and Inestrosa N.C. (2000). Wnt signaling function in Alzheimer’s disease. 
Brain Res. Brain Res. Rev. 33, 1–12. 
De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura 
K., Van Leuven F. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amy-
loid precursor protein. Nature 391, 387–390. 
De Strooper B. (2003). Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-
secretase complex. Neuron 38, 9–12. 
Decker H., Jürgensen S., Adrover M.F., Brito-Moreira J., Bomfim T.R., Klein W.L., Epstein A.L., 
De Felice F.G., Jerusalinsky D., Ferreira S.T. (2010). N-methyl-D-aspartate receptors are re-
quired for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J. Neurochem. 
115, 1520-1529. 
Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. (2005). Calcium dysregulation 
and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oli-






Demuro A., Parker I., Stutzmann G.E. (2010). Calcium signaling and amyloid toxicity in Alz-
heimer disease. J. Biol. Chem. 285, 12463-12468.  
Dickson D.W. (1995). Correlation of synaptic and pathological markers with cognition of the 
elderly. Neurobiol. Aging 16, 285-298. 
Diociaiuti M., Polzi L.Z., Valvo L., Malchiodi-Albedi F., Bombelli C., Gaudiano M.C. (2006). Cal-
citonin forms oligomeric pore-like structures in lipid membranes. Biophys. J. 91, 2275-
2281. 
Doetsch F., Caille I., Lim D.A., García-Verdugo J.M., Alvarez-Buylla A. (1999). Subventricular 
zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 703–716. 
Dougherty J.J., Wu J., Nichols R.A. (2003). β-amyloid regulation of presynaptic nicotinic re-
ceptors in rat hippocampus and neocortex. J. Neurosci. 23, 6740–6747. 
Drabikowski W., Lagwińska E., Sarzala M.G. (1973). Filipin as a fluorescent probe for the lo-
cation of cholesterol in the membranes of fragmented sarcoplasmic reticulum. Biochim. 
Biophys. Acta 291, 61–70. 
Drapeau E. and Nora Abrous D. (2008). Stem cell review series: role of neurogenesis in age-
related memory disorders. Aging Cell 7, 569–589. 
Drummen G.P., Gadella B.M., Post J.A., Brouwers J.F. (2004). Mass spectrometric characteri-
zation of the oxidation of the fluorescent lipid peroxidation reporter molecule C11-
BODIPY(581/591). Free Radic. Biol. Med. 36, 1635-1644. 
Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., 
Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. 
(1996). Increased amyloid beta42(43) in brains of mice expressing mutant presenilin 1. 
Nature 383, 710–713. 
Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. (1998). Over-
expression of tau protein inhibits kinesindependent trafficking of vesicles, mitochondria, 
and endoplasmic reticulum: implications for Alzheimer’s disease. J. Cell Biol. 143, 777–
794. 
Eckert G.P., Wood W.G., Müller W.E. (2005). Membrane disordering effects of beta-amyloid 
peptides. Subcell. Biochem. 38, 319-337. 
Egawa H. and Furusawa K. (1999). Liposome adhesion on mica surface studied by atomic 
force microscopy. Langmuir 15, 1660-1666.  
Ehehalt R., Keller P., Haass C., Thiele C., Simons K. (2003). Amyloidogenic processing of the 
Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 160.113-
123.  
Eikelemboom R., Bate C., Van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis, R., 
Williams A. (2002). Neuroinflammation in Alzheimer’s disease and prion disease. Glia 
40, 232-239. 
Endo A., Kuroda M., Tanzawa K. (1976). Competitive inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites 
having hypocholesterolemic activity. FEBS Lett. 72, 323–326.  
Eucher J.N., Uemura E., Sakaguchi D.S., Greenlee M.H. (2007). Amyloid-beta peptide affects 
viability but not differentiation of embryonic and adult rat hippocampal progenitor cells. 
Exp. Neurol. 203, 486-492. 
Evangelisti E., Cecchi C., Cascella R., Sgromo C., Becatti M., Dobson C.M., Chiti F., Stefani M. 
(2012). Membrane lipid composition and its physicochemical properties define cell vul-
nerability to aberrant protein oligomers. Accepted for publication J.Cell Sci.  
Evers F., Jeworrek C., Tiemeyer S., Weise K., Sellin D., Paulus M., Struth B., Tolan M., Winter R. 
(2009). Elucidating the mechanism of lipid membrane-induced IAPP fibrillogenesis and 




its inhibition by the red wine compound resveratrol: a synchrotron X-ray reflectivity 
study. J. Am. Chem. Soc. 131, 9516-9521. 
Fan M.M.Y., Fernandes H. B., Zhang L. Y. J., Hayden M. R., Raymond L. A. (2007). Altered 
NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of 
Huntington’s disease. J. Neurosci. 14, 3768–3779. 
Farzan M., Schnitzler C.E., Vasilieva N., Leung D., Choe H. (2000). BACE2, a β-secretase 
homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precur-
sor protein. Proc. Natl. Acad. Sci. USA 97, 9712–9717. 
Fazzini E., Durso R., Davoudi H., Szabo G.K., Albert M.L. (1990). GM1 gangliosides alter 
acute MPTP-induced behavioral and neurochemical toxicity in mice. J. Neurol. Sci. 99, 
59–68. 
Flanagan L.A., Cunningham C.C., Chen J., Prestwich G.D., Kosik K.S., Janmey P.A. (1997). 
The structure of divalent cation-induced aggregates of PIP2 and their alteration by gel-
solin and tau. Biophys. J. 73, 1440–1447. 
Fodero-Tavoletti M.T., Villemagne V.L., Rowe C.C., Masters C.L., Barnham K.J., Cappai R. 
(2011). Amyloid-β: the seeds of darkness. Int. J. Biochem. Cell Biol. 43, 1247-1251.  
Fu W., Luo H., Parthasarathy S., Mattson M.P. (1998). Catecholamines potentiate amyloid β-
peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and 
perturbed calcium homeostasis. Neurobiol. Dis. 5, 229–243. 
Fujita A., Cheng J., Hirakawa M., Furukawa K., Kusunoki S., Fujimoto T. (2007). Gangli-
osides GM1 and GM3 in the living cell membrane form clusters susceptible to cholesterol 
depletion and chilling. Mol. Biol. Cell. 18, 2112–2122. 
Gasparini L., Racchi M., Binetti G., Trabucchi M., Solerte S.B., Alkon D., Etcheberrigaray R. 
Gibson H.G., Blass J., Paoletti R., Govoni S. (1998). Peripheral markers in testing patho-
physiological hypotheses and diagnosing Alzheimer’s disease. FASEB J. 12, 18-34. 
Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., 
Morozova-Roche L.A. (2007). Lysozyme amyloid oligomers and fibrils induce cellular 
death via different apoptotic/necrotic pathways. J. Mol. Biol. 365, 1337-13349. 
Glabe C.G. (2004). Conformation-dependent antibodies target diseases of protein misfolding. 
Trends Biochem. Sci. 29, 542-547. 
Glabe C.G. (2008). Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 
29639–29643. 
Glenner G.G. and Wong C.W. (1984). Alzheimer’s disease: Initial report of the purification 
and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. 
Commun. 120, 885–890. 
Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., 
Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Peri-
cak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. (1991). Segrega-
tion of a missense mutation in the amyloid precursor protein gene with familial Alz-
heimer’s disease. Nature 349,704–706 
Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. (1988). Cloning and se-
quencing of the cDNA encoding a core protein of the paired helical filament of Alz-
heimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. 
Sci. USA 85, 4051–4055. 
Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. (1992). Tau proteins of Alzheimer 







Goedert M., Spillantini M.G., Jakes R., Crowther R.A., Vanmechelen E., Probst A., Götz, J., 
Burki K., Cohen P. (1995). Molecular dissection of the paired helical filament. Neurobiol. 
Aging 16, 325–334. 
Gorbenko G.P. and Kinnunen P. K.. (2006). The role of lipid-protein interactions in amyloid-
type protein fibril formation. Chem. Phys. Lipids 141, 72-82. 
Gosal W.S., Morten I.J., Hewitt E.W., Smith D.A., Thomson N.H., Radford S.E. (2005). Compet-
ing pathways determine fibril morphology in the self-assembly of beta2-microglobulin 
into amyloid. J. Mol. Biol. 351, 850-64. 
Gottfries C.G. (1994). Therapy options in Alzheimer’s disease. Br. J. Clin. Pract. 48, 327–330. 
Götz J. (2001). Tau and transgenic animal models. Brain Res. Brain Res. Rev. 35, 266–286. 
Götz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., Chen F. 
(2004). Transgenic animal models of Alzheimer’s disease and related disorders: histo-
pathology, behavior and therapy. Mol. Psychiatr. 9, 664–683. 
Gotz M. and Huttner W.B. (2005). The cell biology of neurogenesis. Nat. Rev. Mol. Cell. Biol. 
6, 777–788. 
Grace E.A., Rabiner C.A., Busciglio J. (2002). Characterization of neuronal dystrophy induced 
by fibrillar amyloid β: implications for Alzheimer's disease. Neuroscience 114, 265–273. 
Green J.D., Kreplak L., Goldsbury C., Li Blatter X., Stolz M., Cooper G.S., Seelig A., Kistler J., Aebi 
U. (2004). Atomic force microscopy reveals defects within mica supported lipid bilayers in-
duced by the amyloidogenic human amylin peptide. J. Mol. Biol. 342, 877-887.  
Greeve I., Hermans-Borgmeyer I., Brellinger C., Kasper D., Gomez-Isla T., Behl C., Levkau B., 
Nitsch R.M. (2000). The human DIMINUTO/DWARF1 homolog seladin-1 confers re-
sistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J. 
Neurosci. 20, 7345-7352. 
Guentchev M., Voigtlander T., Haberler C., Groschup M.H., Budka H. (2000). Evidence for 
oxidative stress in experimental prion disease. Neurobiol. Dis. 7, 270–273. 
Guirland C. and Zheng J.Q. (2007). Membrane lipid rafts and their role in axon guidance. 
Adv. Exp. Med. Biol. 621, 144–155. 
Gujiarro J.I., Sunde M., Jones J.A., Campbell I.D., Dobson C.M. (1998). Amyloid fibril for-
mation by an SH3 domain. Proc. Natl. Acad. Sci. USA 95, 4224-4228. 
Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieber-
burg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. (1992). Amyloid β-peptide is pro-
duced by cultured cells during normal metabolism. Nature 359, 322–325. 
Hadjiconstantinou M. and Neff N.H. (1998). GM1 ganglioside: in vivo and in vitro trophic 
actions on central neurotransmitter systems. J. Neurochem. 70, 1335–1345. 
Hakomori S. and Igarashi Y.(1995). Functional role of glycosphingolipids in cell recognition 
and signaling. J. Biochem. 118, 1091–1103. 
Hakomori S. (2003). Structure, organization, and function of glycosphingolipids in mem-
brane. Curr. Opin. Hematol. 10, 16–24. 
Harder T. and Engelhardt K.R. (2004). Membrane domains in lymphocytes – from lipid rafts 
to protein scaffolds. Traffic 5, 265 – 275. 
Hardy J. and Selkoe D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science 297, 353-356. 
Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. (1997). Observation of metastable Abeta 
amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125. 
Harris D.A. (1999). Cellular biology of prion diseases. Clin. Microbiol. Rev. 12, 429-444. 
Haughey N.J., Liu D., Nath A., Borchard A.C., Mattson M.P. (2002). Disruption of neurogen-
esis in the subventricular zone of adult mice, and in human cortical neuronal precursor 




cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's 
disease. Neuromolecular. Med. 1, 125-135. 
Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., 
Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C.A., Selkoe D.J., Naiki H., 
Yanagisawa K. (2004). A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 4894–
4902. 
He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. 
(2004). Tumor necrosis factor death receptor signaling cascade is required for amyloid-β 
protein-induced neuron death. J. Neurosci. 24, 1760 -1771. 
Hering H., Lin C.C, Sheng M. (2003). Lipid rafts in the maintenance of synapses, dendritic 
spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262–3271. 
Hojjati M.R. and Jiang X.C. (2006). Rapid, specific, and sensitive measurements of plasma 
sphingomyelin and phosphatidylcholine. J. Lipid Res. 47, 673-676. 
Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., 
Olney J., McKeel D., Wozniak D., Paul S.M. (2000). Apolipoprotein E isoform-dependent 
amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. 
Proc. Natl. Acad. Sci. USA 97; 2892–2897. 
Hou X., Parkington H.C., Coleman H.A., Mechler A., Martin L.L., Aguilar M.I., Small D.H. 
(2007). Transthyretin oligomers induce calcium influx via voltage-gated calcium chan-
nels. J. Neurochem. 100, 446-457. 
Hung L.W., Ciccotosto G.D., Giannakis E., Tew D.J., Perez K., Masters C.L., Cappai R., Wade J.D., 
Barnham K.J. (2008). Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the 
rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J. 
Neurosci. 28, 11950-11958. 
Hyun D.H, Lee M., Hattori N., Kubo S., Mizuno Y., Halliwell B., Jenner P. (2002). Effect of 
wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and 
the proteasome. J. Biol. Chem. 277, 28572-28577. 
Imahori K. and Uchida T. (1997). Physiology and pathology of tau protein kinases in relation 
to Alzheimer’s disease. J. Biochem. 121, 179-188. 
Inoue S. (2008). In situ Abeta pores in AD brain are cylindrical assembly of Abeta protofila-
ments. Amyloid 15, 223-233. 
Ionescu-Zanetti C., Khurana R., Gillespie J.R., Petrick J.S., Trabachino L.C., Minert L.J., Carter 
S.A., Fink A.L. (1999). Monitoring the assembly of Ig light-chain amyloid fibrils by atom-
ic force microscopy. Proc. Natl. Acad. Sci. USA  96, 13175-13179. 
Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T., Imahori K. (1992). 
Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating 
an epitope of paired helical filaments. Neurosci. Lett. 148, 202-206. 
Jahn T.T. and Redford S.E. (2008). Folding versus aggregation: polypeptide conformations on 
competing pathways. Arch. Biochem. Biophys. 469, 100-117. 
Jan A., Gokce O., Luthi-Carter R., Lashuel H.A. (2008). The ratio of monomeric to aggregated 
forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, 
fibrillogenesis, and toxicity. J. Biol. Chem. 283, 28176-28189.  
Jarrett J.T., Berger E.P., Lansbury P.T.Jr. (1993). The carboxy terminus of the beta amyloid 
protein is critical for the seeding of amyloid formation: implications for the pathogenesis 
of Alzheimer’s disease. Biochemistry 32, 4693–4697. 
Jenkins S.M. and Johnson G.V. (1998). Tau complexes with phospholipase C-gamma in situ. 






Ji S.R., Wu Y., Sui S.F. (2002). Cholesterol is an important factor affecting the membrane inser-
tion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. 
J. Biol. Chem. 277, 6273-6279. 
Jin K., Galvan V., Xie L., Mao X.O., Gorostiza O.F., Bredesen D.E., Greenberg D.A. (2004). En-
hanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw,Ind) mice. Proc. 
Natl. Acad. Sci. USA 101, 13363–13367.  
Ju Yeon B. and Yeon Hee S. (2005). Blockade of 5-HT(3) receptor with MDL 72222 and Y 
25130 reduces beta-amyloid protein (25–35)-induced neurotoxicity in cultured rat corti-
cal neurons Eur. J. Pharmacol. 520, 12–21. 
Jurevics H. and Morell P. (1995). Cholesterol for synthesis of myelin is made locally, not im-
ported into brain. J. Neurochem. 64, 895-901. 
Kagan B.L., Azimov R., Azimova R. (2004). Amyloid peptide channels. J. Membr. Biol. 202, 1-
10.  
Kagan B.L. and Thundimadathil J. (2010). Amyloid peptide pores and the beta sheet confor-
mation. Adv. Exp. Med. Biol. 677,150-167. 
Kaiser R.D. and London E. (1998). Location of diphenylhexatriene (DPH) and its derivatives 
within membranes: comparison of different fluorescence quenching analyses of mem-
brane depth. Biochemistry 37, 8180–8190. 
Kakio A., Nishimoto S.I., Yanagisawa K., Kozutsumi Y., Matsuzaki K. (2001). Cholesterol-
dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed 
for Alzheimer amyloid. J. Biol. Chem. 276, 24985–24990. 
Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., Matsuzaki K. (2002). Interactions of 
amyloid beta-protein with various gangliosides in raft-like membranes: importance of 
GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Bioche-
mistry 41, 7385-7390. 
Kakio A., Nishimoto S., Kozutsumi Y., Matsuzaki K. (2003). Formation of a membrane-active 
form of amyloid beta-protein in raft-like model membranes. Biochem. Biophys. Res. 
Commun. 303, 514-518.  
Kalanj S., Kracun I., Rosner H., Cosovic C. (1991). Regional distribution of brain gangliosides 
in Alzheimer’s disease. Neurol. Croat. 40, 269–281. 
Kamiguchi H. (2006). The region-specific activities of lipid rafts during axon growth and 
guidance. J. Neurochem. 98, 330–335. 
Kaminski Schierle G.S., Van de Linde S., Erdelyi M., Esbjörner E.K., Klein T., Rees E., Berton-
cini C.W., Dobson C.M., Sauer M., Kaminski, C.F. (2011). In situ measurements of the 
formation and morphology of intracellular β-amyloid fibrils by super-resolution fluores-
cence imaging. J. Am. Chem. Soc. 133, 12902-12905.  
Kaneko I., Morimoto K., Kubo T. (2001). Drastic neuronal loss in vivo by β-amyloid race-
mized at Ser(26) residue: conversion of non-toxic [D-Ser(26)] beta-amyloid 1–14 to toxic 
and proteinase-resistant fragments. Neuroscience 104, 1003–1011. 
Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., 
Beyreuther K., Müller-Hill B. (1987). The precursor of Alzheimer's disease amyloid A4 
protein resembles a cell-surface receptor. Nature 325, 733-736. 
Kawahara M., Kuroda Y., Arispe N., Rojas E. (2000). Alzheimer’s β-amyloid, human islet am-
ylin, and prion protein fragment evoke intracellular free calcium elevation by a common 
mechanism in a hypopthalamic GnRH neuronal cell line. J. Biol. Chem. 275, 14077–
14083. 
Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., Matsubara 
E., Abe K., Ashe K.H., Younkin S.G. (2004). Dimeric amyloid beta protein rapidly accumu-




lates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the 
Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 24, 3801-3809. 
Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. 
(2003). Common structure of soluble amyloid oligomers implies common mechanism of 
pathogenesis. Science 300, 486–489. 
Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., Glabe C.G. (2004). Per-
meabilization of lipid bilayers is a common conformation-dependent activity of soluble 
amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363-46366. 
Kayed R. and Glabe C.G. (2006). Conformation-dependent anti-amyloid oligomer antibodies. 
Methods Enzymol. 413, 326-344. 
Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo 
L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G. (2007). Fibril specific, con-
formation dependent antibodies recognize a generic epitope common to amyloid fibrils 
and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 1-18. 
Kayed R., Pensalfini A., Margol L., Sokolov Y., Sarsoza F., Head E., Hall J., Glabe C.G. (2009). 
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. 
J. Biol. Chem. 284, 4230-4237. 
Kempermann G. and Gage F.H. (1999). New nerve cells for the adult brain. Sci. Am. 280, 48–
53. 
Kenworthy A.K., Petranova N., Edidin M. (2000). High-resolution FRET microscopy of chol-
era toxin B-subunit and GPI-anchored proteins in cell plasma membranes. Mol. Biol. 
Cell. 11, 1645-1655. 
Kenworthy A.K., Nichols B.J., Remmert C.L., Hendrix G.M., Kumar M., Zimmerberg J., Lip-
pincott-Schwartz J. (2004). Dynamics of putative raft-associated proteins at the cell sur-
face. J. Cell Biol. 165, 735 – 746. 
Kim H.Y., Cho M.K., Kumar A., Maier E., Siebenhaar C., Becker S., Fernandez C.O., Lashuel 
H.A., Benz R., Lange A., Zweckstetter M. (2009). Structural properties of pore-forming oli-
gomers of alpha-synuclein. J. Am. Chem. Soc. 131, 17482-17489. 
Kimura N. and Yanagisawa K. (2007). Endosomal accumulation of GM1 ganglioside-bound 
amyloid β-protein in neurons of aged monkey brains. Neuroreport 18, 1669–1673. 
Kinoshita A., Fukumoto H., Shah T., Whelan C.M., Irizarry M.C., Hyman B.T. (2003). Demon-
stration by FRET of BACE interaction with the amyloid precursor protein at the cell sur-
face and in early endosomes. J. Cell Sci. 116, 3339-3346.  
Klyubin I., Walsh D.M., Lemere C.A., Cullen V.K., Shankar G.M., Betts V., Spooner E.T., 
Jiang L., Amwyl R., Selkoe D.J., Rowan M.J. (2005). Amyloid beta protein immunothera-
py neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556-
561. 
Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza 
M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. (2009). 
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excit-
atory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA 106, 4012-4017. 
Koike H., Tomioka S., Sorimachi H., Saido T.C., Maruyama K., Okuyama A., Fujisawa-Sehara 
A., Ohno S., Suzuki K., Ishiura S. (1999). Membrane-anchored metallopro-tease MDC9 
has an a-secretase activity responsible for processing the amyloid precursor protein. Bio-
chem. J. 343, 371–375. 
Kojro E., Gimpl G., Lammich S., März W., Fahrenholz F. (2001). Low cholesterol  stimulates 
the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 Proc. Natl. 






Kölsch H., Heun R., Kerksiek A., Bergmann K.V., Maier W., Lütjohann D. (2004). Altered 
levels of plasma 24S-hydroxycholesterol and 7-hydroxycholesterol in demented patients. 
Neurosci. Lett. 368, 303-308. 
Koudinov A.R. and Koudinova N.V. (2005). Cholesterol homeostasis failure as a unifying 
cause of synaptic degeneration. J. Neurol. Sci. 230, 233-240.  
Kourie J.I. (2001). Mechanisms of amyloid β protein-induced modification in ion transport 
systems: implications for neurodegenerative diseases. Cell. Mol. Neurobiol. 21, 173–213. 
Kourie J.I., Farrelly P.V., Henry C.L. (2001). Channel activity of deamidated isoforms of prion 
protein fragment 106-126 in planar lipid bilayers. J. Neurosci. Res. 66, 214-220. 
Kourie J.I. and Henry C.L. (2002). Ion channel formation and membrane-linked pathologies 
of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin. 
Exp. Pharmacol. Physiol. 29, 741–753. 
Kracun I., Kalanj S., Talan-Hranilovic J., Cosovic C. (1992). Cortical distribution of gangli-
osides in Alzheimer’s disease. Neurochem. Int. 20, 433–438. 
Kranenburg O., Bouma B., Kroon-Batenburg L.M.J., Reijerkerk A., Wu Y.P., Voest E.E., 
Gebbink M.F.B.G. (2002). Tissue-type plasminogen activator is a multiligand cross-beta 
structure receptor. Current Biol. 12, 1833-1839. 
Kremer J.J., Pallitto M.M., Sklansky D.J., Murphy R.M. (2000). Correlation of beta-amyloid ag-
gregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Bi-
ochemistry 39, 10309-10318. 
Kreutz F., Frozza R.L., Breier A.C., de Oliveira V.A., Horn A.P., Pettenuzzo L.F., Netto C.A., 
Salbego C.G., Trindade V.M (2011). Amyloid-β induced toxicity involves ganglioside ex-
pression and is sensitive to GM1 neuroprotective action. Neurochem. Int. 59, 648-655. 
Kumar S. and Udgaonkar J.B. (2009). Structurally distinct amyloid protofibrils form on sepa-
rate pathways of aggregation of a small protein. Biochemistry 48, 6441-6449. 
Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., 
Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein, 
W.L.(1998). Diffusible nonfibrillar ligands derived from Abeta 1-42 are potent central 
nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453. 
Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., 
Finch C.E., Klein W.L. (2001). Vaccination with soluble Abeta oligomers generates toxici-
ty-neutralizing antibodies. J. Neurochem. 79, 595-605. 
Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury, P.T.Jr. (2002) Neurodegenerative 
disease: amyloid pores from pathogenic mutations. Nature 418, 291. 
Lashuel H.A. and Lansbury P.T.Jr. (2006). Are amyloid diseases caused by protein aggregates 
that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167-201.  
Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. (2009). Cellular prion 
protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 
457, 1128–1132. 
Ledeen R.W., Wu G., Lu Z.H., Kozireski-Chuback D., Fang Y. (1998). The role of GM1 and 
other gangliosides in neuronal differentiation. Overview and new finding. Ann. N.Y. 
Acad. Sci. 845, 161–175. 
Ledeen R.W. and Wu G. (2007). GM1 in the nuclear envelope regulates nuclear calcium 
through association with a nuclear sodiumcalcium exchanger. J. Neurochem. 103, 126–
134. 
Ledesma M.D. and Dotti C.G. (2005). The conflicting role of brain cholesterol in Alzheimer’s 
disease: lessons from the brain plasminogen system. Biochem. Soc. Symp. 72, 129-138. 
Ledesma M.D. and Dotti C.G. (2006). Amyloid excess in Alzheimer's disease: what is choles-
terol to be blamed for? FEBS Lett. 580, 5525-5532. 




Lee G. and Rook S.L. (1992). Expression of tau protein in non-neuronal cells:microtubule-
binding and stabilization. J. Cell Sci. 102, 227–237. 
Lee I.P., McKenzie S., Muller F.J., Snyder E.Y. (2008). Neural stem cell transplantation in 
mouse brain. Curr. Protoc. Neurosci. 3, 3-10. 
Lee S., Fernandez E.J., Good T.A. (2007). Role of aggregation conditions in structure, stabil-
ity, and toxicity of intermediates in the Abeta fibril formation pathway. Protein Sci. 16, 
723-732.  
Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., Kosik K.S. (2003). A detergent-
insoluble membrane compartment contains A beta in vivo. Nat. Med. 4, 730-734.  
Lee V.M., Goedert M., Trojanowski J.Q. (2001). Neurodegenerative tauopathies. Annu. Rev. 
Neurosci. 24, 1121–1159. 
Leissring M.A., Murphy M.P., Mead T.R., Akbari Y., Sugarman M.C., Jannatipour M., Anlik-
er B., Müller U., Saftig P., Strooper B.D., Wolfe M.S., Golde T.E., LaFerla F.M. (2002). A 
physiologic signaling role for the γ-secretase-derived intracellular fragment of APP. Proc. 
Natl. Acad. Sci. USA 99, 4697–4702. 
Lentz B.R. (1989). Membrane “fluidity” as detected by diphenylhexatriene probes. Chem. 
Phys. Lipids 50, 171–190. 
Lentz B.R. (1993). Use of fluorescent probes to monitor molecular order and motions within 
liposome bilayers. Chem. Phys. Lipids 64, 99–116. 
Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. 
(2006). A specific amyloid β protein assembly in the brain impairs memory. Nature 440, 
352-357. 
Levison S.W. and Goldman J.E. (1993). Both oligodendrocytes and astrocytes develop from 
progenitors in the subventricular zone of postnatal rat forebrain. Neuron 10, 201–212. 
Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., 
Jondro P.D., Schmidt S.D., Wang K. (1995). Candidate gene for the chromosome 1 familial 
Alzheimer’s disease locus. Science 269, 973–977. 
Lewis V. and Hooper N.M. (2011). The role of lipid rafts in prionprotein biology. Front. Bi-
osci. 16, 151–168. 
Li G., Peskind E.R., Millard S.P., Chi P., Sokal I., Yu C.E., Bekris L.M., Raskind M.A., Galasko 
D.R., Montine T.J. (2009). Cerebrospinal fluid concentration of brain-derived neu-
rotrophic factor and cognitive function in non-demented subjects. PLoS One 4, e5424. 
Li X. and Zuo P. (2005). Effects of Abeta25-35 on neurogenesis in the adult mouse subven-
tricular zone and dentate gyrus. Neurol. Res. 27, 218–222. 
Lichtenberg B., Mandelkow E.M., Hagestedt T., Mandelkow E. (1988). Structure and elasticity 
of microtubule-associated protein tau. Nature 334, 359–362. 
Lin H., Bhatia R., Lal R. (2001). Amyloid beta protein forms ion channels: implications for 
Alzheimer's disease pathophysiology. FASEB J. 15, 2433-2444. 
Lin M.S., Chen L.Y., Wang S.S., Chang Y., Chen W.Y. (2008). Examining the levels of gangli-
oside and cholesterol in cell membrane on attenuation the toxicity of beta-amyloid pep-
tide. Coll. Surf. B Biomem. 65, 173-177. 
Lingwood D. and Simons K. (2010). Lipid rafts as a membrane-organizing principle. Science 
327, 46-50. 
Litvinovich S.V., Brew S.A., Aota S., Akiyama S.K., Haudenschild C., Ingham K.C. (1998). 
Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin 
type III module. J. Mol. Biol. 280, 245-258. 
Liu Q. and Zhao B. (2004). Nicotine attenuates β-amyloid peptide-indueed neurotoxicity, free 







Liu R., McAllister C., Lyubchenko Y., Sierks M.R. (2004). Residues 17–20 and 30–35 of beta-
amyloid play critical roles in aggregation. J. Neurosci. Res. 75, 162–171. 
Lledo P.M. and Gheusi G. (2003). Olfactory processing in a changing brain. Neuroreport 14, 
1655–1663. 
Lois C. and Alvarez-Buylla A. (1993). Proliferating subventricular zone cells in the adult 
mammalian forebrain can differentiate into neurons and glia. Proc. Natl. Acad. Sci. USA 
90, 2074–2077. 
López-Toledano M.A. and Shelanski M.L. (2004). Neurogenic effect of beta-amyloid peptide 
in the development of neural stem cells. J. Neurosci. 24, 5439-5444.  
Lopez-Toledano M.A. and Shelanski M.L. (2007). Increased neurogenesis in young transgenic 
mice overexpressing human APP(Sw, Ind). J. Alzheimers. Dis. 12, 229–240.  
Lunn J.S., Sakowski S.A., Hur J., Feldman E.L. (2011). Stem cell technology for neurodegenera-
tive diseases. Ann. Neurol. 70, 353-361.  
Maas T., Eidenmuller J., Brandt R. (2000). Interaction of tau with the neuralmembrane cortex 
is regulated by phosphorylation at sites that are modified in paired helical filaments. J. 
Biol. Chem. 275, 15733–15740. 
MacManus A., Ramsden M., Murray M., Henderson Z., Pearson H.A., Campbell V. A. 
(2000). Enhancement of (45)Ca2+ influx and voltage-dependent Ca2+ channel activity by 
β-amyloid-(1–40) in rat cortical synaptosomes and cultured cortical neurons. Modula-
tion by the proinflammatory cytokine interleukin-1β. J. Biol. Chem. 275, 4713–4718. 
Mahley RW. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in 
cell biology. Science 240, 622-630. 
Malchiodi-Albedi F., Contrusciere V., Raggi C., Fecchi K., Rainaldi G., Paradisi S., Matteucci A., 
Santini M.T., Sargiacomo M., Frank .C, Gaudiano M.C., Diociaiuti M. (2010). Lipid raft dis-
ruption protects mature neurons against amyloid oligomer toxicity. Biochim. Biophys. 
Acta 1802, 406-415. 
Malchiodi-Albedi F., Paradisi S., Matteucci A., Frank C., Diociaiuti M. (2011). Amyloid oli-
gomer neurotoxicity, calcium dysregulation, and lipid rafts. Int. J. Alzheimers Dis. 8, 906964. 
Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., 
Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., Agadjanyan M.G. (2007). Anti-A beta 1-
11 antibody binds to different beta-amyloid species, inhibits fibril formation, and dis-
aggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282, 22376-
22386. 
Mandal P.K. and Pettegrew J.W. (2004). Alzheimer’s disease: NMR studies of asialo (GM1) 
and trisialo (GT1b) ganglioside interactions with Aβ(1-40) peptide in a membrane mim-
ic environment. Neurochem. Res. 29, 447–453. 
Marcon G., Plakoutsi G., Canale C., Relini A., Taddei N., Dobson C.M., Ramponi G., Chiti F. 
(2005). Amyloid formation from HypF-N under conditions in which the protein is ini-
tially in its native state. J. Mol. Biol. 347, 323-335.  
Martins I.C., Kuperstein I., Wilkinson H., Maes E., Vanbrabant M., Jonckheere W., Van Gel-
der P., Hartmann D., D'Hooge R., De Strooper B., Schymkowitz J., Rousseau F. (2008). 
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in 
mice. EMBO J. 27, 224-33. 
Mason R.P., Shoemaker W.J., Shajenko L., Chambers T.E., Herbette L.G. (1992). Evidence for 
changes in the Alzheimer’s disease brain cortical membrane structure mediated by cho-
lesterol. Neurobiol. Aging 13, 413-419. 
Masters C.L., Cappai R., Barnham K.J., Villemagne V.L. (2006). Molecular mechanisms for 
Alzheimer’s disease: implications for neuroimaging and therapeutics. J. Neurochem. 97, 
1700–1725. 




Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. (1985). 
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. 
Acad. Sci. USA 82, 4245–4249. 
Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., 
Shiratori C., Lemere C,. Duff K. (2003). Novel therapeutic approach for the  treatment of 
Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. 
J. Neurosci. 23, 29–33. 
Matsuzaki K. (2007). Physicochemical interactions of amyloid beta-peptide with lipid bilayers. 
Biochim. Biophys. Acta 1768, 1935-1942.  
Matsuzaki K., Kato K., Yanagisawa K. (2010). Abeta polymerization through interaction with 
membrane gangliosides. Biochim. Biophys. Acta 1801, 868-877. 
Mattson M.P. (1999). Impairment of membrane transport and signal transduction systems by 
amyloidogenic proteins. Methods  Enzymol. 309, 733-768.  
Mayeux R. (2010). Clinical practice. Early Alzheimer's disease. N. Engl. J. Med. 362, 2194-2201. 
Mazur-Kolecka B., Golabek A., Nowicki K., Flory M., Frackowiak J. (2006). Amyloid-beta 
impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol. 
Aging 27, 1181-1192. 
McLaurin J. and Chakrabartty A. (1996). Membrane disruption by Alzheimer β-amyloid pep-
tides mediated through specific binding to either phospholipids or gangliosides. Implica-
tions for neurotoxicity. J. Biol. Chem. 271, 26482–26489. 
McLaurin J., Franklin T., Fraser P.E., Chakrabartty A. (1998). Structural transitions associat-
ed with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J. Biol. 
Chem. 273, 4506-4515. 
McLaurin J., Yang D., Yip C.M., Fraser P.E. (2000) Review: modulating factors in amyloid-
beta fibril formation. J. Struct. Biol. 130, 259-270. 
Mehta T. K., Dougherty J. J., Wu J., Choi C. H., Khan G. M., Nichols R. A. (2008). Defining 
pre-synaptic nicotinic receptors regulated by beta amyloid in mouse cortex and hippo-
campus with receptor null mutants. J. Neurochem. 109, 1452–1458. 
Michel G., Mercken M., Murayama M., Noguchi K., Ishiguro K., Imahori K., Takashima A. 
(1998). Characterization of tau phosphorylation in glycogen synthase kinase-3beta and 
cyclin dependent kinase-5 activator (p23) transfected cells. Biochim. Biophys. Acta 1380, 
177-182. 
Mirzabekov T.A., Lin M.C., Kagan B.L. (1996). Pore formation by the cytotoxic islet amyloid 
peptide amylin. J. Biol. Chem. 271, 1988-1992. 
Mizuno T., Nakata M., Naiki H., Michikawa M., Wang R., Haass C., Yanagisawa K. (1999). 
Cholesterol-dependent generation of a seeding amyloid β-protein in cell culture. J. Biol. 
Chem. 274, 15110–15114. 
Mohanty J.G., Jaffe J.S., Schulman E.S., Raible D.G. (1997). A highly sensitive fluorescent mi-
cro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxa-
zine derivative. J. Immunol. Methods 202, 133-141. 
Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Mansson J.E., Fredman P. 
(2005). Structural membrane alterations in Alzheimer brains found to be associated with 
regional disease development; increased density of gangliosides GM1 and GM2 and loss 
of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92, 171–182. 
Monoi H., Futaki S., Kugimiya S., Minakata H., Yoshihara K. (2000). Poly-L-glutamine forms 







Moreira P.I., Santos M.S., Moreno A., Rego A.C., Oliveira C. (2002). Effect of amyloid beta-
peptide on permeability transition pore: a comparative study. J. Neurosci. Res. 15, 257–
267.  
Mori T., Buffo A., Gotz M. (2005). The novel roles of glial cells revisited: the contribution of 
radial glia and astrocytes to neurogenesis. Curr. Top. Dev. Biol. 69, 67–99. 
Morishima-Kawashima M. and Kosik K.S. (1996). The pool of map kinase associated with 
microtubules is small but constitutively active. Mol. Biol. Cell. 7, 893–905. 
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-
risk individuals: a randomized placebo-controlled trial. (2002). Lancet 360, 7-22.  
Murray I.V., Liu L., Komatsu H., Uryu K., Xiao G., Lawson J.A., Axelsen P.H. (2007). Membrane-
mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta pro-
teins. J. Biol. Chem. 282, 9335-9345. 
Mutoh T., Hirabayashi Y., Mihara T., Ueda M., Koga H., Ueda A., Kokura T., Yamamoto H. 
(2006). Role of glycosphingolipids and therapeutic perspectives on Alzheimer’s disease. 
CNS Neurol. Disord. Drug Targets 5, 375–380. 
Naguib Y.M. (1998). A fluorometric method for measurement of peroxyl radical scavenging 
activities of lipophilic antioxidants. Anal. Biochem. 265, 290-298. 
Necula M., Kayed R., Milton S., Glabe C.G. (2007). Small molecule inhibitors of aggregation 
indicate that amyloid beta oligomerization and fibrillization pathways are independent 
and distinct. J. Biol. Chem. 282,10311–10324. 
Nekooki-Machida Y., Kurosawa M., Nukina N., Ito K., Oda T., Tanaka M. (2009). Distinct 
conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cyto-
toxicity. Proc. Natl. Acad. Sci. USA 106, 9679-9684. 
Nelson R., Sawaya M.R., Balbirnie M., Madsen, A.Ø., Riekel C., Grothe R., Eisenberg D. 
(2005). Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773-778. 
Neri T., Bucciantini M., Rosti V., Raimondi S., Relini A., Massa M., Zuccotti M., Donadei S., 
Stefani M., Redi C.A., Merlini G., Stoppini M., Garagna S., Bellotti V. (2010). Embryonic 
stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the 
differentiation potency in culture. Amyloid 17, 137-145. 
Ngamukote S., Yanagisawa M., Ariga T., Ando S., Yu R.K. (2007). Developmental changes of 
glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem. 103, 
2327–2341. 
Nicolet Y., Piras C., Legrand P., Hatchikian C.E., Fontecilla-Camps J.C. (1999). Desulfovibrio 
desulfuricans iron hydrogenase: the structure shows unusual coordination to an active 
site Fe binuclear center. Structure 7, 13-23. 
Novitskaya V., Bocharova O.V., Bronstein I., Baskakov I.V. (2006). Amyloid fibrils of mam-
malian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. 
Chem. 281, 13828-13836. 
O’Nuallain B. and Wetzel R. (2002). Conformational Abs recognizing a generic amyloid fibril 
epitope. Proc. Natl. Acad. Sci. USA 99, 1485-1490. 
Okada T., Wakabayashi M., Ikeda K., Matsuzaki K. (2007). Formation of toxic fibrils of Alzhei-
mer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane 
component. J. Mol. Biol. 371, 481-489. 
Okada T., Ikeda K., Wakabayashi M., Ogawa M., Matsuzaki K. (2008). Formation of toxic 
Abeta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: poly-
morphisms in Abeta(1-40) fibrils. J. Mol. Biol. 382,1066-1074.  
Olzscha H., Schermann S.M., Woerner A.C., Pinkert S., Hecht M.H., Tartaglia G.G., Ven-
druscolo M., Hayer-Hartl M., Hartl F.U., Vabulas R.M. (2011). Amyloid-like aggregates 
sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78. 




Oma Y., Kino Y., Sasagawa N., Ishiura S. (2005). Comparative analysis of the cytotoxicity of 
homopolymeric amino acids. Biochim. Biophys. Acta 1748, 174-179. 
Orrenius S., Zhovotovsky B., Nicotera P. (2003). Regulation of cell death: the calcium-
apoptosis link. Nat Rev 4, 552–565. 
Pappolla M.A., Omar R.A., Chyan Y.J., Ghiso J., Hsiao K., Bozner P., Perry G., Smith M.A., 
Cruz-Sanchez F. (2001). Induction of NADPH cytochrome P450 reductase by the Alz-
heimer β-protein. Amyloid as a “foreign body. J. Neurochem. 78, 121–128. 
Parton R.G. (1994). Ultrastructural localization of gangliosides; GM1 is concentrated in cave-
olae. J. Histochem. Cytochem. 42, 155–166. 
Paschos A., Glass R.S., Böck A. (2001). Carbamoylphosphate requirement for synthesis of the 
active center of [NiFe]-hydrogenases. FEBS Lett. 488, 9-12. 
Paterson J.A., Privat A., Ling E.A., Leblond C.P. (1973). Investigation of glial cells in semithin 
sections. 3 Transformation of subependymal cells into glial cells, as shown by radioau-
tography after 3 H-thymidine injection into the lateral ventricle of the brain of young 
rats. J. Comp. Neurol. 149, 83–102. 
Patrick G.N., Zukerberg L., Nikolic M., de da Monte S., Dikkes P., Tsai L.H. (1999). Conver-
sion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 
402, 615-622. 
Pearson X.H., Teng Y.D., Snyder E.Y. (2008). Important precautions when deriving patient-
specific neural elements from pluripotent cells. Cytotherapy 11, 815-824. 
Pedersen J.S., Christensen G., Otzen D.E. (2004). Modulation of S6 fibrillation by unfolding 
rates and gatekeeper residues. J. Mol. Biol. 341, 575-588. 
Pellistri F., Bucciantini M., Relini A., Gliozzi A., Robello M., Stefani M. (2008). Generic inter-
action of pre-fibrillar amyloid aggregates with NMDA and AMPA receptors results in 
free Ca2+increase in primary neuronal cells. J. Biol. Chem. 283, 29950-29960.  
Pensalfini A., Zampagni M., Liguri G., Becatti M., Evangelisti E., Fiorillo C., Bagnoli S., Celli-
ni E., Nacmias B., Sorbi S., Cecchi C. (2011). Membrane cholesterol enrichment prevents 
Aβ-induced oxidative stress in Alzheimer's fibroblasts. Neurobiol. Aging 32, 210-22.  
Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., Tycko R. (2005). Self-
propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 
307, 262-265. 
Pfrieger F.W. (2003). Cholesterol homeostasis and function in neurons of the central nervous 
system. Cell. Mol. Life Sci. 60, 1158-11571. 
Pike L.J. (2003). Lipid rafts: bringing order to chaos. J. Lipid Res. 44, 655 – 667. 
Poirier J., Baccichet A., Dea D., Gauthier S. (1993). Cholesterol synthesis and lipoprotein 
reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55, 81-
90. 
Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. (1993). Apolipopro-
tein E polymorphism and Alzheimer’s disease. Lancet 342, 697–699. 
Poirier J. (2003).Apolipoprotein E and cholesterol metabolism in the pathogenesis and treat-
ment of Alzheimer’s disease. Trends Mol. Med. 9, 94-101. 
Pollard H.B., Arispe N., Rojas E. (1995). Ion channel hypothesis for Alzheimer amyloid peptide 
neurotoxicity. Cell. Mol. Neurobiol. 15, 513-526.  
Pope-Coleman A., Tinker J.P, Schneider J.S. (2000). Effects of GM1 ganglioside treatment on 
pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. 
Synapse 36, 120–128. 
Porat Y., Kolusheva S., Jelinek R., Gazit E. (2003). The human islet amyloid polypeptide 






Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., 
Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., Leuven F.V., Fahrenholz F. 
(2004). A disintegrin-metalloproteinase prevents amyloid plaque formation and hippo-
campal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456–1464. 
Prusiner S.B., Scott M.R., deArmond S.J., Cohen F.E. (1998). Prion protein biology. Cell 93, 
337- 348.  
Puglielli L., Tanzi R.E., Kovacs D.M. (2003). Alzheimer’s disease: the cholesterol connection. 
Nat. Neurosci. 6, 7212-72121. 
Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong J.S. (2002). Microglia enhance β-amyloid 
peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive 
oxygen species. J. Neurochem. 83, 973–983. 
Qiu L., Lewis A., Como J., Vaughn M.W., Huang J., Somerharju P., Virtanen J., Cheng K.H. 
(2009) Cholesterol modulates the interaction of beta-amyloid peptide with lipid bilayers. Bio-
phys. J. 20, 4299-3407. 
Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., Brito R.M. (2001). Tetramer dissociation and 
monomer partial unfolding precedes protofibril formation in amyloidogenic transthyret-
in variants. J. Biol. Chem. 276, 27207-27213.  
Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., Lal R. (2005). 
Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. 
Natl. Acad. Sci. USA 102, 10427-10432.  
Rasband W.S. (1997-2008). ImageJ. U.S. National Institutes of Health, Bethesda, Maryland, 
USA, http://rsb.info.nih.gov/ij/. 
Reissmann S., Hochleitner E., Wang H., Paschos A., Lottspeich F., Glass R.S., Böck A. (2003). 
Taming of a poison: biosynthesis of the NiFe-hydrogenase cyanide ligands. Science 299, 
1067-10670. 
Reixach N., Deechingkit S., Jiang X., Kelly J.W., Buxbaum J.N. (2004). Tissue damage in the 
amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic 
species in tissue culture. Proc. Natl. Acad. Sci. USA 101, 2817-2822. 
Relini A., Torrassa S., Rolandi R., Gliozzi A., Rosano C., Canale C., Bolognesi M., Plakoutsi G., 
Bucciantini M., Chiti F., Stefani M. (2004). Monitoring the process of HypF fibrillization 
and liposome permeabilization by protofibrils. J. Mol. Biol. 338, 943-957. 
Relini A., Canale C., De Stefano S., Rolandi R., Giorgetti S., Stoppini M., Rossi A., Fogolari F., 
Corazza A., Esposito G., Gliozzi A., Bellotti V. (2006). Collagen plays an active role in the 
aggregation of beta2-microglobulin under physiopathological conditions of dialysis-
related amyloidosis. J. Biol. Chem. 281, 16521–16529. 
Repetto E., Russo C., Venezia V., Nizzari M., Nitsch R.M., Schettini G. (2004). BACE1 over-
expression regulates amyloid precursor protein cleavage and interaction with the ShcA 
adapter. Ann. NY Acad. Sci. 1030, 330–338. 
Resende R., Pereira C., Agostinho P., Vieira A.P., Malva J.O., Oliveira C.R. (2007). Suscepti-
bility of hippocampal neurons to Aβ peptide toxicity is associated with perturbation of 
Ca2+ homeostasis. Brain Res. 1143, 11–21. 
Reszka A.A., Seger R., Diltz C.D., Krebs E.G., Fischer E.H. (1995). Association of mitogen-
activated protein kinase with the microtubule cytoskeleton. Proc. Natl. Acad. Sci. USA 92, 
8881–8885. 
Richardson J.S. and Richardson D.C. (2002). Natural beta-sheet proteins use negative design to 
avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. USA 99, 2754-2759. 
Rinia H.A., Kik R.A., Demel R.A., Snel M.M.E., Killian J.A., van der Eerden J.P.J.M., de Krui-
jff B. (2000). Visualization of highly ordered striated domains induced by transmem-
brane peptides in supported phosphatidylcholine bilayers. Biochemistry 39, 5852-5858. 




Rodrıguez J.J., Jones V.C., Verkhratsky A. (2009). Impaired cell proliferation in the subven-
tricular zone in an Alzheimer’s disease model. Neuroreport 20, 907–912.  
Romiti E., Meacci E., Tanzi G., Becciolini L., Mitsutake S., Farnararo M., Ito M., Bruni P. (2001). 
Localization of neutral ceramidase in caveolin-enriched light membranes of murine en-
dothelial cells. FEBS Lett. 506, 163-168. 
Rosano C., Zuccotti S., Bucciantini M., Stefani M., Ramponi G., Bolognesi M. (2002). Crystal 
structure and anion binding in the prokaryotic hydrogenase maturation factor HypF 
acylphosphatase-like domain. J. Mol. Biol. 321, 785-796. 
Rosenberg R.N. (2000). The molecular and genetic basis of AD: the end of the beginning: the 
2000 Wartenberg lecture. Neurology 54, 2045-2054. 
Rothblat D.S. and Scneider J.S. (1999). Regional differences in striatal dopamine uptake and 
release associated with recovery from MPTP-induced parkinsonism: an in vivo electro-
chemical study. J. Neurochem. 72, 724–733. 
Rovira C., Arbez N., Mariani J. (2002). Aβ(25–35) and Aβ(1–40) act on different calcium 
channels in CA1 hippocampal neurons. Biochem. Biophys. Res. Commun. 296, 1317–1321. 
Sakono M. and Zako T. (2010). Amyloid oligomers: formation and toxicity of Abeta oligomers. 
FEBS J. 277; 1348-1358.  
Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi N., Nakano H., Ikeda S., Yamagishi 
T., Kitamoto T., Saito T., Makita Z. (2002). Advanced glycation end products (AGE) and 
their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion 
plaques. Neurosci. Lett. 326, 117-120. 
Satija N.K., Singh V.K., Verma Y.K., Gupta P., Sharma S., Afrin F., Sharma M., Sharma P., 
Tripathi R.P., Gurudutta G.U. (2009). Mesenchymal stem cellbased therapy: a new para-
digm in regenerative medicine. J. Cell. Mol. Med. 13, 4385–4402. 
Saulino M.F. and Schengrund C.L. (1994). Differential accumulation of gangliosides by the 
brains of MPTP-lesioned mice. J. Neurosci. Res. 37, 384–391. 
Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton 
M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg 
G., Tanzi R., Wasco W., Lannfelt L., Selkoe D.J., Younkin S. (1996). Secreted amyloid beta-
protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by 
the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat 
Med. 2, 864–870. 
Schneider J.S., Pope A., Simpson K., Taggart J., Smith M.G., DiStefano L. (1992). Recovery 
from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 
256, 843–846. 
Schweers O., Schonbrunn-Hanebeck E., Marx A., Mandelkow E. (1994). Structural studies of 
tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. 
J. Biol. Chem. 269, 24290–24297. 
Seaberg R.M. and van der Kooy D. (2002). Adult rodent neurogenic regions: the ventricular 
subependyma contains neural stem cells, but the dentate gyrus contains restricted pro-
genitors. J. Neurosci. 22, 1784–1793. 
Selkoe D.J. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–
766. 
Selkoe D.J. (2007). Developing preventive therapies for chronic diseases: lessons learned from 
Alzheimer's disease. Nutr. Rev. 65, S239-S243. 







Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., Arnsdorf M.F., 
Lindquist S.L. (2000). Nucleated conformational conversion and the replication of confor-
mational information by a prion determinant. Science 289, 1317-1321. 
Serpell L.C., Sunde M., Benson M.D., Tennent G.A., Pepys M.B., Fraser P.E. (2000). The pro-
tofilament substructure of amyloid fibrils. J. Mol. Biol. 300, 1033-1039. 
Sethuraman A. and Belfort G. (2005). Protein structural perturbation and aggregation on 
homogeneous surfaces.Biophys. J. 88, 1322–1333. 
Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., 
Whaley J., Swindlehurst C., McCormack R., Selkoe D.J., Lieberburg I., Schenk D. (1992). 
Isolation and quantitation of soluble Alzheimer’s β-peptide from biological fluids. Nature 
359, 325–327. 
Shadek G.M., Kummer M.P., Lu D.C., Galvan V., Bredesen D.E., Koo E.H. (2006). Aβ induc-
es cell death by direct interaction with its cognate extracellular domain on APP (APP 
597-624). FASEB J. 20, 1254-1266. 
Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li 
G., Holman K., Tsuda T., Mar L., Foncin J.F., Bruni A.C., Montesi M.P., Sorbi S., Rainero 
I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Was-
co W., Da Silva H.A., Haines J.L., Perkicak-Vance M.A., Tanzi R.E., Roses A.D., Fraser 
P.E., Rommens J.M., St George-Hyslop P.H. (1995). Cloning of a gene bearing missense 
mutations in early-onset familial Alzheimer’s disease. Nature 375, 754–760. 
Shinitzky M. and Barenholz Y. (1974). Dynamics of the hydrocarbon layer in liposomes of 
lecithin and sphingomyelin containing dicetylphosphate. J. Biol. Chem. 249, 2652–2657. 
Shobab L.A., Hsiung G.Y.R., Feldman H.H. (2004). Cholesterol in Alzheimer’s disease. Lancet 
Neurol. 5, 841-852.  
Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner 
R., Frangione B., Younkin S.G. (1992). Production of the Alzheimer amyloid β protein by 
normal proteolytic processing. Science 258, 126–129. 
Shruster A., Melamed E., Offen D. (2010). Neurogenesis in the aged and neurodegenerative 
brain. Apoptosis 15, 1415–1421. 
Simakova O. and Arispe N.J. (2007). The cell-selective neurotoxicity of the Alzheimer's Abeta 
peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane 
binding is required for Abeta toxicity. J. Neurosci 27, 13719-13729. 
Simons K. and Ikonen E. (1997). Functional rafts in cell membranes. Nature 387, 569–572. 
Simons K. and Toomre D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell 
Biol. 1, 31–39. 
Sirangelo I., Malmo C., Iannuzzi C., Mezzogiorno A., Bianco M.R., Papa M., Irace G.(2004). 
Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant 
W7FW14F. J. Biol. Chem. 279, 13183-13189. 
Sjögren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelsø C., Skoog I., 
Wallin A., Wahlund L.O., Marcusson J., Nägga K., Andreasen N., Davidsson P., Vanmeche-
len E., Blennow K. (2001). Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–
93 years of age: establishment of reference values. Clin. Chem. 47, 1776–1781. 
Sjögren M., Mielke M., Gustafson D., Zandi P., Skoog I. (2006). Cholesterol and Alzheimer’s 
disease–is there a relation? Mech. Ageing. Develop. 127, 138-147. 
Skovronsky D.M., Moore D.B., Milla M.E., Doms R.W., Lee V.M.Y. (2000). Protein kinase C-
dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor 
protein in the trans-golgi network. J. Biol. Chem. 275, 2568–2575. 




Sokolov Y., Kozak J.A., Kayed R., Chanturiya A., Glabe C., Hall J.E. (2006). Soluble amyloid oli-
gomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 128, 
637-647.  
Sokolova T.V., Zakharova I.O., Furaev V.V., Rychkova M.P., Avrova N.F. (2007). Neuropro-
tective effect of ganglioside GM1 on the cytotoxic action of hydrogen peroxide and amy-
loid β-peptide in PC12 cells. Neurochem. Res. 32, 1302–1313. 
Song H., Stevens C.F., Gage F.H. (2002). Astroglia induce neurogenesis from adult neural 
stem cells. Nature 417, 39–44. 
Sontag E., Nunbhakdi-Craig V., Lee G., Brandt R., Kamibayashi C., Kuret J., White III C.L., 
Mumby M.C., Bloom G.S. (1999). Molecular interactions among protein phosphatase 
2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and 
the development of tauopathies. J. Biol. Chem. 274, 25490–25498. 
Squier T.C. (2001). Oxidative stress and protein aggregation during biological aging. Exp. 
Gerontol. 36, 1539–1550. 
Stefani M., Taddei N., Ramponi G. (1997). Insights into acylphosphatase structure and catalytic 
mechanism. Cell. Mol. Life Sci. 53, 141-151. 
Stefani M. and Dobson C.M. (2003). Protein aggregation and aggregate toxicity: new insights 
into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81,678-699.  
Stefani M. (2004). Protein misfolding and aggregation: new examples in medicine and biolo-
gy of the dark side of the protein world. Biochim. Biophys. Acta 1739,5-25. 
Stefani M. (2007). Generic cell dysfunction in neurodegenerative disorders: role of surfaces in 
early protein misfolding, aggregation, and aggregate cytotoxicity. Neuroscientist 13, 519–
531. 
Stefani M. (2008). Protein folding and misfolding on surfaces. Int. J. Mol. Sci. 9, 2515-2542.  
Stefani M. and Liguri G. (2009). Cholesterol in Alzheimer’s disease: unresolved questions. 
Curr. Alzh. Res. 6, 15–29. 
Stefani M. (2010a). Structural polymorphism of amyloid oligomers and fibrils underlies different 
fibrillization pathways: immunogenicity and cytotoxicity. Curr. Protein Pept. Sci. 11, 343-354.  
Stefani M. (2010b). Biochemical and biophysical features of both oligomer/fibril and cell mem-
brane in amyloid cytotoxicity. FEBS J. 277, 4602-4613.  
Steiner H., Winkler E., Haass C. (2008). Chemical cross-linking provides a model of the 
gamma-secretase complex subunit architecture and evidence for close proximity of the 
C-terminal fragment of presenilin with APH-1. J. Biol .Chem. 283, 34677-34686. 
Suk J.Y., Zhang F., Balch W.E., Linhardt R.J., Kelly J.W. (2006). Heparin accelerates gelsolin 
amyloidogenesis. Biochemistry 45, 2234–2242. 
Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L. Jr., Eckman C., Golde T.E., Younkin S.G. 
(1996). An increased percentage of long amyloid beta protein secreted by familial amy-
loid beta protein precursor (beta APP717) mutants. Science 264, 1336–1340. 
Svennerholm L. and Gottfries C.G. (1994). Membrane lipids, selectively diminished in Alz-
heimer brains, suggest synapse loss as a primary event in early-onset form (type I) and 
demyelination in late-onset form (type II). J. Neurochem. 62, 1039–1047. 
Tabner B.J., Turnbull S., El-Agnaf O.M.A., Allsop D. (2002). Formation of hydrogen peroxide 
and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in 
Alzheimer’s disease and Parkinson’s disease. Free Radic. Biol. Med. 32, 1076–1083. 
Takashima A., Noguchi K., Sato K., Hoshino T., Imahori K. (1993). Tau protein kinase I is 







Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., Walter J. (2005). Inhibition of gly-
cosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and 
amyloid β-peptide. J. Biol. Chem. 280, 28110-28117. 
Taupin P. and Gage F.H. (2002). Adult neurogenesis and neural stem cells of the central 
nervous system in mammals. J. Neurosci. Res. 69, 745–749. 
Teller H.W., Waring A.J., Lehrer R.I., Harroun T.A., Weiss T.M., Yang L., Huang H.W. 
(2000). Membrane thinning effect of the β-sheet antimicrobial peptide protegrin. Bio-
chemistry 39, 139-145. 
Terzi E., Holzemann G., Seelig J. (1995). Self-association of β-amyloid peptide (1-40) in solu-
tion and binding to lipid membranes. J. Mol. Biol. 252, 633–642. 
Tesco G., Vergelli M., Amaducci L., Sorbi S. (1993). Growth properties of familial Alzheimer 
skin fibroblasts during in vitro aging. Exp. Gerontol. 28, 51–58. 
The dementia study group of the italian neurological society. (2000). Guidelines for the diag-
nosis of dementia and Alzheimer’s disease. Ital. J. Neurol. Sci. 21, 87–194.  
Tjernberg L., Hosia W., Bark N., Thyberg J., Johansson J. (2002). Charge attraction and β 
propensity are necessary for amyloid fibril formation from tetrapeptides. J. Biol. Chem. 
277,43243–43246. 
Tsai L.H., Delalle I., Caviness V.S. Jr., Chae T., Harlow E. (1994). p35 is a neural-specific 
regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423. 
Turley S.D., Burns D.K., Rosenfeld C.R., Dietschy J,M. (1996). Brain does not utilize low den-
sity lipoprotein-cholesterol during fetal and neonatal development in the sheep. J. Lipid 
Res. 37, 1953-1961. 
Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. (2000). Review: Alzheimer’s amyloid 
β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 
184–208. 
Verret L., Jankowsky J.L., Xu G.M., Borchelt D.R., Rampon C. (2007). Alzheimer’s-type amy-
loidosis in transgenic mice impairs survival of newborn neurons derived from adult hip-
pocampal neurogenesis. J. Neurosci. 27, 6771–6780. 
Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T.Jr. 
(2001). Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the 
pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.  
Volles M.J. and Lansbury P.T.Jr. (2002). Vesicle permeabilization by protofibrillar alpha-
synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like 
mechanism. Biochemistry 41, 4595-4602. 
Wakabayashi M. and Matsuzaki K. (2007). Formation of amyloids by Aβ(1-42) on NGF-
differentiated PC12 cells: roles of gangliosides and cholesterol. J. Mol. Biol. 371, 924–933. 
Wakabayashi M. and Matsuzaki K. (2009). Gangliosideinduced amyloid formation by human 
islet amyloid polypeptide in lipid rafts. FEBS Lett. 583, 2854–2858. 
Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., 
Selkoe D.J., Teplow D.B. (1999). Amyloid beta-protein fibrillogenesis. Structure and bio-
logical activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952. 
Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe 
D.J. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippo-
campal longterm potentiation in vivo. Nature 416, 535-539. 
Wang S.S., Good T.A., Rymer D.L. (2005). The influence of phospholipid membranes on bo-
vine calcitonin peptide's secondary structure and induced neurotoxic effects. Int. J. Bio-
chem. Cell. Biol. 37, 1656-1669. 




Weisblum B. and Haenssler E. (1974). Fluorometric properties of the bibenzimidazole deriva-
tive Hoechst 33258, a fluorescent probe specific for AT concentration in chromosomal 
DNA. Chromosoma 46, 255-260. 
Williams T.L. and Serpell L.C. (2011). Membrane and surface interactions of Alzheimer's Aβ 
peptide--insights into the mechanism of cytotoxicity. FEBS J. 278, 3905-3917. 
Williamson M.P., Suzuki Y., Bourne N.T., Asakura T. (2006). Binding of amyloid β-peptide 
to ganglioside micelles is dependent on histidine-13. Biochem. J. 397, 483–490. 
Williamson R., Usardi A., Hanger D.P., Anderton B. H. (2008). Membrane-bound β-amyloid 
oligomers are recruited into lipid rafts by a Fyn-dependent mechanism FASEB J. 22, 
1552-1559. 
Wischik C.M., Crowther R.A., Stewart M., Roth M. (1985). Subunit structure of paired helical 
filaments in Alzheimer’s disease. J. Cell. Biol. 100, 1905–1912. 
Wisniewski K.E., Wisniewski H.M., Wen G.Y. (1985). Occurrence of neuropathological 
changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann. Neurol. 17, 
278–282. 
Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. (1999). Two 
transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and 
gamma-secretase activity. Nature 398, 513–517. 
Wood W.G., Schroeder F., Avdulov N.A., Chochina S.V., Igbavboa U. (1999). Recent advanc-
es in brain cholesterol dynamics: transport, domains and Alzheimer’s disease. Lipids 34, 
225-234. 
Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell 
M., Schapira A., Orntoft T.F., Kato K., Rubinsztein D.C. (2001). Polyglutamine expan-
sions cause decreased CRE-mediated transcription and early gene expression changes 
prior to cell death in an inducible cell model of Huntington’s disease. Hum. Mol. Genet. 
10, 1829–1845. 
Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., Haass C., Seubert P., 
Koo E.H., Selkoe D.J. (1997). Enhanced production and oligomerization of the 42-residue 
amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant prese-
nilins. J. Biol. Chem. 272, 7977–7982. 
Xuan A.G., Long D.H., Gu H.G., Yang D.D., Hong L.P., Leng S.L. (2008). BDNF improves the 
effects of neural stem cells on the rat model of Alzheimer’s disease with unilateral lesion 
of fimbria-fornix. Neurosci. Lett. 440, 331–335. 
Xue W.F., Hellewell A.L., Gosal W.S., Homans S.W., Hewitt E.W, Radford S.E. (2009). Fibril 
fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 284, 34272-34282. 
Yamamoto N., Igbabvoa U., Shimada Y., Ohno-Iwashita Y., Kobayashi M., Wood W.G., Fuji-
ta S.C., Yanagisawa K. (2004). Accelerated Aβ aggregation in the presence of GM1-
ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 
569, 135–139. 
Yamamoto N., Yokoseki T., Shibata M., Yamaguchi H., Yanagisawa K. (2005). Suppression of 
Aβ deposition in brain by peripheral administration of Fab fragments of anti-seed anti-
body. Biochem. Biophys. Res. Commun. 335, 45–47. 
Yamamoto N., Matsubara T., Sato T. Yanagisawa K. (2008). Age-dependent high density 
clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-
protein fibrillogenesis. Biochim. Biophys. Acta 1778, 2717-2726. 
Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhan M., Nagashima J., 
Morser A., Migheli P., Nawroth D., Stern A.M., Schmidt A.M. (1996). RAGE and amy-






Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., Roher A.E. (1998). RAGE-Abeta 
interactions in the pathophysiology of Alzheimer's disease. Resto. Neurol. Neurosci. 12, 
167-173. 
Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M. Stern 
D., Kindy M. (2000). Receptor-dependent cell stress and amyloid accumulation in sys-
temic amyloidosis. Nat. Med. 6, 643-651. 
Yanagisawa K., Odaka A., Suzuki N., Ihara Y. (1995). GM1 ganglioside-bound  amyloid β-
protein (Aβ): a possible form of preamyloid in Alzheimer’s disease. Nat. Med. 1, 1062–
1066. 
Yanagisawa K. (2007). Role of gangliosides in Alzheimer’s disease. Biochim. Biophys. Acta 
1768, 1943–1951. 
Yanagisawa M. and Yu R.K. (2007). The expression and functions of glycoconjugates in neu-
ral stem cells. Glycobiology 17, 57R–74R. 
Yanagisawa M., Ariga T., Yu R.K. (2010). Cytotoxic effects of G(M1) ganglioside and amyloid 
beta-peptide on mouse embryonic neural stem cells. ASN Neuro 15, 2(1):e00029. 
Yanagisawa K. (2011). Pathological significance of ganglioside clusters in Alzheimer's disease. 
J. Neurochem. 116, 806-812. 
Yancey P.G., Rodrigueza W.V., Kilsdonk E.P., Stoudt G.W., Johnson W.J., Phillips M.C., 
Rothblat G.H. (1996). Cellular cholesterol efflux mediated by cyclodextrins. Demonstra-
tion of kinetic pools and mechanism of efflux. J. Biol. Chem. 271, 16026-16034. 
Yang L.J., Zeller C.B., Shaper N.L., Kiso M., Hasegawa A., Shapiro R.E., Schnaar R.L. (1996). 
Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc. Natl. Acad. 
Sci. USA 93, 814–818. 
Yankner B.A., Duffy L.K., Kinschner D.A. (1990). Neurotrophic and neurotoxic effects of 
amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279-282.  
Yip C.M., Elton E.A., Darabie A.A., Morrison M.R., McLaurin J. (2001). Cholesterol, a modu-
lator of membrane-associated Abeta-fibrillogenesis and neurotoxicity, J. Mol. Biol. 311, 
723-734 
Younkin S.G. (1998). The role of A beta 42 in Alzheimer’s disease. J. Physiol. Paris 92, 289–
292. 
Yu R.K. (1994). Development regulation of ganglioside metabolism. Prog. Brain Res. 101, 31–
44. 
Yu R.K., Usuki S., Ariga T. (2006). Ganglioside molecular mimicry and its pathological roles 
in Guillain-Barre` syndrome and related diseases. Infect. Immun. 74, 6517–6527. 
Yu R.K., Yanagisawa M., Ariga.T. (2007). Glycosphingolipid structures. In Comprehensive 
Glycoscience. Elsevier Oxford UK. 73–122. 
Yuyama K., Yamamoto N., Yanagisawa K. (2006). Chloroquine-induced endocytic pathway 
abnormalities: cellular model of GM1 ganglioside-induced Aβ fibrillogenesis in Alz-
heimer’s disease. FEBS Lett. 580, 6972–6976. 
Zampagni M., Cascella R., Casamenti F., Grossi C., Evangelisti E., Wright D., Becatti M., Li-
guri G., Mannini B., Campioni S., Chiti F., Cecchi C. (2011). A comparison of the bio-
chemical modifications caused by toxic and nontoxic protein oligomers in cells J. Cell. 
Mol. Med. 15, 2106-2116. 
Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Steinberg 
M., Welsh-Bohmer K.A., Breitner J.C. (2005). Do statins reduce the risk of incident de-
mentia and Alzheimer’s disease? Arch. Gen Psychiatry 62, 217-224. 
Zhang H., Li Q., Graham R. K., Slow E., Hayden M. R., Bezprozvanny I. (2008). Full length 
mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons 
in the YAC mouse model of Huntington’s disease. Neurobiol. Dis. 31, 80–88. 




Zhao H., Tuominen E.K.J., Kinnunen P.K.J. (2004). Formation of amyloid fibers triggered by 
phosphatidylserine-containing membranes. Biochemistry 43, 10302–10307. 
Zhao C., Deng W., Gage F.H. (2008). Mechanisms and functional implications of adult neu-




premio tesi di dottorato
anno 2007
Bracardi M., La Materia e lo Spirito. Mario Ridolfi nel paesaggio umbro 
Coppi E., Purines as Transmitter Molecules. Electrophysiological Studies on Purinergic Signalling in Different 
Cell Systems 
Mannini M., Molecular Magnetic Materials on Solid Surfaces 
Natali I., The Ur-Portrait. Stephen Hero ed il processo di creazione artistica in A Portrait of the Artist as a 
Young Man 
Petretto L., Imprenditore ed Università nello start-up di impresa. Ruoli e relazioni critiche 
anno 2008
Bemporad F., Folding and Aggregation Studies in the Acylphosphatase-Like Family 
Buono A., Esercito, istituzioni, territorio. Alloggiamenti militari e «case Herme» nello Stato di Milano (secoli 
XVI e XVII) 
Castenasi S., La finanza di progetto tra interesse pubblico e interessi privati 
Colica G., Use of Microorganisms in the Removal of Pollutants from the Wastewater 
Gabbiani C., Proteins as Possible Targets for Antitumor Metal Complexes: Biophysical Studies of their 
Interactions 
anno 2009
Decorosi F., Studio di ceppi batterici per il biorisanamento di suoli contaminati da Cr(VI) 
Di Carlo P., I Kalasha del Hindu Kush: ricerche linguistiche e antropologiche 
Di Patti F., Finite-Size Effects in Stochastic Models of Population Dynamics: Applications to Biomedicine and 
Biology
Inzitari M., Determinants of Mobility Disability in Older Adults: Evidence from Population-Based 
Epidemiologic Studies 
Macrì F., Verso un nuovo diritto penale sessuale. Diritto vivente, diritto comparato e prospettive di riforma 
della disciplina dei reati sessuali in Italia 
Pace R., Identità e diritti delle donne. Per una cittadinanza di genere nella formazione 
Vignolini S., Sub-Wavelength Probing and Modification of Complex Photonic Structures 
anno 2010
Fedi M., «Tuo lumine». L’accademia dei Risvegliati e lo spettacolo a Pistoia tra Sei e Settecento 
Fondi M., Bioinformatics of genome evolution: from ancestral to modern metabolism. Phylogenomics and 
comparative genomics to understand microbial evolution 
Marino E., An Integrated Nonlinear Wind-Waves Model for Offshore Wind Turbines 
Orsi V., Crisi e Rigenerazione nella valle dell’Alto Khabur (Siria). La produzione ceramica nel passaggio dal 
Bronzo Antico al Bronzo Medio 
Polito C., Molecular imaging in Parkinson’s disease 
Romano R., Smart Skin Envelope. Integrazione architettonica di tecnologie dinamiche e innovative per il 
risparmio energetico 
anno 2011
Acciaioli S., Il trompe-l’œil letterario, ovvero il sorriso ironico nell’opera di Wilhelm Hauff
Bernacchioni C., Sfingolipidi bioattivi e loro ruolo nell’azione biologica di fattori di crescita e citochine
Fabbri N., Bragg spectroscopy of quantum gases: Exploring physics in one dimension
Gordillo Hervás R., La construcción religiosa de la Hélade imperial: El Panhelenion
Mugelli C., Indipendenza e professionalità del giudice in Cina
Pollastri S., Il ruolo di TAF12B e UVR3 nel ciclo circadiano dei vegetali
Salizzoni E., Paesaggi Protetti. Laboratori di sperimentazione per il paesaggio costiero euro-mediterraneo
anno 2012
Evangelisti E., Structural and functional aspects of membranes: the involvement of lipid rafts in Alzheimer’s 
disease pathogenesis. The interplay between protein oligomers and plasma membrane physicochemical 
features in determining cytotoxicity
Bondì D., Filosofia e storiografia nel dibattito anglo-americano sulla svolta linguistica 
Petrucci F., Petri Candidi Decembrii Epistolarum iuvenilium libri octo. A cura di Federico Petrucci
Alberti M., La ‘scoperta’ dei disoccupati. Alle origini dell’indagine statistica sulla disoccupazione nell’Italia 
liberale (1893-1915)
Gualdani R., Using the Patch-Clamp technique to shed light on ion channels structure, function and 
pharmacology
Adessi A., Hydrogen production using Purple Non-Sulfur Bacteria (PNSB) cultivated under natural or 
artificial light conditions with synthetic or fermentation derived substrates
Ramalli A., Development of novel ultrasound techniques for imaging and elastography. From simulation to 
real-time implementation


